<SEC-DOCUMENT>0001193125-22-123703.txt : 20220427
<SEC-HEADER>0001193125-22-123703.hdr.sgml : 20220427
<ACCEPTANCE-DATETIME>20220427163053
ACCESSION NUMBER:		0001193125-22-123703
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220613
FILED AS OF DATE:		20220427
DATE AS OF CHANGE:		20220427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		22860123

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d352067ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE&nbsp;14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Rule
14a-101) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&nbsp;&nbsp;&#9744;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by
<FONT STYLE="white-space:nowrap">Rule&nbsp;14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item&nbsp;25(b) per Exchange Act
<FONT STYLE="white-space:nowrap">Rules&nbsp;14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF
ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To be Held on June&nbsp;13, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 27, 2022 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders of Alaunos
Therapeutics, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cordially invite you to the 2022 annual meeting of stockholders (the &#147;Annual Meeting&#148;) of Alaunos Therapeutics, Inc.
(&#147;we,&#148; &#147;Alaunos&#148; or the &#147;Company&#148;), which will be held virtually and exclusively online via live audio-only webcast, on June&nbsp;13, 2022, at 9:00 a.m. Eastern Time, for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect each of the seven nominees for director named in the accompanying proxy statement (the &#147;proxy
statement&#148;) to hold office until the 2023 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal (&#147;Proposal 1&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the selection of RSM US LLP as the independent registered public accounting firm of the Company for
its fiscal year ending December&nbsp;31, 2022 by the audit committee (the &#147;audit committee&#148;) of the board of directors of the Company (the &#147;Board&#148;) (&#147;Proposal 2&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers as disclosed
in the proxy statement (&#147;Proposal 3&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the amendment and restatement of the Company&#146;s amended and restated certificate of
incorporation, as amended (our &#147;Charter&#148;), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company&#146;s issued and outstanding
common stock, par value $0.001 per share, including stock held by the Company as treasury shares, at a reverse stock split ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15,</FONT></FONT> inclusive (&#147;Proposal 4&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the Company&#146;s Charter, in substantially the form attached to the proxy
statement as Annex B, to, at the discretion of our Board, increase the number of shares of common stock authorized for issuance thereunder from 350,000,000 shares to 420,000,000 shares (&#147;Proposal 5&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit
further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 4 and Proposal 5 (&#147;Proposal 6&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact any other business as may properly come before the Annual Meeting or any adjournments thereof.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the proxy statement accompanying this notice. The proxy statement accompanying this
notice is being issued in connection with the solicitation by the Board of a proxy on the enclosed form of proxy card for use at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
will be able to attend and participate in the Annual Meeting online, submit your questions during the Annual&nbsp;Meeting and vote your shares electronically during the meeting by visiting www.virtualshareholdermeeting.com/TCRT2022. <B>Because the
Annual Meeting is being held electronically, you will not be able to attend the Annual Meeting in person.</B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The record date for the Annual Meeting is April&nbsp;22, 2022. Only stockholders of record at the close of
business on that date may vote at the Annual Meeting or any adjournment or postponement thereof. To participate in and vote at the Annual Meeting, stockholders will need the unique <FONT STYLE="white-space:nowrap">16-digit</FONT> control number
(printed in the box marked by the arrow) in their Notice of Internet Availability of Proxy Materials or proxy card (if you requested a printed copy of the proxy materials). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board of Directors,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Melinda Lackey</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Melinda Lackey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SVP, Legal and Secretary</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston,
Texas</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">April 27, 2022</P></TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Your vote is very important. Whether or not you attend the Annual Meeting virtually, it is important that your
shares be represented. You may vote your proxy through the Internet, by telephone or, if you receive a paper proxy card by mail, by completing and returning the proxy card mailed to you. Voting instructions are provided in the Notice of Internet
Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card and included in the proxy statement. If you participate virtually in the Annual Meeting, you may vote at that time, even
if you previously submitted your vote. Even if you plan to participate in the Annual Meeting, we urge you to vote as soon as possible over the internet, by telephone or by mail as described in the proxy statement. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_1">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND
VOTING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_2">PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_3">Proposal 1 Election of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_4">Proposal 2 Ratification of Selection of Independent Registered Public Accounting
 Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_5">Proposal 3 Advisory Vote on Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_6">Proposal 4 Approval of Reverse Stock Split</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_7">Proposal 5 Approval of Increase in Authorized Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_8">Proposal 6 Adjournment of Annual Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_9">STOCKHOLDER PROPOSALS FOR THE 2023 ANNUAL MEETING OF
STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_10">CURRENT DIRECTORS, DIRECTOR NOMINEES AND EXECUTIVE
OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_11">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_12">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_13">Narrative to the Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_14">Role of our Compensation Committee, Management and Consultant</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_15">Outstanding Equity Awards at 2021 Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_16">Stockholder Engagement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_17">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE
GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_18">Independence of the Board </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_19">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_20">Nasdaq Diversity Matrix</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_21">Director Attendance at Board and Stockholder Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_22">Board Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_23">Director Nomination Process</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_24">Risk Management and Oversight</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_25">Stockholder Communications with Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_26">Code of Ethics and Business Conduct</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_27">Corporate Governance Guidelines</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_28">Whistleblower Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_29">Corporate Governance Documents</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_30">Report of the Audit Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_31">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_32"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_33">Director Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_34">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
PLANS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_35">LIMITATION OF LIABILITY AND INDEMNIFICATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_36">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_37">Related-Party Transaction Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_38">Certain Related-Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_42">DELINQUENT SECTION 16(A) REPORTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_39">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_40">HOUSEHOLDING OF PROXY MATERIALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc352067_41">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held On June&nbsp;13, 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_1"></A>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is soliciting my vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are providing you with
these proxy materials because the board of directors (the &#147;Board&#148;) of Alaunos Therapeutics, Inc. ( &#147;we,&#148; &#147;Alaunos&#148; or the &#147;Company&#148;) is soliciting your proxy to vote at the 2022 annual meeting (the
&#147;Annual Meeting&#148;), including at any adjournments or postponements thereof. The Annual Meeting will be held on June&nbsp;13, 2022 at 9:00 a.m., Eastern Time virtually and exclusively online via live audio-only webcast at
www.virtualshareholdermeeting.com/TCRT2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a notice regarding the availability of proxy materials through the internet? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to rules adopted by the Securities and Exchange Commission (the &#147;SEC&#148;), we have elected to provide access to our proxy materials over the
internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) because the Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements thereof.
All stockholders will have the ability to access the proxy materials through the website referred to in the Notice or to request a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request
a printed set of the proxy materials may be found in the Notice. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to mail the Notice on or about April 27, 2022 to all stockholders of
record entitled to vote at the Annual Meeting. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why are you holding a virtual annual meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our effort to maintain a safe and healthy environment for our directors, members of management and stockholders who wish to attend the Annual
Meeting, in light of the ongoing coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> pandemic we believe that hosting a virtual meeting is in the best interest of the Company and its stockholders and enables increased stockholder
attendance and participation because stockholders can participate from any location around the world. Stockholders will have the same rights and opportunities to participate as they would have at an <FONT STYLE="white-space:nowrap">in-person</FONT>
meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will I receive any other proxy materials by mail? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may send you a proxy card, along with a second Notice, on or after April 27, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I attend the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You cannot attend
the Annual Meeting physically. You can attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/TCRT2022, where you will be able to listen to the Annual Meeting live, submit questions and vote online. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Annual Meeting will start at 9:00 a.m. Eastern Time on June&nbsp;13, 2022. We encourage you to access the Annual Meeting prior to the start time to allow
time for online <FONT STYLE="white-space:nowrap">check-in.</FONT> We have worked to offer the same </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participation opportunities as would be provided at an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting while further enhancing the online experience available to all stockholders
regardless of their location. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. If you experience technical difficulties during
the Annual Meeting, you should call the technical support phone number provided when you log in to the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to enter the Annual
Meeting virtually, you will need the unique <FONT STYLE="white-space:nowrap">16-digit</FONT> control number, which is included in the Notice or on your proxy card if you are a stockholder of record of the shares, or included with your voting
instruction card and voting instructions received from your broker, bank, trustee, or nominee if you are the beneficial owner of the shares held in &#147;street name.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I cannot virtually attend the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote your shares electronically before the meeting by internet, by proxy or by telephone as described below. You do not need to access the Annual
Meeting audio-only webcast to vote if you submitted your vote via proxy, by internet or by telephone in advance of the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who can vote at
the Annual Meeting? </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on April&nbsp;22, 2022 (the &#147;Record Date&#148;) will be entitled to
vote at the Annual Meeting. On the Record Date, there were 215,950,561 shares of common stock outstanding and entitled to vote. A list of such holders will be open to the examination of any stockholder for any purpose germane to the Annual Meeting
at Alaunos Therapeutics, Inc., 8030 El Rio Street, Houston, TX 77054 for a period of 10 days prior to the Annual Meeting. Please contact the Secretary of the Company to make arrangements to inspect the list. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record&#151;Shares Registered in Your Name:</I> If on April&nbsp;22, 2022, your shares were registered directly in your name with our
transfer agent, American Stock Transfer&nbsp;&amp; Trust Company, LLC (&#147;AST&#148;), then you are a stockholder of record. As a stockholder of record, you may vote at the Annual Meeting virtually or vote by proxy prior to the Annual Meeting.
Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy through the internet, by telephone or using a proxy card that you may request as instructed below, to ensure your vote is counted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner&#151;Shares Registered in the Name of a Broker or Bank:</I> If on April&nbsp;22, 2022, your shares were not registered in your name, but
instead are held in an account at a brokerage firm, bank, dealer or similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization
holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account.
You are also invited to attend the Annual Meeting. Since you are not the stockholder of record, however, you may not vote your shares at the Annual Meeting even if you participate virtually unless you request and obtain a valid proxy from your
broker, bank or other agent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What am I voting on? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are six matters scheduled for a vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect each of the seven nominees for director named in this proxy statement (the &#147;proxy
statement&#148;) to hold office until the 2023 annual meeting of stockholders and until his or her successor is duly elected and qualified or, if sooner, until his or her earlier death, resignation or removal (&#147;Proposal 1&#148;);
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the selection of RSM US LLP as the independent registered public accounting firm of the Company for
its fiscal year ending December&nbsp;31, 2022 by the audit committee (the &#147;audit committee&#148;) of the Board (&#147;Proposal 2&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers as disclosed
in the proxy statement (&#147;Proposal 3&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the amendment and restatement of the Company&#146;s amended and restated certificate of
incorporation, as amended (our &#147;Charter&#148;), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company&#146;s issued and outstanding
common stock, par value $0.001 per share, including stock held by the Company as treasury shares, at a reverse stock split ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15,</FONT></FONT> inclusive (&#147;Proposal 4&#148; or the &#147;Reverse Stock Split Proposal&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the Company&#146;s Charter, in substantially the form attached to the proxy
statement as Annex B, to, at the discretion of our Board, increase the number of shares of common stock authorized for issuance thereunder from 350,000,000 shares to 420,000,000 shares (&#147;Proposal 5&#148; or the &#147;Authorized Stock Increase
Proposal&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve a proposal to adjourn the Annual Meeting to a later date, if necessary or appropriate, to permit
further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 4 and Proposal 5 (&#147;Proposal 6&#148; or the &#147;Adjournment Proposal&#148;).
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How does the Board recommend that I vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board unanimously recommends that you: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vote your shares &#147;FOR&#148; Proposal 1 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vote your shares &#147;FOR&#148; Proposal 2 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vote your shares &#147;FOR&#148; Proposal 3 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vote your shares &#147;FOR&#148; Proposal 4 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vote your shares &#147;FOR&#148; Proposal 5 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vote your shares &#147;FOR&#148; Proposal 6 </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if another matter is properly brought before the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual
Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I
vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to Proposal 1, you may vote &#147;For&#148; all the nominees to the Board, or you may &#147;Withhold&#148; your vote for any of the
nominees you specify. With respect to the other proposals, you may vote &#147;For&#148; or &#147;Against,&#148; or you may abstain from voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
procedures for voting are fairly simple: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record&#151;Shares Registered in Your Name:</I> If you are a stockholder of record, you may
vote electronically over the internet before or during Annual Meeting, vote by proxy over the telephone, vote by proxy through the internet, or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time.
Whether or not you plan to attend the virtual Annual Meeting, we urge you to vote by proxy to ensure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
your vote is counted. You may still attend the Annual Meeting virtually and vote electronically at the Annual Meeting even if you have already voted by proxy. You may vote as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote through the internet before the Annual Meeting, go to www.proxyvote.com to complete an electronic proxy
card. You will be asked to provide the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number from the Notice. Your vote must be received by 11:59 p.m. Eastern Time, on June&nbsp;12, 2022 to be counted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote your shares electronically at the Annual Meeting, you will need to visit
www.virtualshareholdermeeting.com/TCRT2022 during the Annual Meeting while the polls are open and follow the instructions provided on the Notice or the proxy card. You will be asked to provide the control number from the notice and follow the
instructions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote over the telephone from a location in the United States, dial toll-free <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903,</FONT></FONT></FONT> using a touch-tone phone and follow the recorded instructions. You will be asked to provide the <FONT STYLE="white-space:nowrap">16-digit</FONT> control
number from the Notice. Your vote must be received by 11:59 p.m. Eastern Time, on June&nbsp;12, 2022 to be counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote using a proxy card, you may request a proxy card by following the instructions in the Notice. Once you
receive the proxy card, simply complete, sign and date the proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner&#151;Shares Registered in the Name of a Broker or Bank:</I> If you are a beneficial owner of shares registered in
the name of your broker, bank or other agent, you should have received a Notice containing voting instructions from that organization rather than from us. Simply follow the voting instructions in the Notice to ensure that your vote is counted. To
vote electronically at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other
agent to request a proxy form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We provide Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the
authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On each matter to be voted
upon, you have one vote for each share of our common stock you own as of the Record Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If I am a stockholder of record and I do not vote, or if I
return a proxy card or otherwise vote without giving specific voting instructions, what happens? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record and do not vote by
completing your proxy card, by telephone, through the internet or by voting electronically at the Annual Meeting, your shares will not be voted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you
return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#147;For&#148; the election of all seven nominees for director, &#147;For&#148; the ratification of the selection by
the audit committee of RSM US LLP as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2022, &#147;For&#148; the approval, on an advisory basis, of the compensation of our named executive officers as
disclosed in this proxy statement, &#147;For&#148; the approval of the Reverse Stock Split Proposal, &#147;For&#148; the Authorized Stock Increase Proposal, and &#147;For&#148; the Adjournment Proposal. If any other matter is properly presented at
the Annual Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with
voting instructions, what happens? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other
agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion on certain &#147;routine&#148; proposals. Under the rules of the New York Stock Exchange (&#147;NYSE&#148;), brokers, banks and
other securities intermediaries that are subject to NYSE rules may use their discretion to vote your &#147;uninstructed&#148; shares with respect to matters considered to be &#147;routine&#148; under NYSE rules, but not with respect to <FONT
STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Proposals 1 and 3 are considered to be <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> under NYSE rules, meaning that your broker, bank or other agent may not vote
your shares on those proposals in the absence of your voting instructions. However, Proposal 2, the Reverse Stock Split Proposal, the Authorized Stock Increase Proposal and the Adjournment Proposal are considered to be &#147;routine&#148; matters
under NYSE rules, meaning that if you do not return voting instructions to your broker, bank or other agent by its deadline, your shares may be voted by your broker, bank or other agent in its discretion on Proposal 2, the Reverse Stock Split
Proposal, the Authorized Stock Increase Proposal and the Adjournment Proposal. Accordingly, if you own shares through a nominee, such as a broker, bank or other agent, please be sure to instruct your nominee how to vote to ensure that your vote is
counted on all of the proposals </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way
you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent. </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are proxies solicited for the Annual Meeting? </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
will pay the cost of soliciting proxies. We have retained Alliance Advisors, LLC, on customary terms, to aid in the solicitation of proxies for an estimated fee of $15,000, plus reimbursement of out-of-pocket expenses. Our directors and employees
may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the
cost of forwarding proxy materials to beneficial owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have any questions or require any assistance in voting your shares, please contact: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alliance Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 Broadacres
Drive, 3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bloomfield, NJ 07003 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toll-Free: 833-757-0787 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-mail:
TCRT@allianceadvisors.com </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I receive more than one Notice? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on
each Notice to ensure that all of your shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote after submitting my proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy
in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may submit another properly completed proxy card with a later date (which automatically revokes the earlier
proxy). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may grant a subsequent proxy by telephone or through the internet. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may send a timely written notice that you are revoking your proxy to our Secretary at our principal executive
offices at 8030 El Rio Street, Houston, TX 77054. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may attend the Annual Meeting virtually and vote electronically. Simply attending the Annual Meeting
virtually will not, by itself, revoke your proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if you plan to attend the Annual Meeting virtually, we recommend that you
also submit your proxy or voting instructions or vote by telephone or through the Internet so that your vote will be counted if you later decide not to attend the Annual Meeting. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your most current proxy card, telephone proxy or internet proxy is the one that is counted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker, bank or other agent as a nominee, you should follow the instructions provided by such broker, bank or other agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are votes counted? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Votes will be counted by the
inspector of election appointed for the Annual Meeting, who will separately count, for the proposal to elect directors (Proposal 1), votes &#147;For,&#148; &#147;Withhold&#148; and broker <FONT STYLE="white-space:nowrap">non-votes;</FONT> and with
respect to all other proposals, votes &#147;For&#148; and &#147;Against,&#148; abstentions and, if applicable, broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions will have the same effect as &#147;Against&#148; votes on Proposal
2, Proposal 3, the Reverse Stock Split Proposal, the Authorized Stock Increase Proposal and the Adjournment Proposal, and will have no effect on Proposal 1. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> on Proposals 1 and 3 will have no
effect and will not be counted towards the vote total for either of those proposals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are &#147;broker
<FONT STYLE="white-space:nowrap">non-votes&#148;?</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, when a beneficial owner of shares held in street name does not give
voting instructions to his or her broker, bank or other agent holding his or her shares as to how to vote on matters deemed to be <FONT STYLE="white-space:nowrap">&#147;non-routine,&#148;</FONT> under the NYSE rules, the broker, bank or agent cannot
vote the shares. These <FONT STYLE="white-space:nowrap">un-voted</FONT> shares are counted as &#147;broker <FONT STYLE="white-space:nowrap">non-votes.&#148;</FONT> Proposals 1 and 3 are considered to be
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> under the NYSE rules and therefore we expect broker <FONT STYLE="white-space:nowrap">non-votes</FONT> to exist in connection with those proposals. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on those proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a reminder, if you are a beneficial owner of shares
held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other
agent. </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed to approve each proposal? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Proposal<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposal Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vote Required for Approval</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect of<BR>Abstentions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect of<BR>Broker<BR><FONT STYLE="white-space:nowrap">Non-Votes</FONT></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Election of directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Directors will be elected by a plurality of the votes cast by the holders of shares present or represented by proxy and entitled to vote on the election of directors. The seven nominees receiving the most &#147;For&#148; votes will
be elected as directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No<BR>effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No effect</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Proposal<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposal Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vote Required for Approval</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect of<BR>Abstentions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect of<BR>Broker<BR><FONT STYLE="white-space:nowrap">Non-Votes</FONT></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ratification of the selection of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Against</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not<BR>Applicable(1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approval, on an advisory basis, of the compensation of our named executive officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Against</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">No effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reverse Stock Split</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of the shares issued and outstanding and entitled to vote at the Annual Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Against</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not<BR>Applicable(1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Authorized Stock Increase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of the shares issued and outstanding and entitled to vote at the Annual Meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Against</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not<BR>Applicable(1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Adjournment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;For&#148; votes from the holders of a majority of the shares present in person or represented by proxy and entitled to vote on the matter.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Against</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Not<BR>Applicable(1)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under NYSE rules, this proposal is considered to be a &#147;routine&#148; matter. Accordingly, if you hold your
shares in street name and do not provide voting instructions to your broker, bank or agent that holds your shares, your broker, bank or other such agent has discretionary authority to vote your shares on this proposal. Any failure by a broker, bank
or other agent to vote a share over which it exercises discretion will have the same effect as a vote against the proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is
the quorum requirement? </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a
majority in voting power of the outstanding shares entitled to vote are deemed present at the Annual Meeting in person or represented by proxy. On the Record Date, there were 215,950,561 shares outstanding and entitled to vote. Thus, the holders of
107,975,281 shares must be deemed present in person or represented by proxy at the Annual Meeting to have a quorum. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your shares will be counted
towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or agent) or if you vote electronically at the Annual Meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will
be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares deemed present at the Annual Meeting in person or represented by proxy may adjourn the Annual Meeting to another date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who will serve as inspector of elections? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
representative of Broadridge Financial Solutions (&#147;Broadridge&#148;) will serve as inspector of elections and Broadridge will tabulate votes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business
days after the Annual Meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an additional Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I have questions for the Company&#146;s transfer agent? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please contact AST, at the phone number or address listed below, if you are a registered stockholder and have questions concerning stock certificates,
transfers or ownership or other matters pertaining to your stock account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">800-937-5449</FONT></FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6201 15th Avenue, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Brooklyn, NY 11219 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_2"></A>PROPOSALS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_3"></A>Proposal 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Election of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board presently
has seven directors: Christopher Bowden M.D.; Kevin S. Boyle, Sr.; James Huang; Robert W. Postma; Mary Thistle; Jaime Vieser; and Holger Weis. Each of Dr.&nbsp;Bowden, Mr.&nbsp;Huang, Mr.&nbsp;Postma, Ms.&nbsp;Thistle, Mr.&nbsp;Vieser and
Ms.&nbsp;Weis was previously elected by the stockholders. Mr.&nbsp;Boyle was appointed as a member of our Board effective August&nbsp;30, 2021, and is standing for election to our Board for the first time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2022, our Board nominated all of our existing directors for election at the Annual Meeting. If elected, each of our proposed nominees has
consented to serve as one of our directors, to hold office until our next annual meeting of stockholders and until his or her successor has been duly elected and qualified, or, if sooner, until his or her earlier death, resignation or removal.
Proxies cannot be voted for a greater number of persons than the number of nominees named in the proxy statement. If any director nominee should withdraw or otherwise become unavailable to serve, the proxies which would have otherwise been voted for
that director nominee may be voted for a substitute director nominee selected by our Board. We are not aware of any reason that a nominee will be unable or unwilling to serve as a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth each nominee to be elected at the Annual Meeting, the year each nominee was first elected as a director, the position(s)
currently held by each nominee with us and the year each nominee&#146;s term will expire, if such nominee is elected at the Annual Meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name&nbsp;of&nbsp;Nominee</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)&nbsp;with</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>the Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;First&nbsp;Became<BR>a Director</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Proposed<BR>Term&nbsp;Will&nbsp;Expire</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Bowden M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Huang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chair</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Postma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaime Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holger Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On August&nbsp;22, 2021, Mr.&nbsp;Boyle was appointed our Chief Executive Officer and a member of our Board, to
be effective August&nbsp;30, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our director resignation policy, any nominee in an uncontested election who does not receive a
majority of the votes cast (i.e. receives a greater number of votes &#147;withheld&#148; from his or her election than votes &#147;for&#148; in such election) shall submit his or her offer of resignation for consideration by the corporate governance
and nominating committee of the Board (the &#147;corporate governance and nominating committee&#148;). The corporate governance and nominating committee shall consider all of the relevant facts and circumstances and recommend to the Board the action
to be taken with respect to such offer of resignation, and the Board will then act on such recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate governance and nominating
committee seeks to assemble a Board that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise and management experience necessary to oversee and direct our business. The corporate governance and
nominating committee maintains a goal of recruiting members who complement and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment and other qualities that the corporate governance and
nominating committee views as critical to effective functioning of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the director nominees are related by blood, marriage or adoption to any of our other director
nominees or executive officers. Certain of our directors were selected or nominated for election as a director, pursuant to the WaterMill Settlement Agreement (as defined below). See the section titled &#147;<I>Certain Relationships and Related
Transactions&#151;Certain Related-Party Transactions&#151;WaterMill Settlement Agreement</I>&#148; in this proxy statement. Mr.&nbsp;Boyle, our Chief Executive Officer and a director, was nominated as a director pursuant to the terms of his
employment agreement as described in the section titled &#147;<I>Executive Compensation&#151;Narrative to the Summary Compensation Table&#151;Employment and Change in Control Agreements&#151;Employment Agreement with Kevin S. Boyle, Sr.</I>&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors are elected by a plurality
of the votes of the holders of shares deemed present in person or represented by proxy and entitled to vote on the election of directors. Accordingly, if a quorum is present, the seven nominees receiving the highest number of &#147;FOR&#148; votes
will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the seven nominees named above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Board recommends that you vote &#147;FOR&#148; the election of each named nominee. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_4"></A>Proposal 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ratification of Selection of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee of the Board has selected RSM US LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2022. RSM US LLP has audited our financial statements since 2010. A representative of RSM US LLP is expected to virtually attend the Annual Meeting. He or she will have an opportunity to make a statement if he or she so desires and will be available
to respond to appropriate questions from stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not required by statute or our bylaws or other governing documents to obtain stockholder
ratification of the appointment of RSM US LLP as our independent registered public accounting firm. The audit committee has submitted the selection of RSM US LLP to the stockholders for ratification as a matter of good corporate practice. If the
stockholders do not ratify the appointment, the audit committee may reconsider its selection. Notwithstanding the proposed ratification of the selection of RSM US LLP by the stockholders, the audit committee, in its discretion, may direct the
appointment of a new independent registered public accounting firm at any time during the year without notice to, or the consent of, the stockholders, if the audit committee determines that such a change would be in our best interest and the best
interest of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accountant Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the aggregate fees billed by RSM US LLP for the years ended December&nbsp;31, 2021 and 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Fee Category</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents fees billed for professional services provided to us in connection with the annual audit of our
financial statements, the review of our quarterly condensed financial statements, the audit of the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (2020 only), as well as
audit services that are normally provided by an independent registered public accounting firm in connection with statutory and regulatory filings or engagements for those fiscal years, such as statutory audits, administrative fees and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as discussed above, we did
not incur any fees of RSM US LLP for audit-related, tax or other services in 2021 or 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees described above were
<FONT STYLE="white-space:nowrap">pre-approved</FONT> by the audit committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policy and
Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee has adopted a policy and procedures for the <FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services rendered by our independent registered public accounting firm, RSM US LLP. The policy generally authorizes <FONT STYLE="white-space:nowrap">pre-approval</FONT> by the audit committee of specified
services in the defined categories of audit services, audit-related services and tax services up to specified amounts. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> may also be given as part of the audit committee&#146;s approval of the scope
of the engagement of the independent registered public accounting firm or on an individual, explicit, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis before the independent registered public
accounting firm is engaged to provide each service. The <FONT STYLE="white-space:nowrap">pre-approval</FONT> of services may be delegated to one or more of the audit committee&#146;s members, but the decision must be reported to the full audit
committee at its next scheduled meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares deemed present in person or represented by proxy and entitled to vote at the annual meeting
will be required to ratify the selection of RSM US LLP. Abstentions will be counted toward the vote total for Proposal 2 and will have the same effect as &#147;AGAINST&#148; votes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Board recommends that you vote &#147;FOR&#148; the ratification of the selection of RSM US LLP as&nbsp;our&nbsp;independent
registered public accounting firm for our fiscal year ending December&nbsp;31, 2022. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_5"></A>Proposal 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Advisory Vote on Executive Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section&nbsp;14A of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), our stockholders are entitled to vote to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC&#146;s rules. At the 2017 annual
meeting of stockholders, our stockholders indicated their preference that we solicit a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of the named executive officers, commonly referred to as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay</FONT></FONT> vote,&#148; every year. The Board has adopted a policy that is consistent with that preference indicated by our stockholders. Accordingly, this year we are
again asking the stockholders to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the
philosophy, policies and practices described in this proxy statement. The compensation of our named executive officers is disclosed in the section titled &#147;<I>Executive Compensation</I>&#148; below, including the tabular and narrative
disclosures set forth in such section under the same heading. We believe that our compensation policies and decisions are focused on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> principles and
strongly aligned with our stockholders&#146; interests. Compensation of our named executive officers is designed to enable us to attract and retain talented and experienced executives, whose knowledge, skills and performance are critical to our
success, and motivate these executive officers to achieve our business objectives and to lead us in a competitive environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are asking our
stockholders to indicate their support for the compensation of our named executive officers as described in this proxy statement by casting a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote &#147;FOR&#148; the following resolution:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;RESOLVED, that the stockholders hereby approve the compensation of the &#147;named executive officers&#148; of Alaunos Therapeutics, Inc., as
disclosed in the section titled &#147;Executive Compensation&#148; in the proxy statement for the Alaunos Therapeutics, Inc. 2022 Annual Meeting of stockholders pursuant to the compensation disclosure rules of the SEC, including the compensation
tables and narrative discussion.&#148; </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares deemed present in person or represented by proxy and entitled to vote at the Annual Meeting
will be required to approve, on an advisory basis, the compensation of our named executive officers as described herein. Because the vote is advisory, it will not be binding on us, the Board or the Board&#146;s compensation committee (the
&#147;compensation committee&#148;). Nevertheless, the views expressed by our stockholders, whether through this vote or otherwise, are important to us and, accordingly, the Board and our compensation committee intend to consider the results of this
vote in making determinations in the future regarding executive compensation arrangements. Abstentions will be counted toward the vote total for Proposal 3 and will have the same effect as &#147;AGAINST&#148; votes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Board recommends that you vote &#147;FOR&#148; the proposal to approve the compensation of our named&nbsp;executive officers, as
described in this proxy statement. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_6"></A>Proposal 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Approval of the Second Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2022, our Board unanimously
approved and recommended that our stockholders approve the amendment and restatement of our Charter to, at the discretion of the Board, effect a reverse stock split with respect to the Company&#146;s issued and outstanding common stock, par value
$0.001 per share, including stock held by the Company as treasury shares, at any reverse stock split ratio within a range of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-15,</FONT></FONT> inclusive, and a proportionate decrease in the number of our total authorized capital stock and common stock, as further described below. As further described below, we are seeking approval of this
Reverse Stock Split Proposal primarily to provide our Board with the authority to effect a reverse stock split if needed to maintain our listing on the Nasdaq Global Select Market. Our Board has accordingly determined that it is advisable and in the
best interest of the Company and its stockholders for this Reverse Stock Split Proposal to be approved so that the Board has the necessary flexibility if, as we near the end of the relevant compliance period (including any granted extensions), we
have not regained compliance with the Minimum Price Standard (as defined below) and the Board makes the determination that a reverse stock split provides us the best chance to regain compliance and avoid delisting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reverse stock split, if implemented, would be at any ratio approved by our stockholders in this proposal within the range described above and would apply
equally to all outstanding shares of our common stock. Accordingly, each stockholder would hold the same percentage of common stock outstanding immediately following a reverse stock split as that stockholder held immediately prior to a reverse stock
split, except for adjustments that may result from the treatment of fractional shares as described below. In addition, a reverse stock split would result in a proportionate reduction in the number of shares of common stock authorized under the
Charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of this proposal would permit, but not require, our Board to effect a reverse stock split by any ratio between <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5</FONT></FONT> to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15,</FONT></FONT> inclusive, with the exact ratio to be selected at a whole number within
this range as determined by our Board in its sole discretion, provided that any reverse stock split is implemented within one year after the conclusion of the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receiving stockholder approval of a reverse stock split, the Board will have the authority, but not the obligation, to elect, in its sole discretion,
without further action on the part of our stockholders and as it determines to be in our and our stockholders&#146; best interests, to effect a reverse stock split and, if so, to select the reverse stock split ratio from within the approved range of
ratios described above, each ratio within such range having been approved by our stockholders. We believe that enabling our Board to select the ratio from within the stated range will provide us with the flexibility to implement a reverse stock
split in a manner designed to maximize the anticipated benefits for our stockholders. In determining the ratio following the receipt of stockholder approval, our Board may consider, among other factors, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical trading price and trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of outstanding shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the then-prevailing trading price and trading volume of our common stock and the anticipated impact of a reverse
stock split on the trading market for our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued listing requirements of the Nasdaq Global Select Market, including the requirement that, subject to
limited exceptions, listed companies maintain a minimum bid price of at least $1.00; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of authorized but unissued shares of our common stock that would result from a reverse stock split,
and potential uses of those additional authorized but unissued shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated impact of a particular ratio on our ability to reduce administrative and transactional costs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevailing general market and economic conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Reverse Stock Split Proposal is approved by the stockholders and the Board determines to implement a
reverse stock split, we will file an amended and restated Charter (the &#147;Second Amended and Restated Charter&#148;), with the Delaware Secretary of State. The material changes in the proposed Second Amended and Restated Charter are described in
this proposal. This description is qualified in its entirety by reference to the complete text of the Second Amended and Restated Charter, which is attached as Annex A to this proxy statement and incorporated into this proposal by reference. You are
strongly encouraged to read the actual text of the Second Amended and Restated Charter. The proposed Second Amended and Restated Charter is subject to revision for such changes as may be required by the Delaware General Corporation Law and any other
changes consistent with this proposal that we may deem necessary or appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Reverse Stock Split Proposal is approved by the stockholders and
a reverse stock split is implemented by our Board, no less than 5 and no more than 15 shares of existing common stock, as determined by our Board, will be combined into one share of common stock. Holders will receive, in lieu of any fractional
share, an amount in cash (without interest) equal to such fraction multiplied by the closing sales price of our common stock as reported on the Nasdaq Global Select Market on the trading day immediately preceding the effective date of the Second
Amended and Restated Charter. The Second Amended and Restated Charter, if adopted, will include only the reverse stock split ratio determined by our Board to be in the best interest of the Company and its stockholders and all of the other ratios
approved by our stockholders within the proposed range will be abandoned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Reverse Stock Split Proposal is approved and the Board elects to
implement a reverse stock split, the number of outstanding shares of our common stock would be reduced in proportion to the ratio of the reverse stock split chosen by our Board. If a reverse stock split is implemented, the number of authorized
shares of our common stock would decrease by the same proportion as the number of shares of common stock that are outstanding at the time of the reverse stock split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board reserves the right to elect not to effect a reverse stock split, including any or all reverse stock split ratios within the proposed range, if it
determines, in its sole discretion, that implementing a reverse stock split is not in the best interest of the Company and its stockholders. If we regain compliance with the Minimum Price Standard (as defined below) prior to the end of the 180
calendar days we have to come into compliance with such standard, our Board may decide to not effect a reverse stock split. If our Board does not implement a reverse stock split on or prior to the one year anniversary of the conclusion of the Annual
Meeting, stockholder approval would again be required prior to implementing any future reverse stock split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background and Reasons for a Reverse Stock
Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As further described below, we and our Board are seeking approval for the Reverse Stock Split Proposal primarily to provide our Board with
authority to effect a reverse stock split if needed to maintain our listing on the Nasdaq Global Select Market. However, we cannot provide assurance that a reverse stock split would achieve its intended or desired benefits, and we strongly encourage
you to review the discussion below in the section titled &#147;<I>Risks and Potential Disadvantages Associated with a Reverse Stock Split</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nasdaq Minimum Price Standard </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule
5450(a)(1) requires that companies listed on the Nasdaq Global Select Market maintain a minimum closing bid price of at least $1.00 per share (the &#147;Minimum Price Standard&#148;). Companies are considered out of compliance with the Minimum Price
Standard if the Nasdaq closing bid price is below $1.00 per share for 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), once out of compliance with the Minimum Price Standard, a company has 180 calendar days to regain compliance
by meeting the Minimum Price Standard. The 180 calendar day period for regaining compliance with the Minimum Price Standard ends on September&nbsp;13, 2022. The Minimum Price Standard will be met if the Company&#146;s common stock has a minimum
closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day period to regain compliance with the Minimum Price Standard. If we do not regain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compliance with the Minimum Price Standard by September&nbsp;13, 2022, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to transfer the listing
of our common stock to the Nasdaq Capital Market, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the Minimum Price Standard. To
effect such a transfer, we would also need to pay an application fee and will need to provide written notice of our intention to cure the deficiency during the additional compliance period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement, we are not in compliance with the Minimum Price Standard. The equity markets have experienced and continue to
experience substantial volatility due to, among other factors, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic and the war in Ukraine. On April 22, 2022, the reported closing price of the our common stock was $0.49 per share.
Accordingly, there is a significant risk that we may be unable to gain compliance with the Minimum Price Standard without a reverse stock split. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
primary purpose of a reverse stock split would be to achieve an increase in the per share market price of our common stock as necessary to meet the Minimum Price Standard. A delisting of our common stock would materially and adversely affect a
stockholder&#146;s ability to dispose of, or to obtain accurate quotations as to the market value of, our common stock. Furthermore, any delisting may cause our common stock to be subject to &#147;penny stock&#148; regulations promulgated by the
SEC. Under such regulations, broker-dealers are required to, among other things, comply with disclosure and special suitability determinations prior to the sale of shares of common stock. If our common stock becomes subject to these regulations, the
market price of our common stock and the liquidity thereof would be materially and adversely affected. Absent other factors, we believe that reducing the number of outstanding shares of our common stock is a potentially effective means to increase
the per share market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our shares of common stock are delisted from the Nasdaq Global Select Market, we believe that our
shares of common stock would likely be eligible to be quoted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> on an inter-dealer electronic quotation and trading system operated by OTC Markets Group.
These markets are generally considered not to be as efficient as, and not as broad as, the Nasdaq Global Select Market. Selling our shares of common stock on these markets could be more difficult because smaller quantities of shares would likely be
bought and sold, and transactions could be delayed. In addition, in the event our shares of common stock are delisted, broker-dealers would have certain regulatory burdens imposed upon them with respect to our common stock, which may discourage
broker-dealers from effecting transactions in our common stock, further limiting the liquidity of our common stock. These factors could result in lower prices and larger spreads in the bid and ask prices for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A delisting from the Nasdaq Global Select Market and continued or further declines in our share price could also greatly impair our ability to raise
additional necessary capital through equity or debt financing, or to use our shares for business development or other corporate initiatives, and could significantly increase the ownership dilution to stockholders caused by our issuing equity in
financing or other transactions. Without the ability to raise additional capital, our ability to carry on our business and advance the development of our product candidates would be significantly impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes that the proposed reverse stock split would be a potentially effective means for us to obtain and/or maintain compliance with the Minimum
Price Standard and to avoid, or at least defer, the consequences of our common stock being delisted from the Nasdaq Global Select Market by producing the immediate effect of increasing the bid price of our common stock. <B>Our Board currently
intends to effect a reverse stock split only if, in its sole discretion, it deems it to be a necessary step to regain compliance with the Minimum Price Standard.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General Investment Considerations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we
believe that a reverse stock split could make our common stock more attractive to a broader range of institutional and other investors, as we have been advised that the current market price of our common
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock may affect its acceptability to certain institutional investors and other members of the investing public. In particular, many brokerage houses and institutional investors have internal
policies and practices that may prohibit them from investing in <FONT STYLE="white-space:nowrap">low-priced</FONT> stocks or discourage individual brokers from recommending <FONT STYLE="white-space:nowrap">low-priced</FONT> stocks to their
customers. Moreover, because brokers&#146; commissions on <FONT STYLE="white-space:nowrap">low-priced</FONT> stocks generally represent a relatively high percentage of the stock price, transaction costs would represent a higher percentage of total
share value, which could result in decreased trading volume and increased volatility in the trading price of our common stock. We believe that a reverse stock split could make our common stock a more attractive and cost effective investment for many
investors, which could enhance the liquidity of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks and Potential Disadvantages Associated with a Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes that a reverse stock split is a potentially effective means to increase the per share market price of our common stock and thus enable us to
regain compliance with the Minimum Price Standard. However, there are a number of risks and potential disadvantages associated with a reverse stock split, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Board cannot predict the effect of a reverse stock split upon the market price for shares of our common
stock, and the success of similar reverse stock splits for companies in like circumstances has varied. Some investors may have a negative view of a reverse stock split. Recently, the market price of our common stock has declined substantially, and
the equity markets have experienced and continue to experience substantial volatility due to, among other factors, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic and the war in Ukraine. The principal purpose of a reverse stock
split would be to increase the trading price of our common stock to meet the minimum stock price standards of the Nasdaq Global Select Market. However, the effect of a reverse stock split on the market price of our common stock cannot be predicted
with any certainty, and we cannot assure you that a reverse stock split will accomplish this objective for any meaningful period of time, or at all. Even if a reverse stock split has a positive effect on the market price for shares of our common
stock, performance of our business and financial results, general economic conditions and the market perception of our business, and other adverse factors which may not be in our control could lead to a decrease in the price of our common stock
following a reverse stock split. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Although the Board believes that a higher stock price may help generate the interest of new investors, the
reverse stock split may not result in a <FONT STYLE="white-space:nowrap">per-share</FONT> price that will successfully attract certain types of investors and such resulting share price may not satisfy the investing guidelines of institutional
investors or investment funds. Further, other factors, such as our financial results, market conditions and the market perception of our business, may adversely affect the interest of new investors in the shares of our common stock. As a result, the
trading liquidity of the shares of our common stock may not improve as a result of a reverse stock split and there can be no assurance that a reverse stock split, if completed, will result in the intended benefits described above.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if a reverse stock split does result in an increased market price per share of our common stock, the market
price per share following a reverse stock split may not increase in proportion to the reduction of the number of shares of our common stock outstanding before the implementation of a reverse stock split. Accordingly, even with an increased market
price per share, the total market capitalization of shares of our common stock after a reverse stock split could be lower than the total market capitalization before a reverse stock split. Also, even if there is an initial increase in the market
price per share of our common stock after a reverse stock split, the market price many not remain at that level due to factors described in this proposal or other factors, including the risks described in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as updated in reports we subsequently file with the SEC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If a reverse stock split is implemented and the market price of shares of our common stock then declines, the
percentage decline may be greater than would occur in the absence of a reverse stock split due to decreased liquidity in the market for our common stock. If the market price of shares of our common stock declines after a reverse stock split, the
percentage decline as an absolute number and as a percentage of our overall </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
market capitalization may be greater than would occur in the absence of a reverse stock split. Accordingly, the total market capitalization of our common stock following a reverse stock split
could be lower than the total market capitalization before a reverse stock split. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures for and Effects of Implementing a
Reverse Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Procedures </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reverse stock
split would become effective upon the filing of the Second Amended and Restated Charter with the Secretary of State of the State of Delaware. The exact timing of the filing of the Second Amended and Restated Charter, if it is filed, would be
determined by our Board based on its evaluation as to when such action would be in our and our stockholders&#146; best interests. In addition, our Board reserves the right, notwithstanding stockholder approval and without further action by the
stockholders, to elect not to proceed with a reverse stock split if, at any time prior to filing the Second Amended and Restated Charter, our Board determines in its sole discretion that it is not in our best interest and the best interest of our
stockholders to proceed with a reverse stock split. If the Second Amended and Restated Charter has not been filed with the Secretary of State of the State of Delaware within one year after the conclusion of the Annual Meeting, our Board will abandon
the reverse stock split or seek stockholder reauthorization of a reverse stock split. Following are descriptions of how a reverse stock split would be implemented for beneficial holders, registered book entry holders, and certificated holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Holders</I>. Upon the implementation of a reverse stock split, we intend to treat shares held by stockholders through a broker, bank or other
agent in the same manner as registered stockholders whose shares are registered in their names. Brokers, banks and other agents would be instructed to effect a reverse stock split for their beneficial holders holding our common stock in street name.
However, these brokers, banks and other agents may have different procedures than registered stockholders for processing a reverse stock split. Stockholders who hold shares of our common stock with a broker, bank or other agent and who have any
questions in this regard are strongly encouraged to contact their brokers, banks or other agents for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registered &#147;Book
Entry&#148; Holders</I>. Certain of our registered holders of common stock may hold some or all of their shares electronically in book-entry form with AST. These stockholders do not have stock certificates evidencing their ownership of the common
stock. They are, however, provided with a statement reflecting the number of shares registered in their accounts. If a reverse stock split is implemented, stockholders who hold shares electronically in book-entry form with AST would not need to take
action (the exchange will be automatic) to receive whole shares of post-reverse split common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certificated Holders</I>. If a reverse stock split
is implemented, stockholders holding shares of our common stock in certificated form would be sent a letter of transmittal by AST following the reverse stock split. The letter of transmittal would contain instructions on how a stockholder should
surrender their certificate(s) representing shares of our common stock (the &#147;Old Certificates&#148;) to AST in exchange for certificates representing the appropriate number of whole shares of post-reverse split common stock (the &#147;New
Certificates&#148;). No New Certificates would be issued to a stockholder until such stockholder delivered all Old Certificates, together with a properly completed and executed letter of transmittal, to AST. No stockholder would be required to pay a
transfer or other fee to exchange their Old Certificates. Stockholders would then receive one or more New Certificate(s) representing the number of whole shares of common stock they are entitled to as a result of a reverse stock split, subject to
the treatment of fractional shares described below. Until surrendered, we would deem outstanding Old Certificates held by stockholders to be cancelled and only to represent the number of whole shares of post-reverse split common stock to which these
stockholders are entitled and the right to receive cash in lieu of any fractional shares as described below. Any Old Certificates submitted for exchange, whether because of a sale, transfer or other disposition of stock, would automatically be
exchanged for New Certificates. If an Old Certificate has a restrictive legend on it, the New Certificate would be issued with the same restrictive legends that are on the Old Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a reverse stock split is implemented, we expect that AST would act as the exchange agent for purposes of
implementing the exchange of stock certificates. No service charges would be payable by holders of shares of common stock in connection with the exchange of certificates. We would bear all of such expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STOCKHOLDERS SHOULD <U>NOT</U> DESTROY ANY STOCK CERTIFICATES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STOCKHOLDERS SHOULD NOT SUBMIT STOCK CERTIFICATES FOR EXCHANGE UNLESS AND UNTIL REQUESTED TO DO SO, AND THEN STOCK CERTIFICATES SHOULD BE SUBMITTED ONLY IN
THE MANNER INSTRUCTED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STOCK CERTIFICATES SHOULD <U>NOT</U> BE SUBMITTED DIRECTLY TO THE COMPANY. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Outstanding Shares of Common Stock </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the
ratio for a reverse stock split determined by our Board, a minimum of 5 and a maximum of 15&nbsp;shares of existing common stock would be combined into one new share of common stock. Based on 215,950,561 shares of common stock issued and outstanding
as of April 22, 2022, immediately following a reverse stock split we would have approximately 43,190,112 shares of common stock issued and outstanding (without giving effect to the treatment of fractional shares) if the ratio for a reverse stock
split is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-5,</FONT></FONT> and 14,396,704 shares of common stock issued and outstanding (without giving effect to the treatment of fractional shares) if the ratio for a reverse
stock split is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15.</FONT></FONT> Any other ratio selected within such range would result in a number of shares of common stock issued and outstanding following the reverse stock
split between approximately 35,991,760 and 15,425,040 shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual number of shares issued after giving effect to a reverse stock split, if
implemented, would depend on the reverse stock split ratio that is ultimately selected by our Board. A reverse stock split would affect all holders of our common stock uniformly and would not affect any stockholder&#146;s percentage ownership
interest in the Company, except that, as described below in the section titled &#147;<I>Fractional Shares</I>,&#148; stockholders of record otherwise entitled to a fractional share, as a result of a reverse stock split, would instead receive an
amount in cash. In addition, a reverse stock split would not affect any stockholder&#146;s proportionate voting power, except for adjustments that may result from the treatment of fractional shares as described below. A reverse stock split may
result in some stockholders owning &#147;odd lots&#148; of less than 100 shares of common stock. Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than
the costs of transactions in &#147;round lots&#148; of even multiples of 100 shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reverse stock split would result in a proportionate reduction in the number of authorized shares of our common stock under the Charter at the time a reverse
stock split is effected. A reverse stock split would not have any effect on the number of authorized shares of preferred stock, which would remain at 30,000,000 shares of preferred stock, par value $0.001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, if the Authorized Stock Increase Proposal described below is approved by our stockholders and implemented by our Board, in its discretion,
through the filing of a certificate of amendment to our Charter prior to the implementation of the reverse stock split, the reverse stock split would have the effect of reducing the increased number of authorized shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the effective time of a reverse stock split, any authorized shares of our common stock, if and when issued, would be part of our existing class of
our common stock and would have the same rights and privileges as the shares of our common stock currently outstanding. Our stockholders do not, as such, have preemptive rights or preferential rights to purchase additional shares of our common stock
that we may issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fractional Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We would not issue fractional shares in connection with a reverse stock split. Therefore, we would not issue certificates representing fractional shares
resulting from the reverse stock split because the stockholder owns a number of shares of our common stock not evenly divisible by the ratio. Stockholders would receive, in lieu of any fractional share, an amount in cash (without interest) equal to
such fraction multiplied by the closing sales price of our common stock as reported on the Nasdaq Global Select Market on the trading day immediately preceding the effective date of the Second Amended and Restated Charter. The ownership of a
fractional share interest following a reverse stock split would not give the holder any voting, dividend or other rights, except to receive payment as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our Board elects to implement the proposed reverse stock split, stockholders owning, prior to the reverse stock split, less than the number of whole shares
of common stock that will be combined into one share of common stock in the reverse stock split would no longer be stockholders. The exact number by which the number of holders of our common stock would be reduced will depend on the specific reverse
stock split ratio adopted by the Board and the number of stockholders that hold less than that ratio as of the effective date of the reverse stock split. As of the Record Date, there were approximately 246 holders of record of our common stock, of
which eight held fewer than 15 shares of common stock. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effects on Equity Compensation Plans and Awards, Convertible Securities and Warrants
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a reverse stock split is implemented, proportionate adjustments would generally be required to be made with regard to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the per share exercise price of, and the number of shares issuable upon exercise of, outstanding stock options
issued under our equity compensation plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares deliverable upon vesting and settlement of outstanding restricted stock and restricted stock
unit awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares reserved for issuance under our equity compensation plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the per share conversion price, and the number of shares issuable upon conversion of, outstanding convertible
securities entitling the holders to purchase or convert into, or otherwise acquire shares of our common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strike price and the number of shares issuable upon exercise of warrants entitling the holders to receive
shares of our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of options, convertible securities or other rights to acquire shares of our common stock, these
adjustments would result in approximately the same aggregate price required under such options, convertible securities or other rights upon exercise, conversion, or settlement, and approximately the same value of shares of common stock being
delivered upon such exercise, conversion, or settlement, immediately following a reverse stock split as was the case immediately preceding such reverse stock split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of our outstanding warrants, the number of shares issuable under the warrants will be proportionately decreased and the exercise price of each
warrant proportionately increased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock issuable upon exercise or vesting of outstanding equity awards, options and
warrants and the exercise or purchase price related thereto, if any, would be equitably adjusted in accordance with the terms of our 2012 Equity Incentive Plan and our 2020 Equity Incentive Plan, as applicable, or such stock option grants or
warrants, as the case may be, which may include rounding the number of shares of common stock issuable down to the nearest whole share or the payment of cash for fractional shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exchange Act Registration; Nasdaq Listing; CUSIP </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is currently registered under Section&nbsp;12(b) of the Exchange Act, and we are subject to periodic reporting and other requirements of the
Exchange Act. The implementation of a reverse stock split would not affect the registration of our common stock under the Exchange Act or our reporting or other requirements under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently listed on the Nasdaq Global Select Market under the trading symbol &#147;TCRT.&#148; If our common stock remains listed on the Nasdaq Global
Select Market up to the time of a reverse stock split, then immediately following the reverse stock split our common stock would continue to be listed on the Nasdaq Global Select Market under the TCRT symbol, although it is likely that Nasdaq would
add the letter &#147;D&#148; to the end of the trading symbol for a period of 20 trading days after the effective date of the reverse stock split to indicate that the reverse stock split had occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following a reverse stock split, our common stock would have a new Committee on Uniform Securities Identification Procedures (&#147;CUSIP&#148;) number, which
is a number used to identify our equity securities, and stock certificates with the older CUSIP number will need to be exchanged for stock certificates with the new CUSIP number by following the procedures described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting Matters </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The filing of the Second Amended and
Restated Charter and implementation of a reverse stock split would not affect the par value of our common stock per share, which will remain $0.001. As a result, the stated capital attributable to common stock and the additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital account on our balance sheet would not change due to a reverse stock split. However, the stated capital attributable specifically to our common stock would be reduced proportionally depending on the
reverse stock split ratio, and the additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital account would be credited with the amount by which the stated capital would be reduced. Also, if a reverse stock split is implemented, reported per
share net income or loss would be higher because there will be fewer shares of our common stock outstanding. We do not anticipate that any other accounting consequences would arise as a result of a reverse stock split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stockholders are not entitled to
dissenters&#146; or appraisal rights under the Delaware General Corporation Law with respect to any of the proposals being voted on at the Annual Meeting and described in this proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Federal Income Tax Consequences of a Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following describes certain material U.S. federal income tax considerations of a reverse stock split expected to apply generally to U.S. Holders (as
defined below) of our common stock. This description is based upon current provisions of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), existing Treasury Regulations under the Code and current administrative rulings and court
decisions, all of which are subject to change or different interpretation. Any change, which may or may not be retroactive, could alter the tax consequences to us or our stockholders as described in this section. No ruling from the U.S. Internal
Revenue Service has been or will be requested in connection with a reverse stock split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No attempt has been made to comment on all U.S. federal income
tax consequences of a reverse stock split that may be relevant to particular U.S. Holders, including holders: (i)&nbsp;that are subject to special tax rules such as dealers, brokers and traders in securities, mutual funds, regulated investment
companies, real estate investment trusts, insurance companies, banks or other financial institutions or <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities; (ii)&nbsp;that hold their shares as a hedge or as part of a hedging, straddle,
&#147;conversion transaction,&#148; &#147;synthetic security,&#148; integrated investment or any risk reduction strategy; (iii)&nbsp;that are partnerships, S corporations, or other pass-through entities or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investors in such pass-through entities; or (iv)&nbsp;that do not hold their shares as capital assets for U.S. federal income tax purposes (generally, property held for investment within the
meaning of Section&nbsp;1221 of the Code). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the following discussion does not address the tax consequences of a reverse stock split
under state, local and foreign tax laws. The discussion assumes that for U.S. federal income tax purposes, a reverse stock split will not be integrated, or otherwise treated as part of a unified transaction, with any other transaction. Furthermore,
the following discussion does not address the tax consequences of transactions effectuated before, after or at the same time as a reverse stock split, whether or not they are in connection with a reverse stock split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. Holder&#148; means a beneficial owner of our common stock that is: (i)&nbsp;an individual who is a citizen or
resident of the U.S.; (ii) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the U.S. or under the laws of the U.S. or any subdivision thereof; (iii)&nbsp;an estate the income of
which is includible in gross income for U.S. federal income tax purposes regardless of its source; or (iv)&nbsp;a trust (other than a grantor trust) if (A)&nbsp;a court within the U.S. is able to exercise primary supervision over the administration
of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust or (B)&nbsp;it has a valid election in effect under applicable U.S.&nbsp;Treasury regulations to be treated as a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HOLDERS OF OUR COMMON STOCK ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF A REVERSE STOCK SPLIT IN
LIGHT OF THEIR PERSONAL CIRCUMSTANCES AND THE CONSEQUENCES OF A REVERSE STOCK SPLIT UNDER OTHER FEDERAL, STATE, LOCAL AND FOREIGN TAX LAWS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on
the assumptions above, a reverse stock split will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> recapitalization for U.S. federal income tax purposes. Accordingly, if a reverse stock split is adopted: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A U.S. Holder that receives a reduced number of shares of our common stock pursuant to such reverse stock split
will not recognize any gain or loss, except with respect to the amount of cash (if any) received in respect of a fractional share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A U.S. Holder&#146;s aggregate tax basis in such holder&#146;s shares of common stock received in such reverse
stock split will equal the aggregate tax basis of such stockholder&#146;s shares of common stock held immediately before such reverse stock split, but not including the aggregate tax basis of shares surrendered in exchange for cash received in
respect of a fractional share (if any); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A U.S. Holder&#146;s holding period of shares of our common stock received in such reverse stock split will
include the holding period of the <FONT STYLE="white-space:nowrap">pre-reverse</FONT> stock split shares exchanged therefor; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A U.S. Holder that receives cash in lieu of a fractional share of common stock generally will recognize gain or
loss equal to the difference (if any) between the amount of cash received and the U.S. Holder&#146;s tax basis in the shares of common stock surrendered therefor. Such capital gain or loss generally will be long-term capital gain or loss if the U.S.
Holder&#146;s holding period for the common stock surrendered in the reverse stock split exceeds one year at the effective time of the reverse stock split. Long-term capital gains of non-corporate U.S. Holders are generally subject to preferential
tax rates. There are limitations on the deductibility of capital losses under the Code. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the tax basis and
holding period of shares of our common stock received in a reverse stock split, U.S. Holders that acquired different blocks of shares our common stock at different times for different prices must calculate their basis and holding periods separately
for each identifiable block of such stock exchanged in the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our stockholders may be required to attach a statement to their tax returns for the year in which
a reverse stock split is consummated that contains the information listed in applicable Treasury Regulations. All of our stockholders are advised to consult their own tax advisors with respect to the applicable reporting requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a
majority of the shares issued and outstanding and entitled to vote at the Annual Meeting is required to approve this proposal. Abstentions will be counted toward the vote total for Proposal 4 and will have the same effect as &#147;AGAINST&#148;
votes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of this proposal is not conditioned on the approval or disapproval of Authorized Stock Increase Proposal. However, should both this
proposal and the Authorized Stock Increase Proposal be approved by our stockholders, the Board would, in its discretion, choose which proposal(s) to implement, subject to its discretion to determine that neither proposal is in the best interest of
the Company or its stockholders. In the event that this proposal is approved by the stockholders and the Authorized Stock Increase Proposal is not, the Board currently intends to nonetheless implement this proposal if, in its sole discretion, it
deems it to be a necessary step to regain compliance with the Minimum Price Standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Board recommends that you vote
&#147;FOR&#148; the proposal to approve the Second Amended and Restated Charter to effect a reverse stock split, at our Board&#146;s discretion. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_7"></A>Proposal 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Approval of the Certificate of Amendment to our Charter to Increase our Authorized Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 15, 2022, our Board unanimously
approved and recommended that our stockholders approve an amendment to our Charter to, at the discretion of the Board, increase the authorized shares of our common stock from 350,000,000 shares of common stock to 420,000,000 shares of common stock
within one year after the conclusion of the Annual Meeting, representing an increase of 20%. The number of shares of preferred stock authorized for issuance will remain the same, at 30,000,000 shares of preferred stock, and will not be impacted by
the increase in the authorized shares of capital stock or common stock, if approved by our stockholders. As of April 22, 2022, there were 215,950,561 shares of common stock issued and outstanding, no shares of common stock held as treasury stock, no
shares of preferred stock issued or outstanding and 33,981,996 shares of our common stock reserved for issuance in connection with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise of outstanding warrants to purchase 22,922,342 shares of common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise and/or vesting of outstanding awards in the aggregate amount of 10,969,654 shares of common stock
under our 2012 Equity Incentive Plan and our 2020 Equity Incentive Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the granting of future awards in the aggregate amount of 13,030,732 shares of common stock under our 2020 Equity
Incentive Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April 22, 2022, 87,126,711 authorized shares of common stock remained available for future issuance. Accordingly,
our Board unanimously determined it was advisable and in the best interest of the stockholders and the Company to amend our Charter to increase the number of authorized shares of common stock (the &#147;Share Increase&#148;) and directed that it be
submitted for approval by the stockholders at the Annual Meeting in light of the time and expense that would otherwise be required to convene a special meeting for consideration of the proposed amendment at a later time. The form of the proposed
Share Increase amendment is attached to this Proxy Statement as Annex B. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendment would increase the number of shares of common stock the
Company is authorized to issue by 70,000,000 shares of common stock, or 20%. Thus, if this proposal is approved by our stockholders, our total authorized capital stock would increase from 380,000,000 to 450,000,000, with the number of authorized
shares of our preferred stock remaining unchanged at 30,000,000. The additional shares of common stock proposed to be authorized under this proposal would have rights identical to our currently outstanding shares of common stock. This description is
qualified in its entirety by reference to the complete text of the certificate of amendment to our Charter, which is attached as Annex B to this proxy statement and incorporated into this proposal by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for Increasing the Number of Authorized Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes that the increase in our authorized shares of common stock will provide us with the ability to support our future anticipated growth and
would provide us with greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings. The availability of additional shares of common stock would permit us to undertake certain of
the foregoing actions without the delay and expense associate with holding a special meeting of our stockholders to obtain stockholder approval each time such an opportunity arises. Unless and until we can generate sufficient revenues, we expect to
finance our cash needs in whole or in part through equity offerings. If the authorization of the Share Increase is postponed until the foregoing specific needs arise, the delay and expense incident to obtaining stockholder approval at that time
could impair our ability to meet our objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Possible Effects of Increasing the Number of Authorized Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the conversion or exercise of outstanding convertible or exercisable securities (which conversion or exercise would be at the option of the
respective holders), we currently have no plans, proposals, arrangements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or understandings to issue any authorized but unissued shares of our common stock. However, these additional authorized shares could be used in the future for various purposes without further
stockholder approval, except as such approval may be required in particular cases by our organizational documents, applicable law or the rules of any stock exchange or other system on which our securities may then be listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, authorized but unissued shares of common stock may enable our Board to render more difficult or to discourage an attempt to
obtain control of the Company. One of the consequences of such an action would be to protect the continuity of or entrench our management. This may adversely affect the market price of our common stock. If, in the due exercise of its fiduciary
obligations, for example, our Board were to determine that a takeover proposal were not in the best interest of the Company, such shares could be issued by the Board without stockholder approval in one or more private placements or other
transactions that might prevent or render more difficult or make more costly the completion of any attempted takeover transactions by diluting voting or other rights of the proposed acquirer or insurgent stockholder group, by creating a substantial
voting block in institutional or other hands that might support the position of the incumbent Board, by effecting an acquisition that might complicate or preclude the takeover, or otherwise. We have no current intention to issue shares for
anti-takeover purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to approve this Authorized Stock Increase Proposal could have adverse results for, and effects on, the Company. Without a
reasonable amount of authorized shares available to us for issuance, we may not have the ability to raise additional capital, establish strategic relationships with other companies or expand our business or product lines through acquisition. In
addition, if we effect a reverse stock split as described in Proposal 4, we will have a more limited number of authorized shares available for issuance which could further exacerbate the problems described above. Furthermore, our future success
depends upon our ability to attract, retain and motivate highly-skilled scientific, commercial and managerial employees, and if this proposal is not approved by our stockholders, the lack of sufficient unissued and unreserved authorized shares of
common stock to provide future equity incentive opportunities could adversely impact our ability to achieve these goals. Furthermore, given the decline in the price of our common stock, we may need additional shares of authorized common stock to
satisfy our capital needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effectiveness of Amendment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Share Increase, if approved by our stockholders, would become effective upon the filing and effectiveness of the certificate of amendment, the form of
which is attached hereto as Annex B, with the Secretary of State of the State of Delaware. Such filing would take place only in the event the Board determines, following approval by our stockholders, that it remains in the best interest of the
Company and its stockholders to effect the Share Increase. The exact timing of the filing of the amendment to effect the Share Increase, however, will be determined by our Board based on its evaluation as to when such action will be the most
advantageous to the Company and our stockholders; provided, however, that the Share Increase amendment must be effective within one year after the conclusion of the Annual Meeting. In addition, our Board reserves the right, notwithstanding
stockholder approval and without further action by the stockholders, to elect not to proceed with the Share Increase amendment if, at any time prior to the filing of the Share Increase amendment with the Secretary of State of the State of Delaware,
our Board, in its sole discretion, determines that it is no longer in our Company&#146;s best interest or the best interest of our stockholders to proceed with the Share Increase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bifurcation of Proposals 4 and 5 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of this
proposal is not conditioned on the approval of the Reverse Stock Split Proposal. To the extent that only one of either of these proposals is approved by our stockholders, only the amendment to our Charter to affect the proposal that was approved by
our stockholders may be filed with the Secretary of State of the State of Delaware. To the extent that both the Authorized Stock Increase Proposal and Reverse Stock Split Proposal are approved by our stockholders, the amendment to our Charter to
effect the Share Increase is expected, subject the Board&#146;s discretion, to be filed in advance of the Second Amended and Restated Charter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding approval of these proposals by our stockholders, our Board has reserved its right to abandon, at any time, either or both of the proposed amendments if, in its sole discretion, it
determines doing so is in the best interest of the Company and our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares issued and outstanding and entitled to vote at the Annual Meeting is required to approve this
proposal. Abstentions will be counted toward the vote total for Proposal 5 and will have the same effect as &#147;AGAINST&#148; votes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of
this proposal is not conditioned on the approval or disapproval of Reverse Stock Split Proposal. However, should both this proposal and the Reverse Stock Split Proposal be approved by our stockholders, the Board would, in its discretion, choose
which proposal(s) to implement, subject to its discretion to determine that neither proposal is in the best interest of the Company or its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Board recommends that you vote &#147;FOR&#148; the proposal to approve the amendment to implement the Share Increase, at our
Board&#146;s discretion. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_8"></A>Proposal 6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adjournment of Annual Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
asking you to vote to approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve either the Reverse Stock Split Proposal or the
Authorized Stock Increase Proposal at the time of the Annual Meeting or if we do not have a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our stockholders approve this Adjournment
Proposal, we could adjourn the Annual Meeting and any reconvened session of the Annual Meeting and use the additional time to solicit additional proxies, including proxies from stockholders that have previously returned properly executed proxies
voting against the approval of the Reverse Stock Split Proposal or the Authorized Stock Increase Proposal. Among other things, approval of the Adjournment Proposal could mean that, even if we had received proxies representing a sufficient number of
votes against the approval of the Reverse Stock Split Proposal or the Authorized Stock Increase Proposal such that the proposal to approve any such proposal would be defeated, we could adjourn the Annual Meeting without a vote on the approval of
such proposal and seek to convince the holders of those shares to change their votes to votes in favor of approval of such proposal. Additionally, we may seek to adjourn the Annual Meeting if a quorum is not present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes that it is in the best interest of the Company and our stockholders to be able to adjourn the Annual Meeting to a later date or dates if
necessary or appropriate for the purpose of soliciting additional proxies in respect of the approval of the Reverse Stock Split Proposal or the Authorized Stock Increase Proposal if there are insufficient votes to approve either or both at the time
of the Annual Meeting or in the absence of a quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares of common stock present in person or represented by proxy and entitled to vote at the Annual
Meeting is required for approval of the Adjournment Proposal. Abstentions will be counted toward the vote total for Proposal 6 and will have the same effect as &#147;AGAINST&#148; votes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Board recommends that you vote &#147;FOR&#148; approval of the adjournment of the Annual Meeting, if necessary, to solicit additional
proxies if there are insufficient votes at the time of the Annual Meeting to approve either the Reverse Stock Split Proposal or the Authorized Stock Increase Proposal. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_9"></A>STOCKHOLDER PROPOSALS FOR THE 2023 ANNUAL MEETING OF
STOCKHOLDERS </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a proposal to be considered for inclusion in our proxy materials for presentation at the 2023 annual meeting of stockholders
pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act, the proposal must be received by our Secretary at our principal executive offices at 8030 El Rio Street, Houston, TX 77054, by no later than December 28, 2022,
unless the date of 2023 annual meeting of stockholders is changed by more than 30 days from the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of this year&#146;s annual meeting, in which case the deadline will be a reasonable time
before we begin to distribute the proxy materials for the 2023 annual meeting of stockholders. Due to the complexity of the respective rights of the stockholders and us in this area, any stockholder desiring to propose such an action is advised to
consult with his or her legal counsel with respect to such rights. We suggest that any such proposal be submitted to us by certified mail, return receipt requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule <FONT STYLE="white-space:nowrap">14a-4</FONT> under the Exchange Act governs our use of our discretionary proxy voting authority with respect to a
stockholder proposal that the stockholder has not sought to include in our proxy statement. Rule <FONT STYLE="white-space:nowrap">14a-4</FONT> provides that if a proponent of a proposal fails to notify us at least 45 days prior to the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the day of mailing of the prior year&#146;s proxy statement, management proxyholders will be allowed to use their discretionary voting authority as to whether the proposal is raised at the
annual meeting, without any discussion of the matter. If a stockholder wishes to bring a matter before the stockholders at the 2023 annual meeting of stockholders but does not notify us before March 13, 2023 (or a reasonable time before we begin to
distribute the proxy materials for the 2023 annual meeting of stockholders if the date of the 2023 annual meeting of stockholders is changed by more than 30 days from the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of this
year&#146;s annual meeting), for all proxies we receive, the management proxyholders will have discretionary authority to vote on the matter, including discretionary authority to vote in opposition to the stockholder&#146;s proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recommendations for candidates to be considered for election to the Board at the 2023 annual meeting of stockholders may be submitted to the corporate
governance and nominating committee by our stockholders. In order to make such a recommendation, a stockholder must submit the recommendation in writing to the Chairperson of the corporate governance and nominating committee, in care of our
Secretary at our principal executive offices at 8030 El Rio Street, Houston, TX 77054, at least 120 days prior to the mailing date of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the previous year&#146;s annual meeting proxy
statement. To enable the corporate governance and nominating committee to evaluate the candidate&#146;s qualifications, stockholder recommendations must include the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The name and address of the nominating stockholder and of the director candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A representation that the nominating stockholder is a holder of record of ours entitled to vote at the current
year&#146;s annual meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A description of any arrangements or understandings between the nominating stockholder and the director candidate
or candidates being recommended pursuant to which the nomination or nominations are to be made by the stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A resume detailing the educational, professional and other information necessary to determine if the nominee is
qualified to become a director of ours; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Such other information regarding each nominee proposed by such stockholder as would have been required to be
included in a proxy statement filed pursuant to the proxy rules of the SEC had each nominee been nominated by the Board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The consent of each nominee to serve as a director of ours if so elected. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_10"></A>CURRENT DIRECTORS, DIRECTOR NOMINEES AND EXECUTIVE OFFICERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below are the names and
certain information about each of our directors as of April&nbsp;14, 2022. The information presented includes each director&#146;s age, principal occupation and business experience for the past five years and the names of other public companies of
which he or she has served as a director during the past five years. In addition, the table contains information about the specific and particular experience, qualifications, attributes or skills of each current director and each nominee for
director at the Annual Meeting that led the corporate governance and nominating committee to believe that such current director was appropriate for nomination at a previous annual meeting of stockholders or otherwise and, in the case of each nominee
for director at the Annual Meeting, that such nominee should serve on the Board following election at the Annual Meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Positions and Offices Held</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Bowden M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Huang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Postma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaime Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holger Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christopher&nbsp;Bowden,&nbsp;M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bowden, an oncology drug development executive with more than 20 years of leadership experience including the approval of several
cancer medicines, has served as a member of our Board since October 2019. He was the Chief Medical Officer of Agios Pharmaceuticals from May 2014 to September 2021. Previously, Dr.&nbsp;Bowden was Vice President Product Development Oncology, at
Genentech for eight years. From 2003 to 2006, he was the Executive Director for EMEA regions for Bristol-Myers Squibb. Earlier, Dr.&nbsp;Bowden held positions of increasing responsibility in oncology clinical development, at Pharmacia Corporation
and Janssen Pharmaceutical. Prior to industry, Dr.&nbsp;Bowden was on the oncology faculty at the University of Virginia Health Science Center. From September 2017 to October 2020, Dr.&nbsp;Bowden served as a member of the board of directors of
miRagen Therapeutics, Inc., a publicly traded biopharmaceutical company discovering and developing proprietary <FONT STYLE="white-space:nowrap">RNA-targeted</FONT> therapies with a specific focus on microRNAs. Dr.&nbsp;Bowden received his M.D. from
Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute
Medicine Branch. Dr.&nbsp;Bowden is board certified in internal medicine and medical oncology.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes that Dr.&nbsp;Bowden&#146;s extensive background in drug development and leadership experience at several leading life science and
pharmaceutical companies qualifies him to serve on the Board.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kevin S. Boyle, Sr. <BR><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kevin S. Boyle, Sr., was appointed our Chief Executive Officer and a member of our Board in August 2021. Mr.&nbsp;Boyle has over 20 years of experience in leading businesses in competitive and transformative situations and has a
strong track record of delivering shareholder value. He is also an accomplished capital markets professional with strong banking relationships cultivated by raising over</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$2.0&nbsp;billion in equity and debt capital over his career. Prior to joining the Company, Mr.&nbsp;Boyle served in various roles at Kuur
Therapeutics, Inc. (formerly known as Cell Medica Ltd.). Mr.&nbsp;Boyle first served as Kuur&#146;s chief financial officer from February 2018 until January 2020. From January 2020 until May 2021, Mr.&nbsp;Boyle served as Kuur&#146;s Chief Executive
Officer where he led the company through a successful transformation, culminating in a $185&nbsp;million acquisition in May 2021 by Athenex, Inc. (NASDAQ: ATNX). Following the acquisition, Athenex engaged Mr.&nbsp;Boyle as a consultant to assist in
the integration of Kuur. Prior to joining Kuur, Mr.&nbsp;Boyle served as the chief financial officer of FloWorks International, LLC, Sigma3 Integrated Reservoir Solutions, Recover Care, and SPT Inc. Mr.&nbsp;Boyle graduated with a B.S. from Carnegie
Mellon University and a J.D. from the University of Pennsylvania Carey Law School.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes that Mr.&nbsp;Boyle&#146;s prior experience as a Chief Executive Officer in the life sciences industry and significant fundraising
experience qualifies him to serve on the Board.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James Huang <BR><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Huang has served as a member of our Board since July 2020. He served as Chair from January 2021 until February 2021 and Executive
Chair from February 2021 to March&nbsp;29, 2022, when he returned to his role as Chair. Mr.&nbsp;Huang joined Kleiner Perkins Caufield&nbsp;&amp; Byers China, or KPCB China, as a managing partner in 2011 and focuses on the firm&#146;s life sciences
practice. Prior to joining KPCB China, Mr.&nbsp;Huang was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Before joining Vivo in 2007, Mr.&nbsp;Huang was president of Anesiva, a
biopharmaceutical company focused on pain-management treatments. During his <FONT STYLE="white-space:nowrap">20-year</FONT> career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and
R&amp;D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson&nbsp;&amp; Johnson). Mr.&nbsp;Huang is also founding and managing partner of Panacea Venture, a global venture fund focusing
on investments in innovative and transformative early and growth stage healthcare and life science companies. Mr.&nbsp;Huang is Chairman of the board at Kindstar Global (Beijing) Technology, Inc., Windtree Therapeutics, Inc., JHL Biotech, Inc.,
Tactiva Therapeutics, LLC, and Chime Biologics Limited and Director at CASI Pharmaceuticals Inc. and XW Laboratories Inc. Mr.&nbsp;Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from
the University of California, Berkeley.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes that
Mr.&nbsp;Huang&#146;s extensive experience in life science investments and serving on the boards of directors of a number of life sciences and pharmaceutical companies qualifies him to serve on the Board.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Robert W. Postma <BR><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Postma has served as a member of our Board since February 2021. Mr.&nbsp;Postma has also served as the president of WaterMill
Asset Management Corp. (&#147;WaterMill&#148;), a company which he founded in July 1999. WaterMill actively trades in municipal bonds and equities, using the funds of Mr.&nbsp;Postma. Mr.&nbsp;Postma has over 44 years of trading experience and
received a B.A. in Business and Economics from Lafayette College.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes
that Mr.&nbsp;Postma&#146;s management and trading experience allows Mr.&nbsp;Postma to provide financial guidance to us and qualifies him to serve on the Board.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mary Thistle <BR><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Thistle has served as a member of our Board since November 2020. Ms.&nbsp;Thistle has served as Special Advisor to the
Bill&nbsp;&amp; Melinda Gates Medical Research Institute, a <FONT STYLE="white-space:nowrap">non-profit</FONT> biotech organization, since October 2020, and was its Chief of Staff from January 2018 until October 2020. Prior to then, she held senior
leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including serving as its Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, Inc., she spent
six years at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, where she held various leadership positions, including serving as its Senior Vice President, Business Development from 2014 to 2015, Vice President, Business Development from
2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to then, she held various positions at ViaCell, Inc. and PerkinElmer Inc. Ms.&nbsp;Thistle serves as a member of the boards of directors of Homology Medicines, Inc.
(NASDAQ: FIXX), Entrada Therapeutics, Inc. (NASDAQ: TRDA) and the board of directors of private companies, Enterome SA and Cocoon Biotech Inc. Ms.&nbsp;Thistle holds a B.S. in Accounting from the University of Massachusetts, Boston.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes that Ms.&nbsp;Thistle&#146;s perspective, financial expertise,
business development and leadership experience at several biopharmaceutical companies provides her with the qualifications and skills to serve on the Board.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jaime Vieser <BR><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Vieser has served as a member of our Board since December 2020. Mr.&nbsp;Vieser currently manages Brushwood LLC, a private
investment firm. From 2010-2017, he was a Managing Partner and <FONT STYLE="white-space:nowrap">co-principal</FONT> of Castle Hill Asset Management LLC, a $2.7&nbsp;billion asset manager and hedge fund focusing on high yield and distressed debt.
Prior to founding Castle Hill, Mr.&nbsp;Vieser was responsible for Deutsche Bank&#146;s High Yield Sales and Trading Group in London from 1998 to 2008. Mr.&nbsp;Vieser originally joined Bankers Trust in New York in 1994 and worked in the Investment
Banking/Leveraged Finance division. Mr.&nbsp;Vieser graduated from the University of Michigan with a degree in Economics and from the Cox School of Business at Southern Methodist University with a Master&#146;s in Business Administration.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes that Mr.&nbsp;Vieser&#146;s financial expertise and investment
experience allows Mr.&nbsp;Vieser to provide business to us and qualifies him to serve on the Board.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holger Weis <BR><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mr.&nbsp;Weis has served as a member of our Board since December 2020. Mr.&nbsp;Weis continues to serve as the principal of Weis Advisors, Inc., a company that provides consulting services to life science companies, since
founding the company in April 2018. Prior to that, he served in a number of roles at DemeRx, Inc., a clinical stage pharmaceutical company developing <FONT STYLE="white-space:nowrap">non-addictive</FONT> treatments for drug addiction, including
serving as Chief Operating Officer and Chief Financial Officer from December 2011 to July 2017, and also as President from September 2014 to July 2017, and as a Consultant from July 2017 to April 2018. Earlier in his career, Mr.&nbsp;Weis served as
the Chief Financial Officer of EnSA Holdings, LLC, a company that focuses on environmentally sustainable agriculture techniques and technologies for the production of rice, from August 2010 to November 2011. From 2006 to 2010, he served as the Vice
President&nbsp;&amp; Chief Financial Officer, Secretary and Treasurer of NovaVision, Inc., a therapeutic and diagnostic vision restoration company. Prior to that, he served as the Chief Financial Officer&nbsp;&amp; Treasurer of GMP Companies, Inc.,
a company that develops and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Mr.&nbsp;Weis served as a Senior Manager at Ernst&nbsp;&amp; Young, a multinational professional services company, from 1986 to
2000. Mr.&nbsp;Weis has <FONT STYLE="white-space:nowrap">co-authored</FONT> a</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">number of scientific papers and presentations and is an inventor on a number of patents and patent applications. Mr.&nbsp;Weis also serves
on the board of directors of Jupiter NeuroSciences, Inc. Mr.&nbsp;Weis received a Bachelor of Business Administration in Accounting from the University of Georgia and is a Certified Public Accountant.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Our Board believes that Mr.&nbsp;Weis&#146;s management and industry experience, as well
as his financial expertise, qualify him to serve on the Board.</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement to Appoint Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Postma, Mr.&nbsp;Vieser and Mr.&nbsp;Weis were all nominated for election as directors at our last annual meeting pursuant to the WaterMill Settlement
Agreement. See the section titled &#147;<I>Certain Relationships and Related Transactions, and Director Independence&#151;Certain Related-Party Transaction&#151;WaterMill Settlement Agreement</I>&#148; for more information. Mr.&nbsp;Boyle, our Chief
Executive Officer and a director, was nominated as a director pursuant to the terms of his employment agreement as described in the section titled &#147;<I>Executive Compensation&#151;Narrative to the Summary Compensation Table&#151;Employment and
Change in Control Agreements&#151;Employment Agreement with Kevin S. Boyle, Sr.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information concerning our executive officers as of April&nbsp;14, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Wong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eleanor de Groot, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Melinda Lackey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Legal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drew Deniger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Research and Development</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kevin&nbsp;S.&nbsp;Boyle,&nbsp;Sr.<BR><I>Chief Executive Officer and Director</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mr.&nbsp;Boyle&#146;s biography is included above under the section titled &#147;Our Board.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael Wong <BR><I>Vice President, Finance</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Michael Wong was appointed to be our Vice President, Finance in September 2021. Mr.&nbsp;Wong has more than 17 years of experience leading teams and has had numerous management roles on complex finance projects. Previously, from
February 2019 to September 2021, Mr.&nbsp;Wong was Director, Technical Accounting at McDermott International, Ltd., where he also served as Interim Head, Audit Services. Prior to joining McDermott, Mr.&nbsp;Wong was an Audit Senior Manager at
Ernst&nbsp;&amp; Young LLP. Mr.&nbsp;Wong was most recently based in Houston, but also spent 14 years, from 2005 to 2019, with Ernst&nbsp;&amp; Young in both the London, U.K. and Toronto, Canada offices. Mr.&nbsp;Wong is a licensed CPA in Texas and
Canada and has a Bachelor of Commerce from Queen&#146;s University, Canada.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eleanor de Groot, Ph.D. <BR><I>Executive Vice President, Operations</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr.&nbsp;de Groot has served as our Executive Vice President, Operations since September 2021. She previously served as our Executive Vice President, GM Cell Therapy beginning in January 2019 and oversaw our <FONT
STYLE="white-space:nowrap">TCR-T</FONT> cell therapy platform, including the collaboration with MD Anderson. She initially joined us in July 2015 as our Senior Vice President, Program Management and Business Development. Prior to joining us,
Dr.&nbsp;de Groot was Vice President of Technical Operations and Project Planning and Management at Helsinn Therapeutics US, Inc. While at Helsinn and its predecessor companies, Sapphire</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Therapeutics and Rejuvenon Corporation, Dr.&nbsp;de Groot held multiple roles of increasing responsibility, leading technical operations, in particular chemistry, manufacturing, and controls development for its drug candidates from
preclinical through Phase III, from April 2002 to July 2015. Prior to Helsinn, Dr.&nbsp;de Groot was a staff engineer at Guilford Pharmaceuticals (now Eisai) and a process engineer at Shell Chemical Company. She earned Ph.D. and M.S. degrees in
chemical engineering from Stanford University in 1995 and 1991, respectively, and a B.S. in chemical engineering from Massachusetts Institute of Technology in 1990. Dr.&nbsp;de Groot received an M.B.A. degree from Rice University in 2014.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Melinda Lackey, <BR><I>Senior Vice President, Legal</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ms.&nbsp;Lackey joined as our Senior Vice President, Legal in November 2021. She previously served as Counsel for Hogan Lovells from August 2021 until November 2021, where she supported life sciences companies at all stages with a
focus on licensing and intellectual property. Ms.&nbsp;Lackey previously served as legal counsel Kuur Therapeutics, Inc. (and after its acquisition by Athenex, Inc., Athenex) from June 2018 until August 2021. Before industry, Ms.&nbsp;Lackey
practiced law for 10 years focusing on intellectual property strategy and patent litigation from March 2008 until June 2018. Ms.&nbsp;Lackey has a J.D. from University of Houston Law Center (2007)&nbsp;and graduated from Texas Tech Health Sciences
Center with an M.S. in medical microbiology and immunology (2003), focusing on molecular biology and immunology and a B.S. in Microbiology from Texas Tech University (1998).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drew Deniger</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President of Research and
Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dr.&nbsp;Deniger joined as our Vice President, Immunology in July 2019. He previously led <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT>
efforts to translate <FONT STYLE="white-space:nowrap">TCR-T</FONT> cell and TIL therapies for the treatment of metastatic epithelial cancers and identify TCRs targeting tumor mutations under the mentorship of Steven A. Rosenberg, M.D., Ph.D. at the
National Cancer Institute from 2013 until 2019. Dr.&nbsp;Deniger has over 14 years of experience with <I>Sleeping Beauty</I> transposition, one of the leading <FONT STYLE="white-space:nowrap">non-viral</FONT> gene transfer technologies for cell
therapy, in the setting of <FONT STYLE="white-space:nowrap">TCR-T</FONT> and <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapy. Dr.&nbsp;Deniger graduated in 2002 with B.S. in Chemistry and Biochemistry from the University of Texas at
Austin. He received his Ph.D. in Cancer Biology (MS) and Immunology from MD Anderson Cancer Center in 2013 and post-doctoral training at the NCI Surgery Branch immediately before joining us.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors, director nominees or executive officers. None of our executive
officers is related by blood, marriage or adoption to any of our directors, director nominees or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_11"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_12"></A>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to or earned by our named executive officers. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Principal Position</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,435,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,790,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,573,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi Hagen (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306,947</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,795,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,254</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,730,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Interim Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurence James Neil Cooper (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,229,203</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,531,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">917,000</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">703,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,210</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,007,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jill Buck (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">(12)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">668,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">423,874</TD>
<TD NOWRAP VALIGN="bottom">(13)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,873,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former EVP, GM Gene Therapy</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,315</TD>
<TD NOWRAP VALIGN="bottom">(14)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">488,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eleanor de Groot (15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">382,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">480,875</TD>
<TD NOWRAP VALIGN="bottom">(16)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,078,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,428</TD>
<TD NOWRAP VALIGN="bottom">(17)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,174,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>EVP, Operations</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,028</TD>
<TD NOWRAP VALIGN="bottom">(18)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">935,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raffaele Baffa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">302,875</TD>
<TD NOWRAP VALIGN="bottom">(19)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,976</TD>
<TD NOWRAP VALIGN="bottom">(20)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,034,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">884,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,072</TD>
<TD NOWRAP VALIGN="bottom">(21)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,673,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These amounts have been calculated in accordance with ASC Topic 718. Pursuant to SEC rules, the amounts shown
exclude the impact of estimated forfeitures related to service-based vesting conditions. For a discussion of the assumptions relating to our valuations of these restricted stock awards and stock options, please see Note 3 to the financial statements
included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021. These amounts reflect our accounting expense for these restricted stock awards and stock options and do not correspond to
the actual value that may be recognized by our named executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Boyle joined as our Chief Executive Officer in August 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the dollar value of group term life insurance premiums we paid for the benefit of Mr.&nbsp;Boyle
during 2021. We did not contribute to Mr.&nbsp;Boyle&#146;s 401(k) plan account pursuant to our matching program in 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Hagen resigned as our interim Chief Executive Officer in August 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, $19,447 represents the amount we paid Ms.&nbsp;Hagen for her services as a member of our Board
in 2021, and the remaining amount represents $287,500 in salary while serving as interim Chief Executive Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $448 represents the dollar value of group term life insurance premiums we paid for the
benefit of Ms.&nbsp;Hagen during 2021 and (ii) $20,359 represents accrued vacation paid at departure. We did not contribute to Ms.&nbsp;Hagen&#146;s 401(k) plan account pursuant to our matching program in 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Cooper ceased being our Chief Executive Officer, effective February&nbsp;25, 2021, and left his
position as a scientific advisor employee on April&nbsp;9, 2021, at which time he became a consultant to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $774 represents the dollar value of group term life insurance premiums we paid for the
benefit of Dr.&nbsp;Cooper during 2021, (ii) $11,600 represents the amount we contributed to Dr.&nbsp;Cooper&#146;s 401(k) plan account pursuant to our matching program, (iii) $44,625 represents accrued vacation paid at departure, (iv) $859,500
represents the amount that we paid Dr.&nbsp;Cooper in severance related to his separation from the Company and (v) $26,204 represents taxable perquisites for housing expenses, and (vi) $286,500 represents consulting fees paid to Dr.&nbsp;Cooper
during 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents a fully vested restricted stock award with a grant value of $917,000 awarded to Dr.&nbsp;Cooper as
settlement of Dr.&nbsp;Cooper&#146;s 2020 bonus in connection with his separation, which 2020 bonus had not been paid at the time of the separation. See the section titled &#147;<I>Narrative to the Summary Compensation
Table&#151;</I><B><I></I></B><I>Employment and Change in Control Agreements&#151;Separation Agreement and Consulting Agreement with Laurence James Neil Cooper, M.D., Ph.D.&#148; </I>for additional information. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $1,548 represents the dollar value of group term life insurance premiums we paid for the
benefit of Dr.&nbsp;Cooper during 2020, (ii) $78,462 represents taxable perquisites, including $77,848 for housing expenses and $614 for commuting expenses and (iii) $11,200 represents the amount we contributed to Dr.&nbsp;Cooper&#146;s 401(k) plan
account pursuant to our matching program. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Buck ceased being our Executive Vice President, GM Gene Therapy, effective September&nbsp;15, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Buck was paid $375,000 pursuant to her November&nbsp;23, 2020 retention agreement under which she was
paid the first two tranches, which equaled 75% of her annual base compensation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $383 represents the dollar value of group term life insurance premiums we paid for the
benefit of Ms.&nbsp;Buck during 2021, (ii) $11,600 represents the amount we contributed to Ms.&nbsp;Buck&#146;s 401(k) plan account pursuant to our matching program, (iii) $26,891 represents accrued vacation paid at departure and (iv) $375,000
represents how much we paid Ms.&nbsp;Buck in severance related to her separation from the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $540 represents the dollar value of group term life insurance premiums we paid for the
benefit of Ms.&nbsp;Buck during 2020, (ii) $11,400 represents the amount we contributed to Ms.&nbsp;Buck&#146;s 401(k) plan account pursuant to our matching program, and (iii) $375 represents the amount paid for Ms.&nbsp;Buck&#146;s consulting
services. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;de Groot was promoted from Executive Vice President, GM Cell Therapy, to Executive Vice President,
Operations, effective August&nbsp;30, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, Dr.&nbsp;de Groot was paid $375,000 pursuant to her November&nbsp;23, 2020 retention agreement
under which she was paid the first two tranches which equaled 75% of her annual base compensation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $828 represents the dollar value of group term life insurance premiums we paid for the
benefit of Dr.&nbsp;de Groot during 2021 and (ii) $11,600 represents the amount we contributed to Dr.&nbsp;de Groot&#146;s 401(k) plan account pursuant to our matching program. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $828 represents the dollar value of group term life insurance premiums we paid for the
benefit of Dr.&nbsp;de Groot during 2020 and (ii) $11,200 represents the amount we contributed to Dr.&nbsp;de Groot&#146;s 401(k) plan account pursuant to our matching program. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, Dr.&nbsp;Baffa was paid $175,000 pursuant to his November&nbsp;23, 2020 retention agreement
under which he was paid the first two tranches which equaled 75% of his annual base compensation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $2,376 represents the dollar value of group term life insurance premiums we paid for the
benefit of Dr.&nbsp;Baffa during 2021 and (ii) $11,600 represents the amount we contributed to Dr.&nbsp;Baffa&#146;s 401(k) plan account pursuant to our matching program. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of such amount, (i) $297 represents the dollar value of group term life insurance premiums we paid for the
benefit of Dr.&nbsp;Baffa during 2020 and (ii) $4,775 represents the amount we contributed to Dr.&nbsp;Baffa&#146;s 401(k) plan account pursuant to our matching program. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_13"></A>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our named executive officers.
Base salaries are reviewed annually, typically in connection with our annual performance review process, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and
experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Formal bonus plan goals were not set for 2021 because our CEO was not hired until August 2021. 2021 bonuses were paid out between 69% and
100% of target based on the Committee&#146;s assessment of each individual&#146;s performance. Our employment arrangements with our named executive officers provide that the executive may be eligible to earn an annual performance bonus of up to a
target percentage of the executive&#146;s base salary, as described further below under the section titled &#147;Employment and Change in Control Agreements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, Mr.&nbsp;Boyle was granted an option to purchase 2,625,000 shares of our common stock, which option
has an exercise price of $1.64 per share, and 875,000 shares of restricted common stock in connection with his appointment as our Chief Executive Officer. The new hire award was intended as an inducement for Mr.&nbsp;Boyle to join the Company and a
similar number of equity awards is not expected to be granted in 2022. The options are currently underwater and are not providing the value shown in the Summary Compensation Table, which is a fair value calculated at the time of grant using the
Black Scholes model, rather than the amount earned by Mr.&nbsp;Boyle from the award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Retention </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fourth quarter of 2020, our Board, following the recommendation of the compensation committee, granted certain of our named executive officers,
including Drs. Baffa and de Groot and Ms.&nbsp;Buck, each a cash retention award, a portion of which was contingent upon achievement of certain patient dosing milestones in our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program. The awards were
made following the WaterMill Settlement Agreement and their purpose was to ensure that critical members of the team remained employed with the Company and engaged in their jobs during the period of transition, including the appointment of a new
Chief Executive Officer in 2021. The retention and performance award payments that were made in 2021 were the result of decisions approved in 2020. These are viewed as 2020 compensation decisions rather than 2021 compensation decisions because they
were not made by the current compensation committee and there were no new 2021 special performance or retention award opportunities provided to named executive officers. Dr.&nbsp;de Groot and Ms.&nbsp;Buck were each provided an award for $500,000,
with 40% of the award payable if such individual remained employed with us on April&nbsp;1, 2021, 35% of the award payable if such individual remained employed with us on September&nbsp;1, 2021, and 25% of the award payable if such individual
remained employed with us on December&nbsp;1, 2021. Dr.&nbsp;Baffa was provided an award for $250,000, with 40% of the award payable if Dr.&nbsp;Baffa remained employed with us on April&nbsp;1, 2021, 30% of the award payable if Dr.&nbsp;Baffa
remained employed with us on September&nbsp;1, 2021, and 30% of the award payable if Dr.&nbsp;Baffa remained employed with us on December&nbsp;1, 2021. The final payment of the awards for each of Drs. Baffa and de Groot was contingent upon
achievement of certain patient dosing milestones in our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program, which were not achieved. Therefore, those amounts were not paid. Dr.&nbsp;de Groot and Ms.&nbsp;Buck each received an amount equal to
$375,000 and Dr.&nbsp;Baffa received $175,000. Ms.&nbsp;Buck was not employed with us on December&nbsp;1, 2021 and therefore was not paid the third tranche of her retention award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The performance retention payments made in 2021 were the result of 2020 decisions and there are no other performance retention programs active for executive
officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment and Change in Control Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the following employment agreements in place with our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Kevin S. Boyle, Sr. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Boyle has served as our Chief Executive Officer since August 2021 pursuant to an employment agreement entered into in August 2021. Mr.&nbsp;Boyle has
an <FONT STYLE="white-space:nowrap">at-will</FONT> employment relationship with us. Mr.&nbsp;Boyle&#146;s employment agreement required us to take all steps necessary to elect Mr.&nbsp;Boyle to our Board in connection with his hiring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary.</I> Mr.&nbsp;Boyle&#146;s annual base salary in 2021 was $600,000, <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on the number of
days worked. Under his employment agreement, Mr.&nbsp;Boyle&#146;s annual base salary is subject to review by the Board or the compensation committee at least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Performance Bonus; <FONT STYLE="white-space:nowrap">Sign-on</FONT> Bonus.</I> Under his employment agreement, Mr.&nbsp;Boyle is eligible to receive
an annual bonus based on his performance as determined by the Board or the compensation committee. The target amount of the annual performance bonus is 60% of his base salary, with the actual amount to be received determined by the Board or the
compensation committee. Mr.&nbsp;Boyle also received a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $50,000, referred to as the Boyle Signing Bonus; provided that, in the event that his
employment is terminated for cause or he resigns without good reason (as defined in the employment agreement) on or prior to August&nbsp;30, 2022, Mr.&nbsp;Boyle shall be required to repay the Boyle Signing Bonus in full, subject to certain
deductions and withholding obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Grants.</I> In connection with his appointment as our Chief Executive Officer and
pursuant to his employment agreement, effective as of August&nbsp;24, 2021, the Board granted to Mr.&nbsp;Boyle an option to purchase 2,625,000 shares of our common stock, which option has an exercise price of $1.64 per share and the Company issued
Mr.&nbsp;Boyle 875,000 shares of restricted common stock. Mr.&nbsp;Boyle is also eligible to receive equity awards as determined by the Board in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Severance Provisions.</I> If (i)&nbsp;we terminate Mr.&nbsp;Boyle for a reason other than death, disability or &#147;Cause&#148; (as that term is defined
in his employment agreement), or (ii)&nbsp;Mr.&nbsp;Boyle resigns for &#147;Good Reason&#148; (as that term is defined in his employment agreement), Mr.&nbsp;Boyle will be entitled to receive a severance payment equal to the sum of (x)&nbsp;his
then-current base salary and (y)&nbsp;the target amount of his annual performance bonus for the calendar year in which such termination occurs, which is hereinafter referred to as the Boyle Severance Payment Amount, payment of a <FONT
STYLE="white-space:nowrap">one-time</FONT> severance bonus in an amount equal to a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of the target amount of his annual performance bonus for the calendar year in which such termination occurs,
plus payment of our portion of the contributions for medical and dental insurance coverage for twelve months, subject to Mr.&nbsp;Boyle&#146;s execution and delivery of a general release in favor of the Company. Mr.&nbsp;Boyle will also receive
accelerated vesting of his equity incentive awards through, with respect to time-based equity incentive awards, the next twelve-month period immediately following the effective date of his termination and, with respect to performance-based equity
incentive awards, the next applicable performance period immediately following the effective date of his termination. The accelerated time-based equity awards will be deemed fully exercisable or
<FONT STYLE="white-space:nowrap">non-forfeitable,</FONT> as applicable, as of the later of the termination date or the effective date of the separation agreement. Any vested equity incentive awards held by Mr.&nbsp;Boyle shall remain exercisable
until the earlier of (x)&nbsp;the date that is three years following the termination of his employment and (y)&nbsp;the expiration of the applicable term of the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of either (i)&nbsp;a termination by us for a reason other than death, disability or &#147;Cause,&#148; or (ii)&nbsp;a resignation for &#147;Good
Reason,&#148; in each case that occurs within 90 days prior to and in connection with a &#147;Change of Control&#148; (as that term is defined in his employment agreement), or within 18 months after the occurrence of a &#147;Change of Control,&#148;
then, Mr.&nbsp;Boyle will be entitled to receive a lump sum payment in an amount equal to the product of the Boyle Severance Payment Amount multiplied by two, payment of a <FONT STYLE="white-space:nowrap">one-time</FONT> severance bonus in an amount
equal to a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of the target amount of his annual performance bonus for the calendar year in which such termination occurs, payment of the Company&#146;s portion of the contributions for health
insurance coverage for eighteen months. In addition, all unvested time-based stock options and unvested awards of restricted stock held by Mr.&nbsp;Boyle will be accelerated and deemed to have vested as of the later of the termination date and the
effective date of the separation. In addition, all performance-based equity awards will vest as if the applicable target performance goals were achieved as of the later of (x)&nbsp;the termination date and (y)&nbsp;the effective date of the
separation. Additionally, all outstanding equity awards held by Mr.&nbsp;Boyle will remain exercisable until the earlier of (v)&nbsp;the date that is three years following the termination of employment and (w)&nbsp;the expiration of the applicable
option term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-competition</FONT></I><I></I><I>&nbsp;and</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;
Non-solicitation.</FONT></I><I></I>&nbsp;Mr.&nbsp;Boyle has entered into an invention, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, which provides that he will not
compete with us or solicit our clients or customers for a year after the termination or cessation of his employment with us, and further provides that he will not solicit our employees for one year after the termination or cessation of his
employment with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Eleanor de Groot, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;de Groot has served as our Executive Vice President, Cell Therapy since January&nbsp;1, 2019, and previously as our SVP, Program Management&nbsp;&amp;
Business Development from July&nbsp;13, 2015 to December&nbsp;31, 2018. In April 2019, we entered into an employment agreement with Dr.&nbsp;de Groot, which was amended in November 2020. Dr.&nbsp;de Groot has an
<FONT STYLE="white-space:nowrap">at-will</FONT> employment relationship with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary.</I> In 2021, Dr.&nbsp;de Groot received a base salary of $385,000. Under her employment
agreement, Dr.&nbsp;de Groot&#146;s annual base salary is subject to review by the Board or the compensation committee at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual
Performance Bonus. </I>Under her employment agreement, Dr.de Groot is eligible to receive an annual bonus based on her performance as determined by the Board or the compensation committee. The target amount of the annual performance bonus is 40% of
her base salary, with the actual amount to be received determined by the Board or the compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Grants.</I> Dr.&nbsp;de
Groot is eligible to receive equity awards as determined by the Board in its sole discretion from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Severance Provisions.</I> If
(i)&nbsp;we terminate Dr.&nbsp;de Groot for a reason other than death, disability or &#147;Cause&#148; (as that term is defined in her employment agreement), or (ii)&nbsp;Dr.&nbsp;de Groot resigns for &#147;Good Reason&#148; (as that term is defined
in her employment agreement), Dr.&nbsp;de Groot will be entitled to receive a severance payment equal to twelve months of her then-current base salary, plus payment of our portion of the contributions for medical and dental insurance coverage for
twelve months, subject to Dr.&nbsp;de Groot&#146;s execution and delivery of a general release in favor of the Company. In the case of either (i)&nbsp;a termination by us for a reason other than death, disability or &#147;Cause,&#148; or (ii)&nbsp;a
resignation for &#147;Good Reason,&#148; in each case that occurs within 90 days prior to and in connection with a &#147;Change in Control&#148; (as that term is defined in her employment agreement), or within 18 months after the occurrence of a
&#147;Change in Control,&#148; the, in addition to the foregoing severance provisions, all unvested stock options and unvested awards of restricted stock held by Dr.&nbsp;de Groot at the time that such termination occurs will be accelerated and
deemed to have vested as of her employment termination date, and Dr.&nbsp;de Groot will be entitled to full target amount of her annual performance bonus for the calendar year in which such termination occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-competition</FONT> and <FONT STYLE="white-space:nowrap">Non-solicitation.</FONT></I> Dr.&nbsp;de Groot has entered
into an invention, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, which provides that she will not compete with us or solicit our clients or customers for a year after
the termination or cessation of her employment with us, and further provides that she will not solicit our employees for one year after the termination or cessation of her employment with us<I>.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Raffaele Baffa, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Baffa served as our Chief Medical Officer from November of 2020 to March&nbsp;31, 2022, pursuant to an employment agreement Dr.&nbsp;Baffa entered
into in September 2020, which we subsequently amended in November 2020. Dr.&nbsp;Baffa had an <FONT STYLE="white-space:nowrap">at-will</FONT> employment relationship with us. On March&nbsp;28, 2022, we entered into a letter agreement with
Dr.&nbsp;Baffa (the &#147;Baffa Separation Agreement&#148;) to govern the terms of the separation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary.</I> Dr.&nbsp;Baffa&#146;s annual base
salary in 2021 was $465,000. Under his employment agreement, Dr.&nbsp;Baffa&#146;s annual base salary is subject to review by the Board or the compensation committee at least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Performance Bonus.</I> Under his employment agreement, Dr.&nbsp;Baffa is eligible to receive an annual bonus based on his performance as determined
by the Board or the compensation committee. The target amount of the annual performance bonus is 40% of his base salary, with the actual amount to be received determined by the Board or the compensation committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Grants.</I> Dr.&nbsp;Baffa is also eligible to receive equity awards as determined by the Board in its sole discretion from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Severance Provisions.</I> If (i)&nbsp;we terminate Dr.&nbsp;Baffa for a reason other than death, disability or &#147;Cause&#148; (as that term is
defined in his employment agreement), or (ii)&nbsp;Dr.&nbsp;Baffa resigns for &#147;Good Reason&#148; (as that term is defined in his employment agreement), Dr.&nbsp;Baffa will be entitled to receive a severance payment equal to twelve months of his
then-current base salary, plus payment of our portion of the contributions for medical and dental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance coverage for twelve months, subject to Dr.&nbsp;Baffa&#146;s execution and delivery of a general release in favor of the Company. In the case of either (i)&nbsp;a termination by us for
a reason other than death, disability or &#147;Cause,&#148; or (ii)&nbsp;a resignation for &#147;Good Reason,&#148; in each case that occurs within 90 days prior to and in connection with a &#147;Change of Control&#148; (as that term is defined in
his employment agreement), or within 18 months after the occurrence of a &#147;Change of Control,&#148; then, in addition to the foregoing severance provisions, all unvested stock options and unvested awards of restricted stock held by
Dr.&nbsp;Baffa at the time that such termination occurs will be accelerated and deemed to have vested as of his employment termination date, and Dr.&nbsp;Baffa will be entitled to full target amount of his annual performance bonus for the calendar
year in which such termination occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-competition</FONT> and
<FONT STYLE="white-space:nowrap">Non-solicitation.</FONT></I> Dr.&nbsp;Baffa has entered into an <FONT STYLE="white-space:nowrap">invention,&nbsp;non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation&nbsp;and</FONT> <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreement, which provides that he will not compete with us or solicit our clients or customers for a year after the termination or cessation of his employment with us, and further provides that he
will not solicit our employees for one year after the termination or cessation of his employment with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Separation Agreement with Raffaele Baffa,
M.D., Ph.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Baffa Separation Agreement, in exchange for a release of claims and certain post-employment covenants, Dr.&nbsp;Baffa is
entitled to receive a $155,000 lump sum cash payment and we have waived our right to recover half of his $160,000 <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus which we would otherwise be entitled to since he is departing after the first
anniversary but before the second anniversary of his employment start date. Regardless of whether or not Dr.&nbsp;Baffa executes the Baffa Separation Agreement, we will continue paying Dr.&nbsp;Baffa&#146;s COBRA premiums for four months following
the separation date. The Baffa Separation Agreement supersedes all prior agreements between the parties. In addition, the Baffa Separation Agreement includes confidentiality and intellectual property provisions which continue after
Dr.&nbsp;Baffa&#146;s departure. The Baffa Separation Agreement became effective on April&nbsp;12, 2022, upon the expiration a seven business day revocation period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Laurence James Neil Cooper, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Cooper served as our Chief Executive Officer from May 2015 until February 2021, at which point Dr.&nbsp;Cooper served as a scientific advisor employee
of the Company. As a scientific advisor employee, Dr.&nbsp;Cooper continued receiving his base salary and remained eligible for our employee benefit programs pursuant to the terms of his employment agreement. On April&nbsp;5, 2021, we entered into a
separation agreement with Dr.&nbsp;Cooper (the &#147;Cooper Separation Agreement&#148;) providing for his cessation of employment effective April&nbsp;9, 2021 and a consulting agreement, or the Cooper Consulting Agreement, providing his continued
consulting thereafter. For a description of the material terms of the Cooper Separation Agreement and the Cooper Consulting Agreement see below under &#147;<I>Separation Agreement and Consulting Agreement with Laurence James Neil Cooper, M.D.,
Ph.D.</I>&#148; Below is a summary of the material terms of Dr.&nbsp;Cooper&#146;s employment agreement in place during 2021 when he served as our Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary.</I> In 2021, Dr.&nbsp;Cooper received a base salary of $573,000, including while acting a scientific advisor. Under his employment agreement,
his base salary was subject to review by the Board or the compensation committee at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Performance Bonus.</I> Under his employment
agreement, Dr.&nbsp;Cooper was eligible to receive an annual bonus based on his performance as determined by the Board or the compensation committee. The target amount of the annual performance bonus was 200% of his base salary, with the actual
amount to be received determined by the Board or the compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Grants.</I> Dr.&nbsp;Cooper was eligible under his
employment agreement to receive equity awards as determined by the Board in its discretion from time to time. Under certain circumstances, the vesting of Dr.&nbsp;Cooper&#146;s equity awards could have been accelerated in the event of a change in
control or if Dr.&nbsp;Cooper&#146;s employment with us is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expense Reimbursement.</I> Under his employment agreement, Dr.&nbsp;Cooper was eligible for reimbursement
of normal, usual and necessary expenses incurred by him in furtherance of our business and affairs, including reasonable travel and entertainment expenses and the ordinary and necessary expenses incurred in connection with his commute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-competition</FONT> and <FONT STYLE="white-space:nowrap">Non-solicitation.</FONT></I> Dr.&nbsp;Cooper has entered into
an invention, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, which provides that he will not compete with us or solicit our clients or customers for a year after the
termination or cessation of his employment with us, and further provides that he will not solicit our employees for one year after the termination or cessation of his employment with us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Separation Agreement and Consulting Agreement with Laurence James Neil Cooper, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2021, we entered into the Cooper Separation Agreement, and the Cooper Consulting Agreement. Under the Cooper Separation Agreement, in exchange
for a release of claims and certain post-employment covenants and in lieu of any severance benefits under his employment agreement, Dr.&nbsp;Cooper is entitled to receive continuing payments of his base salary and COBRA premiums for a period of 18
months, a cash payment of $143,250, representing a <FONT STYLE="white-space:nowrap">pro-rata</FONT> target amount of his annual performance bonus for 2021, a fully-vested restricted stock award with a grant value of $917,000, which represented
Dr.&nbsp;Cooper&#146;s 2020 annual bonus, and certain limited reimbursements for legal fees and housing. Dr.&nbsp;Cooper is not entitled to any equity acceleration in connection with his separation, however his equity awards are eligible to continue
to vest pursuant to their terms based on his consulting services to us. The Board determined these severance benefits were appropriate to provide Dr.&nbsp;Cooper, considering the severance benefits provided under the terms of his employment
agreement and his contributions to our Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Cooper Consulting Agreement commenced on Dr.&nbsp;Cooper&#146;s employment separation and
continues for up to three years, subject to earlier termination by either Dr.&nbsp;Cooper or the Company, provided that if Dr.&nbsp;Cooper terminates the agreement within the first year of the term, our sole remedy will be the right to cause
Dr.&nbsp;Cooper to reimburse us certain of his cash severance described in the Separation Agreement. If we terminate the Cooper Consulting Agreement before the first anniversary of the effective date without cause (as defined in the Cooper
Consulting Agreement) or Dr.&nbsp;Cooper terminates the agreement within the first year for good reason (as defined in the Cooper Consulting Agreement), the <FONT STYLE="white-space:nowrap">non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions described above will be deemed waived by us. Unless the Cooper Consulting Agreement is terminated by us with cause or by Dr.&nbsp;Cooper before the first anniversary of the
effective date and without good reason, all unvested restricted stock or options will immediately vest as of the effective date of the termination. Under the Cooper Consulting Agreement, Dr.&nbsp;Cooper may earn consulting fees in amounts of up to
$573,000 for the first year and $300,000 for each of the following two years and is also eligible for reimbursement of reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses. In
addition, the Cooper Consulting Agreement includes confidentiality and intellectual property provisions. Dr.&nbsp;Cooper received $286,500 in fees under the Cooper Consulting Agreement in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Heidi Hagen </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;24, 2021, the Board appointed Heidi Hagen as our Interim Chief Executive Officer, effective February&nbsp;25, 2021. Effective February&nbsp;25, 2021, we entered into an employment agreement with Ms. Hagen, governing the terms of her
employment as our Interim Chief Executive Officer. The majority of the equity value was provided as stock options to require an increase in the stock price and to allow the timeframe required for the long-term price improvement as a reflection of
the long drug development cycle from discovery to commercial product. Ms. Hagen stepped down as Interim Chief Executive Officer on August&nbsp;30, 2021 in connection with Mr.&nbsp;Boyle&#146;s employment as our Chief Executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary; Sign on Bonus. </I>Ms.&nbsp;Hagen&#146;s employment agreement provided for an annual base salary of $575,000,
<FONT STYLE="white-space:nowrap">pro-rated</FONT> for service, and a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $50,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Bonus. </I>While Ms.&nbsp;Hagen was entitled to receive certain performance bonuses if she
remained employed as our Interim Chief Executive Officer after September&nbsp;1, 2021, these were not paid as a result of the appointment of Mr.&nbsp;Boyle as our new Chief Executive Officer effective August&nbsp;31, 2021. Ms.&nbsp;Hagen received a
bonus in the amount of $150,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Grants.</I> In connection with her appointment as our Interim Chief Executive Officer and pursuant
to her employment agreement, on March&nbsp;4, 2021, the Board granted Ms.&nbsp;Hagen 90,000 restricted shares of our common stock, which were scheduled to vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant,
subject to Ms.&nbsp;Hagen&#146;s continued employment with us through such vesting date. In addition, pursuant to her employment agreement, on March&nbsp;4, 2021, the Board granted to Ms.&nbsp;Hagen an option to purchase 675,000 shares of our common
stock, which option has an exercise price of $4.31 per share. The option was scheduled to vest in twelve equal monthly installments over the term of one year, subject to Ms.&nbsp;Hagen&#146;s continued employment with us through each such vesting
date. Ms.&nbsp;Hagen&#146;s employment agreement provided that if Ms.&nbsp;Hagen&#146;s employment terminates either because a replacement, full-time chief executive officer has been hired, or because we terminate her employment without
&#147;Cause&#148; (as defined in her employment agreement), then upon termination of her employment, Ms.&nbsp;Hagen&#146;s shares of restricted stock shall vest in full, and any unvested portion of Ms.&nbsp;Hagen&#146;s option grant shall vest in
full and become exercisable immediately. Upon Ms.&nbsp;Hagen&#146;s resignation as the Company&#146;s Interim Chief Executive Officer on August&nbsp;29, 2021, Ms.&nbsp;Hagen&#146;s 90,000 restricted stock and option grant of 675,000 shares vested in
full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Severance Provisions.</I> Ms.&nbsp;Hagen&#146;s employment agreement provided that if she was terminated by us for any reason other than death,
disability or Cause, then we would be obligated to pay to Ms.&nbsp;Hagen her base salary through the date of termination, any accrued vacation, and any expense reimbursement amounts for expenses incurred through the date of termination. If, within
30 days after the effective date of termination, Ms.&nbsp;Hagen executes a written general release, she will also be entitled to receive continuing payments of her base salary for a period of four months. In addition, unless her employment is
terminated for Cause, we may be required to pay 100% of applicable COBRA premiums for Ms.&nbsp;Hagen for up to 12 months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with
Jill Buck </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Buck most recently served as our Executive Vice President, GM Gene Therapy, joining Alaunos in September 2015, and being promoted
to Executive Vice President, Strategy and Operations in early 2021. Ms.&nbsp;Buck left the Company on September&nbsp;15, 2021. Ms.&nbsp;Buck entered into an employment agreement dated April&nbsp;23, 2019, which we subsequently amended in November
2020, as Executive Vice President, GM Gene Therapy. Ms.&nbsp;Buck had an <FONT STYLE="white-space:nowrap">at-will</FONT> employment relationship with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary.</I> In 2021, Ms.&nbsp;Buck received a base salary of $385,000. Under her employment agreement, Ms.&nbsp;Buck&#146;s annual base salary was
subject to review by the Board or the compensation committee at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Performance Bonus.</I> Under her employment agreement,
Ms.&nbsp;Buck was eligible to receive an annual bonus based on her performance as determined by the Board or the compensation committee. The target amount of the annual performance bonus is 40% of her base salary, with the actual amount to be
received determined by the Board or the compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Grants.</I> Ms.&nbsp;Buck was eligible to receive equity awards as
determined by the Board in its sole discretion from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Severance Provisions.</I> Ms.&nbsp;Buck&#146;s employment agreement provided that if
(i)&nbsp;we terminated Ms.&nbsp;Buck for a reason other than death, disability or &#147;Cause&#148; (as that term is defined in her employment agreement), or (ii)&nbsp;Ms.&nbsp;Buck resigned for &#147;Good Reason&#148; (as that term is defined in
her employment agreement), Ms.&nbsp;Buck was entitled to receive a severance payment equal to twelve months of her then-current base salary, plus payment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our portion of the contributions for medical and dental insurance coverage for twelve months, subject to Ms.&nbsp;Buck&#146;s execution and delivery of a general release in favor of the Company.
In the case of either (i)&nbsp;a termination by us for a reason other than death, disability or &#147;Cause,&#148; or (ii)&nbsp;a resignation for &#147;Good Reason,&#148; in each case that occurs within 90 days prior to and in connection with a
&#147;Change in Control&#148; (as that term is defined in her employment agreement), or within 18 months after the occurrence of a &#147;Change in Control,&#148; all unvested stock options and unvested awards of restricted stock held by
Ms.&nbsp;Buck at the time that such termination occurs would have been accelerated and deemed to have vested as of her employment termination date, and Ms.&nbsp;Buck would have been entitled to full target amount of her annual performance bonus for
the calendar year in which such termination occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with her departure, Ms.&nbsp;Buck received $375,000, pursuant to the terms of her
separation agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-competition</FONT> and <FONT STYLE="white-space:nowrap">Non-solicitation.</FONT></I>
Ms.&nbsp;Buck has entered into an invention, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, which provided that she would not compete with us or solicit our clients or
customers for a year after the termination or cessation of her employment with us, and further provides that she would not solicit our employees for one year after the termination or cessation of her employment with us<I>.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_14"></A>Role of our Compensation Committee, Management and Consultant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee is
responsible for reviewing, evaluating, approving, administering and interpreting our executive compensation and benefits policies, programs and plans, including our equity compensation plans. In particular, with respect to the compensation of our
named executive officers, our compensation committee is responsible for reviewing and recommending to the outside, independent <FONT STYLE="white-space:nowrap">and&nbsp;non-employee&nbsp;members</FONT> of the Board the compensation levels and
performance goals relevant to the compensation of these officers, and for evaluating the officers&#146; performance in light of those goals and objectives. The outside, independent
<FONT STYLE="white-space:nowrap">and&nbsp;non-employee&nbsp;members</FONT> of the Board approved the compensation committee&#146;s recommendations for the 2021 compensation of our named executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Management </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our human resources, finance and legal
departments work with our Chief Executive Officer to design and develop new executive compensation programs, to recommend changes to existing compensation programs, to recommend financial and other performance targets to be achieved under those
programs, to prepare analyses of financial data, to prepare peer group data comparisons and to prepare other briefing materials for consideration by the compensation committee and ultimately, to implement the decisions of the compensation committee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chief Executive Officer recommends to the compensation committee for its discussion and ultimately, approval, proposed corporate performance and
strategic goals and their relative weighting for the upcoming fiscal year, and provides input on the level of attainment of the prior year&#146;s strategic goals, for purposes of determining awards under the annual performance bonus plan for all our
executives, including the Chief Executive Officer. For executives other than the Chief Executive Officer, the compensation committee will consider the individual performance of the executives, as assessed by the Chief Executive Officer, and the
compensation recommendations submitted to the compensation committee by the Chief Executive Officer. Our Chief Executive Officer and other members of management generally attend our compensation committee meetings for a portion of the meeting. No
executive officer was present for or voted in the compensation committee or the Board&#146;s final determinations regarding the amount of any component of his or her own 2021 compensation package. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consultant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning in March 2020, our compensation committee engaged Frederic W. Cook&nbsp;&amp; Co. (&#147;FW Cook&#148;) as its independent compensation consultant.
FW Cook provided independent market findings to the compensation committee and has provided advice to the compensation committee as to employee director compensation, Chief Executive Officer compensation and
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation in 2021 and 2022. FW Cook was determined to be free of conflicts of interest and able to operate as an independent compensation advisor. As part of its duties, FW Cook
provided the compensation committee with the following services: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completed a competitive analysis of our 2020 and 2021 executive compensation programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepared a competitive analysis of the Board&#146;s compensation program, including observations and
recommendations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewed and updated our peer group for use in determining executive compensation for 2022.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trading Policy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a policy
that prohibits our executive officers, directors and other members of management from engaging in short sales, transactions in put or call options, pledging transactions, hedging transactions or other inherently speculative transactions with respect
to our stock. Any violation of these policies may result in disciplinary action, including dismissal for cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_15"></A>Outstanding
Equity Awards at 2021 <FONT STYLE="white-space:nowrap">Fiscal&nbsp;Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding option awards
and restricted stock awards held as of December&nbsp;31, 2021 by our named executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Securities Underlying<BR>Unexercised Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise&nbsp;Price</B><br><B>($/Sh)(1)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares or Units of Stock That<BR>Have Not Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercisable&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurence James Neil Cooper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,067</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/29/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,233</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi Hagen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/2/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/2/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,460,938</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/29/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875,000</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">953,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eleanor de Groot</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/13/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,533</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/29/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,891</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/4/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,900</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,119</TD>
<TD NOWRAP VALIGN="bottom">(11)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raffaele Baffa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">(12)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/30/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">(13)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,764</TD>
<TD NOWRAP VALIGN="bottom">(14)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jill Buck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each stock option was granted with an exercise price equal to the fair market value of our common stock on the
grant date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Market values are calculated based on the closing market price of our common stock as reported on the Nasdaq
Global Select Market on December&nbsp;31, 2021, which was $1.09 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 22,017 shares on March&nbsp;31, 2022, June&nbsp;30, 2022, and December&nbsp;31, 2022, and
with respect to 22,016 on September&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 57,233 shares on December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Options expired on February&nbsp;2, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 164,063 shares on February&nbsp;28, 2022, August&nbsp;30, 2022, February&nbsp;28, 2023,
August&nbsp;30, 2023, February&nbsp;28, 2024, August&nbsp;30, 2024, February&nbsp;28, 2025, and August&nbsp;30, 2025 and with respect to 164,062 shares on May&nbsp;30, 2022, November&nbsp;30, 2022, May&nbsp;30, 2023, November&nbsp;30, 2023,
May&nbsp;30, 2024, November&nbsp;30, 2024, and May&nbsp;30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such shares are subject to transfer and forfeiture restrictions that lapse with respect to 218,750 shares on
each of August&nbsp;30, 2022, August&nbsp;30, 2023, August&nbsp;30, 2024, and August&nbsp;30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 6,883 shares on each of March&nbsp;31, 2022, June&nbsp;30, 2022, and December&nbsp;31,
2022 and with respect to 6,884 shares on September&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 23,824 shares on each of March&nbsp;31, 2022, June&nbsp;30, 2022, September&nbsp;30,
2022, March&nbsp;31, 2023, June&nbsp;30, 2023, September&nbsp;30, 2023, March&nbsp;31, 2024, June&nbsp;30, 2024, and September&nbsp;30, 2024 and with respect to 23,825 shares on December&nbsp;31, 2022, December&nbsp;31, 2023, and December&nbsp;31,
2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such shares are subject to transfer and forfeiture restrictions that lapse with respect to 17,900 shares on
December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such shares are subject to transfer and forfeiture restrictions that lapse with respect to 12,706 shares on
December&nbsp;31, 2022, December&nbsp;31, 2023 and December&nbsp;31, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 31,250 shares on February&nbsp;16, 2022. The remaining unvested shares were forfeited on
March&nbsp;31, 2022 and vested options will expire on June&nbsp;30, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such shares were forfeited on March&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vests with respect to 26,882 shares on February&nbsp;1, 2022. The remaining 26,882 shares were forfeited on
March&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_16"></A>Stockholder Engagement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, our stockholder engagement included participation in investor conferences as well as individual investor meetings with stockholders and prospective
stockholders. Conversations spanned topics including, but not limited to, clinical development plans, corporate strategy and potential restructuring of the Company. Following the appointment of our new Chief Executive Officer, Kevin S. Boyle, Sr.,
on August&nbsp;31, 2021, we outlined our <FONT STYLE="white-space:nowrap">go-forward</FONT> strategy solely focused on <FONT STYLE="white-space:nowrap">TCR-T</FONT> cell therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, we engaged Stern Investor Relations (&#147;SternIR&#148;), an investor relations firm for healthcare and biotechnology companies. In
conjunction with SternIR, we have implemented a proactive campaign including stockholder maintenance, outreach to new prospective institutional investors and engaging with existing and new equity research analysts to broaden visibility amongst the
investment community. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that ongoing, appropriate, and transparent communication with our stockholders is critical to our success long-term. We
will continue to have a strong stockholder engagement program and communicate with our stockholders and prospective stockholders through our press releases, quarterly earnings calls, investor conferences, SEC filings, individual meetings and
investor presentations. We believe that all of these communications together enable us to have a meaningful <FONT STYLE="white-space:nowrap">two-way</FONT> dialogue, where the management team and Board can better listen to and understand stockholder
perspectives, answer questions, and provide context to ongoing activities. Over the course of 2021, our stockholders have provided us with valuable feedback and external viewpoints that inform how we think about our business and strategy, and we are
committed to continuing this dialogue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_17"></A>INFORMATION REGARDING THE BOARD AND CORPORATE GOVERNANCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section provides further information regarding the Board and the independence of our directors and describes key Corporate Governance Guidelines
(the &#147;Corporate Governance Guidelines&#148;) and practices that we have adopted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_18"></A>Independence of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has undertaken a review of the independence of our directors and considered whether any director has a relationship that, in the opinion of the
Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a member of our Board. Based upon information requested from and provided by each director concerning such director&#146;s background,
employment and affiliations, including family relationships, the Board has determined that all of our directors, other than Mr.&nbsp;Boyle and Mr.&nbsp;Huang are &#147;independent directors,&#148; as such term is defined in Nasdaq Rule 5605(a)(2).
In making these determinations, our Board considered the current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with the Company and all other facts and circumstances that our Board deemed
relevant in determining their independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_19"></A>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;29, 2022, the Board appointed Mr.&nbsp;Huang to serve as its Chair. Prior to that, Mr.&nbsp;Huang had served as Executive Chair for most of 2021. The Board has elected to separate the chair function from that of the Chief Executive
Officer, who serves as our principal executive officer, due to a belief that separating these functions, and empowering a <FONT STYLE="white-space:nowrap">non-executive</FONT> director to chair the Board meetings, reinforces the independence of the
Board in its oversight of our business and affairs. In addition, we believe that having a chair separate from the Chief Executive Officer creates an environment that is more conducive to objective evaluation and oversight of management&#146;s
performance, increasing management accountability and improving the ability of the Board to monitor whether management&#146;s actions are in the best interest of the Company and our stockholders. As a result, we believe that having a chair separate
from the Chief Executive Officer can enhance the effectiveness of the Board as a whole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_20"></A>Nasdaq Board Diversity Matrix
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board Diversity Matrix (As of April&nbsp;14, 2022) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Number of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Female</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Male</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Binary</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Did&nbsp;Not&nbsp;Disclose&nbsp;Gender</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part I: Gender Identity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part II: Demographic Background</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_21"></A>Director Attendance at Board and Stockholder Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board met 23 times during 2021, either in person, by teleconference or videoconference. Each current director attended at least 75% of the aggregate number
of meetings of the Board and of the committees on which he or she served which were held during 2021 or the portion thereof that he or she served as a director or committee member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As provided in our Corporate Governance Guidelines, we encourage attendance at our annual meetings by members of the Board. All of the then-current directors
attended our 2021 annual meeting of stockholders either in person or by teleconference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_22"></A>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has established three standing committees: an audit committee, a compensation committee and a corporate governance and nominating committee. Each
committee operates under a charter that has been approved by the Board. Current copies of each committee&#146;s charter are posted on the &#147;Investors&#151;Corporate Governance&#148; section of our website, <I>www.alaunos.com</I>. Our website and
its contents are not incorporated into this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current members of the committees are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominating</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Bowden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Postma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaime Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holger Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Committee Chairperson </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current members of the audit
committee are Mr.&nbsp;Holger Weis, who serves as the committee&#146;s Chair, Ms.&nbsp;Mary Thistle and Mr.&nbsp;Jaime Vieser. As set forth in the audit committee charter, the primary responsibility of the audit committee is to oversee our financial
reporting processes and internal control system on behalf of the Board. In that regard, the audit committee is responsible for, among other things, the appointment, compensation, retention and oversight of the work performed by the independent
registered public accounting firm employed by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the audit committee is an &#147;independent director,&#148; as such term is defined in
Nasdaq Rule 5605(a)(2) and meets the criteria for independence set forth in Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> under the Exchange Act. The Board has also determined that each of the audit committee members is able to read and
understand fundamental financial statements and that at least one member of the audit committee has past employment experience in finance or accounting. The Board has determined that at least one member of the audit committee, Holger Weis, is an
&#147;audit committee financial expert,&#148; as that term is defined in Item 407(d)(5)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee held seven meetings during 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current members of the
compensation committee are Ms.&nbsp;Thistle, who serves as the committee&#146;s Chair, Dr.&nbsp;Christopher Bowden, Mr.&nbsp;Postma and Mr.&nbsp;Weis. As set forth in the compensation committee charter, the compensation committee reviews our
compensation policies and practices and makes recommendations to the Board in connection with all compensation matters affecting our executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the compensation committee is an &#147;independent director,&#148; as such term is defined in
Nasdaq Rule 5605(a)(2) and meets the criteria for independence set forth in Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation committee held ten meetings during 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Governance and Nominating Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
current members of the corporate governance and nominating committee are Mr.&nbsp;Robert&nbsp;W. Postma, who serves as the committee&#146;s Chair, Dr.&nbsp;Christopher Bowden and Mr.&nbsp;Jaime Vieser. As set forth in the corporate governance and
nominating committee charter, the primary responsibility of the corporate governance and nominating committee is to consider and make recommendations to the Board concerning the appropriate size, function and needs of the Board and its committees.
In that regard, the corporate governance and nominating committee is, among other things, responsible for establishing criteria for membership on the Board, recruiting and recommending candidates to fill newly created or vacant positions on the
Board and reviewing any candidates recommended by stockholders. In addition, the corporate governance and nominating committee evaluates and assesses the performance of the Board as a whole and its committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the corporate governance and nominating committee is an &#147;independent director,&#148; as such term is defined in Nasdaq Rule 5605(a)(2),
and meets the criteria for independence set forth in Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate
governance and nominating committee held two meetings during 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_23"></A>Director Nomination Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate governance and nominating committee (or a subcommittee thereof) recruits and considers director candidates and presents qualified candidates to
the full Board for consideration in accordance with the Corporate Governance Guidelines and the corporate governance and nominating committee&#146;s charter, which is available on our website. Our website and its contents are not incorporated into
this proxy statement. The Board and the corporate governance and nominating committee will consider the minimum general criteria set forth in the Corporate Governance Guidelines and may add any specific additional criteria with respect to specific
searches in selecting candidates and existing directors for service on the Board. The corporate governance and nominating committee considers a nominee&#146;s education, general business and industry experience, ability to act on behalf of
stockholders, potential concerns regarding independence or conflicts of interest and other factors relevant in evaluating Board nominees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate
governance and nominating committee believes that a Board comprised of directors with diverse skills and experiences relevant to our industry and operations will result in efficient and competent oversight of our various core competencies, which
include drug development, strategic partnering, commercialization activities, regulatory compliance, corporate finance and accounting. As such, the corporate governance and nominating committee gives consideration to the interplay of a director
candidate&#146;s experience with that of other members of the Board and the evolving needs of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2022, our Board updated our
corporate governance policies to reflect the importance our Board places on diversity. More specifically, we have updated our policies to emphasize our commitment to seeking to attain diversity and balance among directors of race, gender, geography,
thought, viewpoints, backgrounds, skills, experience, and expertise. As a result, under our policies any search firm retained to assist the corporate governance and nominating committee in seeking candidates for the Board will be instructed to seek
to include diverse candidates in terms of race, gender, geography, thought, viewpoints, backgrounds, skills, experience, and expertise from, among other areas, the traditional corporate environment, government, academia, private enterprise, <FONT
STYLE="white-space:nowrap">non-profit</FONT> organizations, and professions such as accounting, finance, marketing, human resources, and legal services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualified candidates will be considered without regard to race, color, religion, sex, ancestry, national
origin or disability, and the corporate governance and nominating committee will consider director candidates recommended by security holders. If the corporate governance and nominating committee approves a candidate for further review following an
initial screening, the corporate governance and nominating committee will establish an interview process for the candidate. Generally, the candidate will meet with at least one member of the corporate governance and nominating committee, along with
other members of the Board and management, including our Chief Executive Officer. Contemporaneously with the interview process, the corporate governance and nominating committee will conduct a comprehensive <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">conflicts-of-interest</FONT></FONT> assessment of the candidate. The corporate governance and nominating committee will consider reports of the interviews and the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">conflicts-of-interest</FONT></FONT> assessment to determine whether to recommend the candidate to the full Board. The corporate governance and nominating committee will also take into consideration the candidate&#146;s
personal attributes, including, without limitation, personal integrity, loyalty to us and concern for our success and welfare, willingness to apply sound and independent business judgment, awareness of a director&#146;s vital part in our good
corporate citizenship and image, time available for meetings and consultation on our matters and willingness to assume broad, fiduciary responsibility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the individuals nominated for <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board pursuant to Proposal 1 were approved for such
nomination by the corporate governance and nominating committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_24"></A>Risk Management and Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the Board&#146;s key functions is informed oversight of the Company&#146;s risk management process. The Board does not have a standing risk management
committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is
responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our audit committee has the responsibility to consider and discuss our major financial risk
exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our corporate governance and nominating committee
monitors the effectiveness of our Corporate Governance Guidelines. Our compensation committee assesses and monitors whether any of our compensation policies and programs have the potential to encourage excessive risk-taking. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In carrying out their risk oversight functions, the Board and its committees routinely request and review management updates, reports from the independent
auditors and legal and regulatory advice from outside experts, as appropriate, to assist in discerning and managing important risks that may be faced by the Company. The Board is committed to continuing to evolve its risk oversight practices as
appropriate given the stage of the Company&#146;s evolution as an immuno-oncology company and the fast-paced changes in the biotechnology industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_25">
</A>Stockholder Communications with Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established means for stockholders and others to communicate with the Board or individual
directors. If a stockholder wishes to address a matter regarding our financial statements, accounting practices or internal controls, the matter should be submitted in writing addressed to the chairperson of the audit committee in care of the
Secretary at our principal executive offices at 8030 El Rio Street, Houston TX 77054. If the matter relates to our governance practices, business ethics or corporate conduct, it should be submitted in writing addressed to the chairperson of the
corporate governance and nominating committee in care of the principal financial officer at our principal executive offices at the address stated above. If a stockholder wishes to address a communication to an individual director, it should be
submitted in writing addressed to such individual director in care of the principal financial officer at our principal executive offices at the address stated above. If a stockholder is unsure where to direct a communication, the stockholder may
direct it in writing to the chairperson of the audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee, or to any one of our independent directors, in care of the principal financial officer at our principal executive offices at the address stated above. All of these stockholder
communications will be forwarded by the principal financial officer to the addressee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_26"></A>Code of Ethics and Business Conduct
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board adopted a Code of Ethics and Business Conduct to be applicable to all officers, directors and employees. The Code of Ethics and Business
Conduct is intended to be designed to deter wrong-doing and promote honest and ethical behavior, full, fair, timely, accurate and understandable disclosure, and compliance with applicable laws. In addition to provisions that are applicable to
officers, directors and employees generally, the Code of Ethics and Business Conduct contains provisions that are specifically applicable to our Chief Executive Officer and senior financial officer(s). The Code of Ethics and Business Conduct is
available on our website at <I>www.alaunos.com</I> and a copy may be obtained without charge upon written request to our Legal department at our principal executive offices at 8030 El Rio Street, Houston, TX 77054. Our website and its contents are
not incorporated into this proxy statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_27"></A>Corporate Governance Guidelines </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has adopted Corporate Governance Guidelines to ensure that the Board will have the necessary authority and practices in place to review and evaluate
our business operations as needed and to make decisions that are independent of our management. The Corporate Governance Guidelines are also intended to align the interests of directors and management with those of our stockholders. The Corporate
Governance Guidelines set forth the practices the Board intends to follow with respect to, among other things, Board composition and selection including diversity, Board meetings and involvement of senior management, Chief Executive Officer
performance evaluation and succession planning, and Board committees and compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_28"></A>Whistleblower Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a whistleblower policy applicable to our employees that provides for protection from retaliation or discrimination by the Company due to
reporting issues relating to compliance with applicable laws and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_29"></A>Corporate Governance Documents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please visit our investor relations website at www.alaunos.com for additional information on our corporate governance, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the charters approved by the Board for the audit committee, compensation committee and nominating and governance
committee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our code of ethics and business conduct. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any amendment to, or waiver from, a provision of our code of ethics and business conduct, we will promptly post on our website relevant
information regarding the amendment or waiver, including the date and the nature of the event. Our website and its contents are not incorporated into this proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_30"></A>Report of the Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee has reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2021 with management of the
Company. The audit committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (the &#147;PCAOB&#148;) and the
SEC. The audit committee has also received the written disclosures and the letter from the independent registered public accounting firm required by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable requirements of the PCAOB regarding the independent accountants&#146; communications with the audit committee concerning independence, and has discussed with the independent registered
public accounting firm the accounting firm&#146;s independence. Based on the foregoing, the audit committee has recommended to the Board that the audited financial statements be included in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AUDIT COMMITTEE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holger Weis (chairperson) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mary Thistle </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jaime Vieser </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This report is not &#147;soliciting
material,&#148; is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended,
whether before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_31"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_32"></A><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was compensated as described below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual cash retainer fee of $50,000 for service on the Board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional annual cash retainer fees for board committee service as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chair</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Governance and Nominating Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The executive chair of our Board also receives further annualized cash compensation of $40,000. All cash retainers were paid
on a quarterly basis in arrears to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who continue to serve as members of the Board on the last business day of each calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 2021, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director equity compensation program was modified to provide an annual equity award for
75,000 options and 10,000 RSUs to be granted on the date of each of our annual shareholder meetings (our prior practice was to grant annual awards in December each year, with the last annual award under our historical director compensation program
made in December 2019). The executive chair also receives an additional 75,000 annual options and an additional 10,000 annual RSUs to recognize his leadership and workload. The annual options vest in equal monthly installments over one year and the
annual RSUs vest in full on the earlier of <FONT STYLE="white-space:nowrap">one-year</FONT> from grant or the next annual shareholder meeting. The foregoing grants to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors joining our Board
other than at an annual stockholder meeting will be prorated for the number of months remaining until our next annual stockholder meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
in connection with a director&#146;s initial election of the Board, he or she receives options to purchase 150,000 shares of our common stock on the date of each new <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s appointment to
our Board. The directors who received this award in 2021 included Ms.&nbsp;Thistle, Mr.&nbsp;Postma, Mr.&nbsp;Weis and Mr.&nbsp;Vieser. <FONT STYLE="white-space:nowrap">One-thirty-sixths</FONT> of the shares underlying these awards will vest in
equal monthly installments commencing, in the case of Ms.&nbsp;Thistle on December&nbsp;15, 2021, in the case of Mr.&nbsp;Postma on March&nbsp;4, 2021 and in the case of Mr.&nbsp;Weis and Mr.&nbsp;Vieser, on January&nbsp;15, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also granted to all of our directors awards of options and restricted stock to reflect the stub period between January and May 2021, when the date of our
annual meeting would become the new grant date of director awards. We agreed to provide directors an award equal to an annual grant of 75,000 options and 10,000 shares of restricted stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These annual amounts were prorated to only cover the 5 months between January and May, and further <FONT STYLE="white-space:nowrap">pro-rated</FONT> for those
who spent less time on the Board. In the case of Ms.&nbsp;Thistle, we provided her an award assuming six months of service, to recognize that she had not yet received any awards since her joining the Board in November 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As set forth in its written charter, the compensation committee annually reviews director compensation practices in consultation with our compensation
consultant and recommends any changes for adoption by the full Board. As such, the director compensation described above is subject to change at the discretion of the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_33"></A>Director Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the compensation earned for service on our Board by our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2021. We reimburse members of our Board for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable travel and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending Board and committee meetings.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid&nbsp;in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;(1)<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(1)<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Bowden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Huang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Postma (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,226</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaime Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,887</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">581,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holger Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,867</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">593,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi Hagen (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Buchi (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Option Awards&#148; and &#147;Stock Awards&#148; columns represent
compensation expense recognized for financial statement purposes under ASC Topic 718. In the case of each of our directors, the option award and/or stock award was granted on March&nbsp;4, 2021. For a discussion of the assumptions relating to our
valuations of these stock options, please see Note 13 to the financial statements included our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021. These costs reflect our accounting expense
for these stock options and do not correspond to the actual value that may be recognized by the directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Thistle joined the Board in the fourth quarter of 2020 but only received her new <FONT
STYLE="white-space:nowrap">non-employee</FONT> director inducement grant of an option to purchase 150,000 shares of our common stock in the first quarter of 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Vieser joined the Board in the fourth quarter of 2020 but only received his new <FONT
STYLE="white-space:nowrap">non-employee</FONT> director inducement grant of an option to purchase 150,000 shares of our common stock in the first quarter of 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Weis joined the Board in the fourth quarter of 2020 but only received his new <FONT
STYLE="white-space:nowrap">non-employee</FONT> director inducement grant of an option to purchase 150,000 shares of our common stock in the first quarter of 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Postma was appointed to the Board effective February&nbsp;4, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Hagen left the Board effective February&nbsp;24, 2021, rejoined the Board effective August&nbsp;30,
2021, and finally resigned from the Board effective November&nbsp;2, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Buchi resigned from the Board effective May&nbsp;19, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_34"></A>SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
PLANS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our 2012 Equity Incentive Plan, or the 2012 Plan, and our 2020 Equity Incentive Plan, or the 2020 Plan, are our only equity compensation plans
approved by our stockholders. The following table sets forth certain information as of December&nbsp;31, 2021 with respect to the 2012 Plan and 2020 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities to<BR>be Issued<BR>Upon<BR>Exercise<BR>of<BR>Outstanding<BR>Options (A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price of<BR>Outstanding<BR>Options (B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Remaining<BR>Available for<BR>Future<BR>Issuance<BR>Under
Equity<BR>Compensation<BR>Plans<BR>(Excluding<BR>Securities<BR>Reflected in<BR>Column (A))<BR>(C)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity compensation plans approved by stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2012 Stock Option Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,847,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,818,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,247,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,665,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,247,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity compensation plans not approved by stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inducement Awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_35"></A>LIMITATION OF LIABILITY AND INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Charter limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the Delaware General Corporation Law.
Our Charter provides that no director will have personal liability to us or to stockholders for monetary damages for breach of fiduciary duty as a director. These provisions do not, however, eliminate or limit the liability of any of the directors
for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of these provisions will not adversely affect any right or protection of a director in respect of any act or omission
occurring prior to such amendment, repeal or modification. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the directors
will be further limited to the greatest extent permitted by the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Charter also provides that we must indemnify
directors and officers in certain circumstances. We believe this provision is important in attracting and retaining qualified individuals to serve as directors and executive officers. Our bylaws, as amended, also provide for the indemnification of
our directors, officers, employees and other agents to the maximum extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain director and officer insurance providing for
indemnification of our directors and officers for certain liabilities, including certain liabilities under the Securities Act of 1933, as amended. We also maintain a general liability insurance policy that covers certain liabilities of directors and
officers arising out of claims based on acts or omissions in their capacities as directors or officers. We have also entered into indemnification agreements with each of our directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_36"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion relates to certain transactions that involve both the Company and one of our executive officers, directors, director nominees or
five-percent stockholders, each of whom we refer to as a &#147;related party.&#148; For purposes of this discussion, a &#147;related-party transaction&#148; is a transaction, arrangement or relationship: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in which we participate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that involves an amount in excess of $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in which a related party has a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_37"></A>Related-Party Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of
related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person,
directly or indirectly, are, were or will be participants in which the amount involved will or may reasonably be expected to exceed $120,000 in any calendar year. Transactions involving compensation for services provided to us as an employee or
director are not covered by this policy. A related person is any person who is, or at any time since the beginning of the Company&#146;s last fiscal year was, an executive officer, director, or nominee to become a director of the Company or a
beneficial owner of more than 5% of any class of our voting securities, including any of such persons&#146; immediate family members and any entity that such persons owned, controlled, held a control position in or held a 5% or greater beneficial
ownership interest in. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a
related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to
our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the
material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third
party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing
or potential related person transactions and to effectuate the terms of the policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering related person transactions, our audit committee, or
other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to: the risks, costs and benefits to us; the impact on a director&#146;s independence in the event that the related
person is a director, immediate family member of a director or an entity with which a director is affiliated; the availability of other sources for comparable services or products; and the terms available to or from, as the case may be, unrelated
third parties or to or from employees generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person
transaction, our audit committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interest and those of our stockholders, as our audit
committee, or other independent body of our Board, determines in the good faith exercise of its discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc352067_38"></A>Certain
Related-Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described below, there have been no transactions since January&nbsp;1, 2021 in which we have been a participant
in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive officers or holders of more than 5% of our common stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation
arrangements which are described elsewhere in this filing under the sections titled &#147;&#151;<I>Executive Compensation</I>&#148; and &#147;&#151;<I>Director Compensation</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration with PGEN and MD Anderson </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;13, 2015, the Company, together with Precigen Inc., or Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson Cancer Center, or MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the
MD Anderson License, the company, together with PGEN, hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR <FONT STYLE="white-space:nowrap">T-cell</FONT>
therapies, <FONT STYLE="white-space:nowrap">non-viral</FONT> gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of
Laurence Cooper, M.D., Ph.D., who served as the Company&#146;s Chief Executive Officer from May 2015 to February 2021 and was formerly a tenured professor of pediatrics at MD Anderson. In partial consideration for entering into the MD Anderson
License, the Company issued MD Anderson an aggregate of 11,722,163 shares of common stock for which the Company incurred a $67.3&nbsp;million charge recorded in 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2021, the Company made payments of $0.1&nbsp;million to MD Anderson compared to $0 during the year ended
December&nbsp;31, 2020. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs for the year ended December&nbsp;31, 2021 was $0 and for the year ended December&nbsp;31, 2020 was $8.1&nbsp;million,
which is included in other current assets on the Company&#146;s balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>WaterMill Settlement Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;4, 2021, we entered into an agreement (the &#147;WaterMill Settlement Agreement&#148;) with WaterMill Asset Management Corp. and Robert W.
Postma (collectively, the &#147;WaterMill Parties&#148;). Pursuant to the WaterMill Settlement Agreement, we increased the size of our Board from eight to nine directors and appointed Mr.&nbsp;Postma to fill the newly created directorship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The WaterMill Settlement Agreement included certain customary standstill restrictions applicable from February&nbsp;4, 2021 until the date that was the
earlier of (i)&nbsp;January&nbsp;1, 2022 and (ii)&nbsp;thirty (30) calendar days prior to the nomination deadline for our 2022 annual meeting of stockholders (the &#147;Standstill Period&#148;). During the Standstill Period, the WaterMill Parties
were, among other things, restricted from engaging in any solicitation of proxies or written consents with respect to the election or removal of directors or, with certain exceptions, any other matter or proposal, or acquiring voting stock that
would result in the WaterMill Parties having beneficial ownership of more than 9.9% of our outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the WaterMill Settlement
Agreement, we agreed that during the Standstill Period, we would nominate each of Mr.&nbsp;Postma, Jaime Vieser and Holger Weis for election at any stockholder meeting at which directors are to be elected and will recommend, support and solicit
proxies for the election of each of Messrs. Postma, Vieser and Weis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The WaterMill Settlement Agreement also provided that at any meeting of our
stockholders held prior to the expiration of the Standstill Period, the WaterMill Parties would vote all of their shares of our securities in accordance with the recommendation of our Board, with respect to the election, removal and/or replacement
of directors. The WaterMill Parties retained the right to vote in their sole discretion with respect to any other publicly announced proposal not made in breach of the WaterMill Settlement Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, pursuant to the WaterMill Settlement Agreement, we agreed to reimburse the WaterMill Parties for up to $400,000 of their reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses out of a total of approximately $650,000 in fees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and expenses actually incurred by the WaterMill Parties in connection with (i)&nbsp;the WaterMill Parties&#146; solicitation of written consents from our stockholders to vote in favor of certain
proposals, as set forth in the definitive consent statement filed by the WaterMill Parties on October&nbsp;30, 2020, and (ii)&nbsp;the negotiation, execution and effectuation of the WaterMill Settlement Agreement. As of February&nbsp;19, 2021, we
have fully reimbursed the WaterMill Parties an aggregate amount of $400,000. During the year ended December&nbsp;31, 2021, we received $250,000 in insurance recoveries associated with legal expenses incurred on this matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joint Venture with TriArm Therapeutics Ltd. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;18, 2018, we launched Eden BioCell, a joint venture with TriArm Therapeutics Ltd, or TriArm, to lead the commercialization of our <I>Sleeping Beauty</I>-generated <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies in the
People&#146;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. Under our agreements with TriArm, we licensed to Eden BioCell the rights in Greater China for its third-generation <I>Sleeping Beauty</I>-generated <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapies targeting the CD19 antigen. Eden BioCell is owned equally by us and TriArm and the parties share decision-making authority. TriArm agreed to contribute up to $10.0&nbsp;million to Eden BioCell and
has committed up to an additional $25.0 million to this joint venture. TriArm also manages all clinical development in the territory pursuant to a Master Services Agreement between TriArm and Eden BioCell. In March 2021 and as announced by the
Company in April 2021, Eden BioCell began treating patients in a clinical trial with the Company&#146;s investigational CD19 RPM <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapy, under the IND cleared by the Taiwan FDA in December. In
September 2021, it was mutually agreed between the parties to dissolve the joint venture. The dissolution of the joint venture and the related entity is in progress. James Huang, who became a director of our Company in July 2020, and was appointed
Chair of our Board of directors in January 2021 and then Executive Chair of our Board in February 2021, was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr.&nbsp;Huang also serves as a member of Eden
BioCell&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration with Vineti Inc. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2020, the Company entered into a master service agreement and statement of work with Vineti, Inc., or Vineti. Pursuant to the agreements,
Vineti is developing a software platform to coordinate and orchestrate the order, cell collection and manufacturing process for the Company&#146;s <FONT STYLE="white-space:nowrap">TCR-T</FONT> clinical programs. Heidi Hagen, who became a director of
the Company in June 2019 and resigned November&nbsp;2, 2021 and served as the Company&#146;s Interim Chief Executive Officer on February&nbsp;25, 2021 through her resignation on August&nbsp;30, 2021, is a
<FONT STYLE="white-space:nowrap">co-founder</FONT> and former officer, of Vineti. The Company recorded expenses of approximately $0.4&nbsp;million during the year ended December&nbsp;31, 2021 and $29,000 during the year ended December&nbsp;31, 2020,
for services performed by Vineti. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into an indemnification agreement with each of our directors. These indemnification agreements and our charter and our bylaws indemnify each of
our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_42"></A>DELINQUENT SECTION&nbsp;16(A) REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity
securities, to file with the SEC reports of beneficial ownership and reports of changes in beneficial ownership in our securities. Based solely on a review of such reports filed electronically with the SEC, we believe that during 2021, all
Section&nbsp;16(a) filings applicable to our directors, officers, and 10% stockholders were filed on a timely basis, except as described in this section. One Form 3 that was filed by Michael Wong in connection with his appointment as an officer of
our Company was not filed on a timely basis. One Form 3 that was filed by Raffaele Baffa in connection with his appointment as an officer of our Company was not filed on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to an administrative oversight, a Form 4 reporting grants of restricted stock and options to purchase our common stock awarded to Christopher Bowden,
James Huang, Robert W. Postma, Mary Thistle, Jaime Vieser, Holger Weis and Kevin Buchi on March&nbsp;4, 2021, were not filed until May&nbsp;6, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_39"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of common stock as of April&nbsp;8, 2022 for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by us to be the beneficial owner of greater than five
percent of our outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and director nominees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers named in the &#147;Executive Compensation&#151;Executive Compensation
Table&#148; section above; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who
possess sole or shared voting power or investment power with respect to those securities, or have the right to acquire such powers within 60 days. Common stock subject to options that are currently exercisable or exercisable within 60 days of
April&nbsp;8, 2022 are deemed to be outstanding and beneficially owned by the person holding the options. These shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. Except as
otherwise indicated, all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. Percentage ownership calculations are based on 215,950,561
shares outstanding as of April&nbsp;8, 2022. Except as otherwise noted below, the addresses for persons listed in the table is c/o Alaunos Therapeutics, Inc., 8030 El Rio Street, Houston, Texas 77054. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned (%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5% Stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MSD Credit Opportunity Master Fund, L.P. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,101,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,633,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,764,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery Capital Management (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,346,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level One Parties (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,178,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State Street Corporation (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,318,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Named Executive Officers and Directors:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,502,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi Hagen (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurence James Neil Cooper (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,752,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eleanor de Groot (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raffaele Baffa (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">436,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jill Buck (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Bowden (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Huang (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Postma (15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,487,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Thistle (16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaime Vieser (17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,132,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holger Weis (18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,689,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents ownership of less than one percent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based in part on a Schedule 13G/A filed with the SEC on February&nbsp;14, 2020 by MSD Partners, L.P., or MSD
Partners. MSD Partners has shared voting power with respect to 15,151,516 shares of our common stock, and may be deemed to beneficially own 15,151,516 shares of our common stock. MSD Partners is the investment manager of, and may be deemed to
beneficially own securities beneficially owned by, MSD Credit Opportunity Master Fund, L.P. MSD Partners (GP), LLC (&#147;MSD GP&#148;) is the general partner of, and may be deemed to beneficially own securities beneficially owned by, MSD Partners.
Each of Glenn R. Fuhrman, John C. Phelan and Marc R. Lisker is a manager of, and may be deemed to beneficially own securities beneficially owned by, MSD GP. The 22,101,509 shares includes 6,949,993 out of the 7,575,758 shares of common stock
issuable upon the full exercise of a warrant, which is the number of shares issuable upon exercise as limited by the Beneficial Ownership Limitation (as defined below) as of April&nbsp;8, 2022. Such warrant is only exercisable to the extent that the
holder thereof, together with its affiliates, would beneficially own no more than 9.99% of the outstanding shares of our common stock after giving effect to such exercise (the &#147;Beneficial Ownership Limitation&#148;). As a result of the
Beneficial Ownership Limitation, the number of shares that may be issued to the holder upon exercise of the warrant may change depending upon changes in the outstanding shares of our common stock. Upon 61 days&#146; prior notice to the Company, the
holder may increase, decrease or terminate the Beneficial Ownership Limitation. The address of MSD Credit Opportunity Master Fund, L.P. is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, <FONT
STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G/A filed with the SEC on February&nbsp;10, 2022 by The Vanguard Group, or
Vanguard. Vanguard is the beneficial owner of 11,633,700 shares and has shared voting power with respect to 395,047 shares, sole dispositive power with respect to 11,076,829 shares and shared dispositive power with respect to 556,871 shares.
Aggregate beneficial ownership reported by Vanguard includes beneficial ownership of its subsidiaries, Vanguard Asset Management, Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisors, LLC, Vanguard Group (Ireland) Limited, Vanguard
Investments Australia Ltd, Vanguard Investments Canada Inc., Vanguard Investments Hong Kong Limited and Vanguard Investments UK, Limited. The address of Vanguard is 100 Vanguard Blvd., Malvern, PA 19355. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G/A filed with the SEC on February&nbsp;3, 2022 by Blackrock, Inc., or BlackRock.
BlackRock, as a parent holding company, is the beneficial owner of 16,764,972 shares and has sole voting power with respect to 16,427,610 shares and sole dispositive power with respect to 16,764,972 shares. Aggregate beneficial ownership reported by
BlackRock is on a consolidated basis and includes beneficial ownership of its subsidiaries, BlackRock Life Limited, Aperio Group, LLC, BlackRock Advisors, LLC, BlackRock (Netherlands) B.V., BlackRock Institutional Trust Company, National
Association, BlackRock Asset Management Ireland Limited, BlackRock Financial Management, Inc., BlackRock Japan Co., Ltd., BlackRock Asset Management Schweiz AG, BlackRock Investment Management, LLC, BlackRock Investment Management (UK) Limited,
BlackRock Asset Management Canada Limited, BlackRock Investment Management (Australia) Limited, BlackRock Fund Advisors and BlackRock Fund Managers Ltd. The address of BlackRock. is 55 East 52nd Street, New York, New York 10055.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G filed with the SEC on February&nbsp;14, 2022 by Discovery Capital Management,
LLC, or Discovery. Discovery is the beneficial owner of 13,346,493 shares and has shared voting power with respect to 13,346,493 shares and shared dispositive power with respect to 13,346,493 shares. Robert K. Citrone, the control person of
Discovery, may be deemed to exercise voting and/or dispositive power over the shares held for the account of Discovery. Aggregate beneficial ownership reported by Discovery includes beneficial ownership of Discovery Global Opportunity Master Fund,
Ltd., a Cayman Islands limited company. The address of Discovery is 20 Marshall Street, Suite 310, South Norwalk, CT 06854. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G jointly filed with the SEC on February&nbsp;11, 2022 by Robert D. Hardie, Mollie
G. Hardie and Level One Partners, LLC (collectively, the &#147;Level One Parties&#148;). The Level One Parties beneficially own 24,178,873 shares. Robert D. Hardie is the beneficial owner of 10,226,937, and has shared voting and dispositive power
with respect to 7,406,823 shares, and sole dispositive and voting power with respect 2,860,114. Molly G. Hardie is the beneficial owner of 7,675,213, and has shared voting and dispositive power with respect to 7,276,723 shares, and sole dispositive
and voting power with respect 398,490. Level One Partners, LLC is the beneficial owner of 6,236,723 shares, and has shared voting and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
dispositive power with respect to all 6,236,723 shares. The address of the Level One Parties is 210 Ridge McIntire Road, Suite 350, Charlottesville, Virginia 22903. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G filed with the SEC on February&nbsp;11, 2022 by State Street Corporation. State
Street Corporation is the beneficial owner of 13,318,734 shares and has shared voting power with respect to 12,875,132 shares and shared dispositive power with respect to 13,318,734 shares. Aggregate beneficial ownership reported by State Street
Corporation includes beneficial ownership of its subsidiaries, SSGA Funds Management, Inc., State Street Global Advisors Limited, State Street Global Advisors, Australia, Limited, State Street Global Advisors Europe Limited, and State Street Global
Advisors Trust Company. The address of State Greet Corporation is State Street Financial Center, 1 Lincoln Street, Boston, MA 02111. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 885,000 shares of common stock held by Mr.&nbsp;Boyle and (ii) 617,187 shares of common stock
issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the best of our knowledge, consists of (i) 145,889 shares of common stock held by Ms. Hagen.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the best of our knowledge, consists of (i) 2,067,017 shares of common stock held by Dr.&nbsp;Cooper and (ii)
685,321 shares of common stock issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 237,106 shares of common stock held by Dr.&nbsp;de Groot and (ii) 475,617 shares of common
stock issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 280,645 shares of common stock held by Dr.&nbsp;Baffa and (ii) 156,250 shares of common stock
issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the best of our knowledge, consists of 127,214 shares of common stock held by Ms.&nbsp;Buck.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 4,167 shares of common stock held by Mr.&nbsp;Bowden and (ii) 175,843 shares of common stock
issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 108,333 shares of common stock held by Mr.&nbsp;Huang and (ii) 62,500 shares of common stock
issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,201,870 shares of common stock held by Mr.&nbsp;Postma, (ii) 4,250,000 shares of common stock
held by WaterMill Asset Management Corp., where Mr.&nbsp;Postma serves as the principal, (iii) 3,574 shares of common stock held by the IRA of Mr.&nbsp;Postma&#146;s spouse, (iv) 946,970 shares of common stock issuable upon the exercise of warrants
exercisable within 60 days of April&nbsp;8, 2022 and (v) 85,416 shares of common stock issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 5,000 shares of common stock held by Ms.&nbsp;Thistle and (ii) 112,500 shares of common stock
issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 705,321 shares of common stock held by Mr.&nbsp;Vieser, (ii) 325,000 shares of common stock
held in Uniform Transfer to Minors Act accounts by Mr.&nbsp;Vieser&#146;s children, and (iii) 102,083 shares of common stock issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 120,167 shares of common stock held by Mr.&nbsp;Weis, (ii) 19,000 shares of common stock held
by Mr.&nbsp;Weis&#146; spouse, (iii) 2,440 shares of common stock held by Mr.&nbsp;Weis&#146; children, and (iv) 102,083 shares of common stock issuable upon the exercise of options exercisable within 60 days of April&nbsp;8, 2022.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_40"></A>HOUSEHOLDING OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (such as brokers) to satisfy the delivery requirements for Notices of Internet Availability
of Proxy Materials or other annual meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other annual meeting materials addressed to those
stockholders sharing the same address. This process, which is commonly referred to as &#147;householding,&#148; potentially provides extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are our stockholders will be &#147;householding&#148; our proxy materials. A single Notice of Internet
Availability of Proxy Materials or other annual meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your
broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in
&#147;householding&#148; and would prefer to receive a separate Notice of Internet Availability of Proxy Materials or other annual meeting materials, please notify your broker. Alternatively, you may direct your written request to Alaunos
Therapeutics, Inc., 8030 El Rio Street, Houston, TX 77054, Attention: Legal Department or contact us at (346) <FONT STYLE="white-space:nowrap">355-4099.</FONT> Stockholders who currently receive multiple copies of the Notice of Internet Availability
of Proxy Materials or other annual meeting materials at their addresses and would like to request &#147;householding&#148; of their communications should contact their brokers or contact us in the way described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc352067_41"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the
Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Board of Directors,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Melinda Lackey</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Melinda Lackey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>SVP, Legal and Secretary</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">April 27, 2022</TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have filed our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year
ended December&nbsp;31, 2021 with the SEC. It is available free of charge at the SEC&#146;s web site at www.sec.gov. Upon written request by an Alaunos stockholder, we will mail without charge a copy of our Annual Report on Form 10-K, including the
consolidated financial statements and financial statement schedules, but excluding exhibits to the Annual Report on Form 10-K. Exhibits to the Annual Report on Form 10-K are available upon payment of a reasonable fee, which is limited to our
expenses in furnishing the requested exhibit. All written requests should be directed to Melinda Lackey, Secretary, Alaunos Therapeutics, Inc., 8030 El Rio Street, Houston, TX 77054. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Annex A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the
provisions of the General Corporation Law of the State of Delaware (the &#147;General Corporation Law&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name under which the Corporation was originally incorporated is EasyWeb, Inc. The date of filing of its original Certificate of
Incorporation with the Secretary of State of the State of Delaware was May&nbsp;16, 2005. The date of filing of its first Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware was April&nbsp;26, 2006
(as amended, the &#147;Existing Certificate&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Board of Directors of the Corporation duly adopted resolutions proposing to
amend and restate the Existing Certificate in its entirety in the form set forth on Exhibit 1, declaring said amendment and restatement to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the officers
of the Corporation to solicit the approval of the stockholders therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This Second Amended and Restated Certificate of
Incorporation, which restates and integrates and further amends the provisions of the Corporation&#146;s Existing Certificate, was duly adopted in accordance with the provisions of Sections 242 and 245 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this Second Amended and Restated
Certificate of Incorporation to be signed by its Chief Executive Officer this [&#9679;] day of [&#9679;], 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT 1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Name</I>. The name of the corporation is Alaunos Therapeutics, Inc. (the &#147;Corporation&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Address; Registered Office and Agent.</I> The address of the Corporation&#146;s registered office is 2711 Centerville Road, Suite 400,
Wilmington, Delaware 19808. The Corporation&#146;s registered agent is the Corporation Service Company. The Corporation may from time to time, in the manner provided by law, change the registered agent and the registered office within the State of
Delaware. The Corporation may also maintain offices for the conduct of its business, either within or without the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<I>Purposes. </I>The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Number of Shares. </I>The total number of shares of all classes of stock that the Corporation shall have the authority to issue is [the
sum of the shares of common stock and the shares of preferred stock] shares, consisting of: [the then-current amount, divided by any whole number between five (5)&nbsp;and fifteen (15), rounded up to the nearest whole share] shares of common stock,
$0.001 par value per share (the &#147;Common Stock&#148;), and Thirty Million (30,000,000) shares of preferred stock, $0.001 par value per share (the &#147;Preferred Stock&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Delaware General Corporation Law, upon the filing and effectiveness (the &#147;Effective Time&#148;) of this Second Amended
and Restated Certificate of Incorporation, each [any whole number between five (5)&nbsp;and fifteen (15)] shares of Common Stock issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall be
combined into one validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of Common Stock, without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share
interests as described below (the &#147;Reverse Stock Split&#148;). No fractional shares shall be issued and, in lieu thereof, any holder who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash
(without interest) in lieu of such fractional share interest, upon the submission of a transmission letter by a holder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of the holder&#146;s Old
Certificates (as defined below), in an amount equal to such fraction multiplied by the closing sales price of the Corporation&#146;s Common Stock as reported on the Nasdaq Global Select Market on the trading day immediately preceding the date of the
Effective Time. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (each, an &#147;Old Certificate&#148;) shall thereafter represent that number of shares of Common Stock into which the shares of Common
Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above. As soon as practicable following the Effective Time, the Corporation will notify its stockholders holding
shares of Common Stock in certificated form to transmit their Old Certificates to the transfer agent, and the Corporation will cause the transfer agent to issue new certificates representing the appropriate number of whole shares of Common Stock
following the Reverse Stock Split for every one share of Common Stock transmitted and held of record as of the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Preferred Stock may be divided into, and may be issued from time to time in one or more series. The Board of Directors of the Corporation (the &#147;Board&#148;) is authorized from time to time to establish and designate any such series of Preferred
Stock, to fix and determine the variations in the relative rights, preferences, privileges and restrictions as between and among such series and any other class of capital stock of the Corporation and any series thereof, and to fix or alter the
number of shares comprising any such series and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designation thereof. The authority of the Board from time to time with respect to each such series shall include, but not be limited to, determination of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. The designation of the series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. The number of shares of the series and (except where otherwise provided in the creation of the series) any subsequent increase or decrease
therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. The dividends, if any, for shares of the series and the rates, conditions, times and relative preferences thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. The redemption rights, if any, and price or prices for shares of the series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">e. The terms and amounts of any sinking fund provided for the purchase or redemption of the series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">f. The relative rights of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the
affairs of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">g. Whether the shares of the series shall be convertible into shares of any other class or series of shares
of the Corporation, and, if so, the specification of such other class or series, the conversion prices or rate or rates, any adjustments thereof, the date or dates as of which such shares shall be convertible and all other terms and conditions upon
which such conversion may be made; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">h. The voting rights, if any, of the holders of such series; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. Such other designations, powers, preference and relative, participating, optional or other special rights and qualifications, limitations
or restrictions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Election of Directors.</I> Unless and except to the extent that the
<FONT STYLE="white-space:nowrap">by-laws</FONT> of the Corporation (the <FONT STYLE="white-space:nowrap">&#147;By-laws&#148;)</FONT> shall so require, the election of directors of the Corporation need not be by written ballot. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Limitation of Liability.</I> To the fullest extent permitted under the General Corporation Law, as amended from time to time, no
director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of the foregoing provision shall not adversely
affect any right or protection of a director of the Corporation hereunder in respect of any act or omission occurring prior to the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Indemnification.</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1.
<I>Right to Indemnification.</I> The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (a &#147;Covered Person&#148;) who was or is made or
is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;Proceeding&#148;), by reason of the fact that he or she, or a person for whom he or she is
the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or
of a partnership, joint venture, trust, enterprise or nonprofit entity (an &#147;Other Entity&#148;), including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#146; fees)
reasonably incurred by such Covered Person. Notwithstanding the preceding sentence, except as otherwise provided in Section&nbsp;7.3, the Corporation shall be required to indemnify a Covered Person in connection with a Proceeding (or part thereof)
commenced by such Covered Person only if the commencement of such Proceeding (or part thereof) by the Covered Person was authorized by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2. <I>Prepayment of Expenses.</I> The Corporation shall pay the expenses (including
attorneys&#146; fees) incurred by a Covered Person in defending any Proceeding in advance of its final disposition, provided, however, that, to the extent required by applicable law, such payment of expenses in advance of the final disposition of
the Proceeding shall be made only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified under this Article 7 or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3. <I>Claims.</I> If a claim for indemnification or advancement of expenses under this Article 7 is not paid in full within 30 days
after a written claim therefor by the Covered Person has been received by the Corporation, the Covered Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense
of prosecuting such claim. In any such action the Corporation shall have the burden of proving that the Covered Person is not entitled to the requested indemnification or advancement of expenses under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4. <I>Nonexclusivity of Rights.</I> The rights conferred on any Covered Person by this Article 7 shall not be exclusive of any other rights
that such Covered Person may have or hereafter acquire under any statute, provision of this Certificate of Incorporation, the <FONT STYLE="white-space:nowrap">By-laws,</FONT> agreement, vote of stockholders or disinterested directors or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5. <I>Other Sources.</I> The Corporation&#146;s obligation, if any, to indemnify or to advance expenses to any Covered Person who was
or is serving at its request as a director, officer, employee or agent of an Other Entity shall be reduced by any amount such Covered Person may collect as indemnification or advancement of expenses from such Other Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.6. <I>Amendment or Repeal.</I> Any repeal or modification of the foregoing provisions of this Article 7 shall not adversely affect any right
or protection hereunder of any Covered Person in respect of any act or omission occurring prior to the time of such repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.7. <I>Other Indemnification and Prepayment of Expenses.</I> This Article 7 shall not limit the right of the Corporation, to the extent and
in the manner permitted by applicable law, to indemnify and to advance expenses to persons other than Covered Persons when and as authorized by appropriate corporate action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Adoption, Amendment and/or Repeal of <FONT STYLE="white-space:nowrap">By-Laws.</FONT></I> In furtherance and not in limitation of the
powers conferred by the laws of the State of Delaware, the Board is expressly authorized to make, alter and repeal the <FONT STYLE="white-space:nowrap">By-laws,</FONT> subject to the power of the stockholders of the Corporation to alter or repeal
any <FONT STYLE="white-space:nowrap">By-law</FONT> whether adopted by them or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Certificate Amendments.</I> The
Corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Second Amended and Restated Certificate of Incorporation, and other provisions authorized by the laws of the State
of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by applicable law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons
whomsoever by and pursuant to this Second Amended and Restated Certificate of Incorporation in its present form or as hereafter amended are granted subject to the rights reserved in this article. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Annex B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION OF ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Section&nbsp;242 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the provisions of the
General Corporation Law of the State of Delaware (the &#147;General Corporation Law&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section&nbsp;242 of the General Corporation Law
proposing this Amendment of the Amended and Restated Certificate of Incorporation and declaring the advisability of this Amendment of the Amended and Restated Certificate of Incorporation, and authorizing the appropriate officers of the Corporation
to solicit the approval of the stockholders therefor, which resolution setting forth the proposed amendment is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>: that the first paragraph of section four of the Amended and Restated Certificate of Incorporation of the Corporation, as
amended, be and it hereby is, deleted in its entirety and the following paragraph is inserted in lieu thereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;4.<I></I><I>&nbsp;Number of Shares.</I>&nbsp;The total number of shares of all classes of stock that the Corporation shall have authority
to issue is Four Hundred Fifty Million (450,000,000) shares consisting of: Four Hundred Twenty Million (420,000,000) shares of common stock, $0.001 par value per share (&#147;Common Stock&#148;); and Thirty Million (30,000,000) shares of preferred
stock, $0.001 par value per share (&#147;Preferred Stock&#148;).&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Certificate of Amendment of the Amended and Restated
Certificate of Incorporation has been duly adopted by the stockholders of the Corporation in accordance with the provisions of Section&nbsp;242 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this Certificate of Amendment of the
Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this [&#9679;] day of [&#9679;], 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g352067g0001.jpg" ALT="LOGO">
 </P>  <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">ALAUNOS THERAPEUTICS, INC. ATTN: SECRETARY 8030 EL RIO STREET HOUSTON, TX 77054 SCAN TO VIEW MATERIALS &amp; VOTE VOTE BY INTERNET
- www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on 06/12/2022. Have your proxy card in hand when you access the web site and
follow the instructions to obtain your records and to create an electronic voting instruction form. VOTE BY PHONE&#151;1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on 06/12/2022. Have your
proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY The Board of Directors recommends you vote
FOR the following: For Withhold For All All All Except To withhold authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below. 1. Election of Directors Nominees 01)
Christopher Bowden 02) Kevin S. Boyle, Sr. 03) James Huang 04) Robert W. Postma 05) Mary Thistle 06) Jaime Vieser 07) Holger Weis The Board of Directors does not have a recommendation for voting on proposals 2. through 6. For Against Abstain 2. To
ratify the selection by the audit committee of the board of directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. 3. To approve, on an advisory basis, the
compensation of the Company&#146;s named executive officers as disclosed in the proxy statement. 4. To approve, if needed in the discretion of the Board, the amendment and restatement of the Company&#146;s amended and restated certificate of
incorporation to effect a reverse stock split at a ratio of 1-for-5 to 1-for-15,inclusive. 5. To approve an amendment to the Company&#146;s amended and restated certificate of incorporation to increase the authorized number of shares of common stock
from 350,000,000 shares to 420,000,000 shares. 6. To approve an adjournment of the meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or
otherwise in connection with, the approval of Proposal 4 and Proposal 5. NOTE: To transact any other business as may properly come before the meeting or any adjournments or postponements thereof. Please sign exactly as your name(s) appear(s) hereon.
When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership
name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g352067g0002.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice &amp; Proxy Statement, Form 10-K
is/are available at www.proxyvote.com ALAUNOS THERAPEUTICS, INC. Annual Meeting of Shareholders June 13, 2022 9:00 AM This proxy is solicited by the Board of Directors The undersigned hereby appoint(s) Kevin S. Boyle, Sr. and Melinda Lackey or any
of them, as proxies, each with the power to act without the other and to appoint his or her substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side, all of the shares of common stock of, ALAUNOS
THERAPEUTICS, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders of the Company to be held at 9:00 AM EDT on June 13, 2022, virtually via live webcast at www.virtualshareholdermeeting.com/TCRT2022, and any
adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors&#146; recommendations. Continued
and to be signed on reverse side 0000570085_2 R1.0.0.24 </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g352067g0001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g352067g0001.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;A(HS(2VR-1N(4N9'&\@CZ=HHHH$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YO_P#!809_X*Q_
M\$Z_^QS\0_\ I'9U^D%?C-_P>$?L;_%O]JCX<_ F^^%GP_\ %_CQO"^IZQ'J
M4?AS3Y=0NK(W$5F86:*$-)L;R)1O"[5( )!90?PXL?\ @E+^UM'?0M<_L[_M
M"2VZNIE2/PAJ:.Z9Y 8PD D9P2#CT- ']L%?GI_P<7C/P2_9O_[.&\'?^AW5
M?CI_P6!_8,L_C#=_#,_LD_L7_M2_#V/3=,N(_%7]J>"M9C6\=O(^RQXD>8O-
M%MN/,F!P_F)\TFW*^#_L'?\ !*7]JNW_ &XO@W=:M\!_C/INEZ?XWT>^N[S5
M?#%]9V5G##>Q222RS31K'&JHK$EB.F.I H _L.HHHH *^0_^"G__  3U\5_M
MG:]X*OO!.O:'X=DFM-1\">.VOFEADU3P9JS6S:I!;O%&Y:Z'V.'R5?8@,LI+
MJ?O?7E% 'YW_ +4W_!*CXD?$?]HCQ%XV\-Q^"]3TN_\ B=9>,K31Y/&^L^#[
MAK"'P4GA]HO[0TRUDN+69;D&4+#E7A7:S#>R57_:7_X)$_$CX\?';QEXLL]8
M\&Z3INN>%;+Q-I&G7&KWMW)I7Q*L+:UL[&]:9K?=)816UG"AN,"X8EF\D<@_
MHQ10!\FV_P"P)XDE_P""=G@CX4ZC>>&M4\66OBWP_P",O%D]Q),^F:G>Q^*K
M3Q#K0C)C,CI-(MZ(@Z+N+QA]@+%?GGX9?\$>/CA\"KC3_$'AWQMX!U+QMX).
MMZ'X+O\ 4I[N--*\/6_AZZTGPK:2[;=B[V\MS+<7.!C=<S;6D(!/Z<44 ?GA
M\,O^".GCO]G7X,?'GX:>%?'FD>*/!_Q:^#L/@K3Y]>C73[O3-;M--N=*M97C
MM+;RVM7LI+599V,EQFS3(ESD=/>?\$[?B1I/[='PG^)5K;>%=:T#PE\//#O@
MO5%7XA:YX;N[.XL-0GN+BY2WLK5H=4A,<PV6UX\<;LN&" DU]T44 ?E*O_!"
M'XH:'^S5X\\)Z=XH\$WVM?$?X>>)?"=\=5U?4;JTT.]NO$#ZE8RZ:TD+FUMI
M[:8I?00QQ(TUG:2!)6#N?9? _P#P3!^+'A/]LC1_CI<?$+2+_P 17_Q#\0:K
MXB\/N0NFIX=U&U&G106]TMH+F6YBL].T!O*E*P&6QDP5!#M]ZT4 ?F*__!,G
M]H;5?V(/@_\ "^X\._!S0_'GP9\/MH/A;XC^'_BCKVGZOX:G^RPV_P#:$"Q:
M/&9HY%1_/T^5_)F"1!I. 4]4_P""M7_!.3XE?MS6_@)?#MYX)UZ'PCIM[LM?
M$5^^DPVVMR&V$&JLL=C>QWUOY*7EO/IEQ&MO<0WCAFR$*?<U% 'R'KW[$OQ4
M^+__  2YUGX4>//%FCW_ ,8$>?5-(\4Q:C<7%J-8M]3.IZ5=L7@66"*.XCM@
M8%67R8H_*5Y@H9N5\'?L!_%[X%:C\&?B'X8;X9^+/B=X8_X2ZX\=:5JNI7>C
MZ5K-WXGO(-2O9[*_BM+B6,VUW:PPQ"6T/F6WRDQ%%%?<U% 'Q1\&?^";'CCX
M<^(/V:M6U+7O"M_J'PT\;>,?'7C+[(+BWMY+GQ!:ZL6M]-C97+107.IA 96C
M+11%\!V\NMO_ ()I?L7^/_V/O&'CZ#Q1IOAJ32?$6N:WK%KJ^F_$+6]3:Z%Y
MK-U?P1G1;JVCL=/9(;HI)):R,TCQY;>7+#Z\HH **** /Q2_X)Y?MJ_&3P-X
MO_:<^#_[/?P=N/B!\1-8^/WB_5[GQ/KTK67@OPA;2W44*/>3J=\TVZ"1OLL9
M60IAE+D%*^P_V>_^"*6FZU\3-/\ BM^U'XSOOVE/BY:CS+0:U;K'X5\+E@"8
MM.TL?N0%./WDBG<T:2B.*3)K[;\-^%M+\&Z7]AT?3;#2;(SS7)M[.W2"(RS2
MO--)M4 ;I)9'=FZLSLQR235^@=PHHHH$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 45^9_Q0_X+1>*M$^)7Q*DM_[!\)_#M[C1K/P'XA\2Z-=6&GSVO_"2:=HF
MJZS)>S,EM=VH_M(W,9MY"B6L$$CLIF94;\4O^"T?BI_C#XZ_X1AM TGX8R6M
MM'X.\4ZUH]U%I-Q;P>)-!T74]?;4'*6MS8(VMS2*8'9$@T])VD"W 50#],J*
M_+SXN_\ !6[XW#67O/ 6C^&]:\-ZQJ&HZ9IES'IDMP$BUB_U;1/!.I(XD"36
MMSJ>B&22524DMM8MF3  9L3Q]_P6$^)SZ+XRU[P[X^^$]I)8VOB0ZQH&N_9]
M+3X:-8:[:V6FZ?=W4\ZK'KU_8IJ;Q6MX4BDN8!A4@@E:4 _5ZBOAS]I7]LSX
M@_"K1O@OK6F^*+K3="O_ (<ZS\1?&L>M>#U@U3^R]'TZVN;F62(R 6=R\][9
M0M#M81F67&2HQXM+_P %4OCP/$/@OP;XJC\*_"[Q3J6O^&/ FM-JB:<9%U9_
M#<^KZO/;>=>QVQ\R:_T"&&W,K2A990$>1@J@'ZF45^3]M_P62^.'B+X5_$:X
MT/0H;SQ=XB:VO?AOI">$+K5+RUTBY?4KZ/69K>QEEDN-/.CQZ9''(523^TKB
M2*9(82CG8^+7_!6'X\CPS\3OBIX2TOPC8_!'1=/LM*T76];AM+:R35M2M-!B
MLY/M,E_&Y$.I:K="X,\$-HEO: _:=^\  _4BBOSY^#?_  44\?\ Q;^-EC\+
M]'\9^!-5\2ZEXFTJW1HK:WO+ZS\-R^$$U^XUZ6*TN'A:U>\NK;3HKB-S;-+M
M"R.T@KROPS_P51^-NC^"?AO?^*/&7@/1]#^(GAK0/$&K^+M6T--/TWP+8^(K
MR\;3+R=C<>4-MAHU_&#,PC-]J-D&PB^5( ?JU17Q;^Q5^WE/\3_VPO'GP^\0
M?%CP;XVL]!-AI/AVX\/06CV6L3R6D\KI<312N\.LH^F:P\]D51%MX[>2-5 E
MSX?\>O\ @K+\==$^)OBZW\#Z#X=U30=/\2ZOX3ME;2Y9[BPN+N[U#PYX:GD*
MRC=&_B;0;^.<G&8+^#"@H&< _4*BOD/]@W]NF/\ :,\?ZX_B'XH>#VUK4O$>
ML^'[/X:VME''JWA0V-Y>1P)>D2M,EY):64LTZ3*J;F41!53=-X7X[_X*W_$G
MQA;_ +0]_P"$+7^Q='TGPO#K7P?GOO"-WCQ-)#?OIS,99F2"]@U"[FL&AEM7
M*QVMW S?O795 /TPHK\Z_P!H+]IG]I7X8?$CXB^$?!'C;POXR\1>'Y/">@>'
M8M3\(+:6FI:[K%S=/=0S-'<9$5GID,%U\I4LTQ#,%%>Z?\$T_P!N36?VX? C
M^)+ZQT?3;'6(+C7]/T^2XD@UK3-,FU;4;+3/M%F8\;)[?3GG$YE!9F=!$!'O
M8 ^H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH YCXB_&7PS\)M5\)V7B+5(]+N/'&M+X=T4212,MY?M;W%RL&Y5*QE
MHK68J9"JLRJ@)=T5O*-*_P""H7P/UWQA8Z)8^,+R^N+Z\AL/M5MX=U2;3;*:
M>_FTZU6ZO5MC;6GVFZ@>.W-Q+&+G,;0F1)8V?J_VR_V9O^&M?@)?>$8/$%QX
M0UJ/4-/UO0O$-M90WEQH.IZ?>PWMG=I%*"DFR:!-R-PZ%T/#&O!K/_@CUI/A
M25?#/AOQI=:9\(=57PBVO^%[K3/M=_>R>&4LXM/^S:CYR&WCEBTZQCN4DAG,
MB0'RGMWD=R =OI__  5N^">K64DMM=_$Z:1-?'A9;-?A3XK^W3:I]EN;M[..
MV_LWSI)H[>TGEE5$8PH@,FS>F[N/BC^W7\,/@Q\=;#X:^(M=U*S\8ZG80:A;
M6D7A_4;J"1+C[=]FB^U0P/;BXG.FWRPVQD$\S6[+'&[%0?'_ (J?\$I;;QSI
MTWV/Q1HLMX?BMJ7Q3BB\2>&!K.F>?>:3<Z:;62V6X@,BQ+<F9)/,4B2-"00,
M5N?&S_@G%IWQ_P#VZ/"?QR7QA_9<OAJWT6*./3].4ZEG2[G5IEC@U#S?W-O=
M#5IH+N'R7,T,?EAX]Q- '>Z#_P % ?A#XH^'-_XNT_QA'>>&-,N-"M+C4XM-
MO&MA-K4=E)ID:MY6'::/4K!\+DQK=1F38#FN5N?^"M'[/\7P\N/%5OXZN-6T
M2SMM;O+N72?#NJ:G-8PZ-=VEIJDD\-O;/+"EO)?6C,TB*#%,LR[H09!5L?\
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M?V%X1B_X05="\%QKIFDZV9;2V2TN%U#2)3?M+<.]R;FUGEB6R\\,EN8X;B8
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M %%%% !1110 4444 %%%% !1110 4444 >9?M*?#GQ)XOE\":]X2M=#U/7O
M'B3^W8=-U:_DT^UU%)-/OM.E0W,<,[1,D=^\JGR7#M"(R8Q(94^7M9_8J_:4
MT?PI8Z/X5\7>$])T^W\-V%E<VR^+-7M8VNEN(YKF"U^RP0_9XB9+EOM1#W4I
M@@C#P0SR1P_1/[;.O?$;PQ\.]-U#X8Z&VO\ B&QEU.Z%KYDBHSQZ#JLEFKJD
MT0D1]02QB*.64^:. 0LB>(^-T_:.T?XP2>)+N^OKZP\+V<VBH=&T.?[#<0W&
MHVSS:JFEK?XNKB*TS$D<K2M&(I98E=G:VF /9OVA_@-XR^+O[*_AWPS'K+7G
MC32=2\-ZG?7QURYT1=4>PU&RN;T-<6,2LGGQ07"@)"J;I%^1  5\"UC]A?\
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M:+H_PQL-6U34-1O+%3#?6NEW=W9W\MLL;O(XAGLIEVNB,^4*!PV0 <C\?/\
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M.1[M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)O &@>&_$UFFL/\ ;M0\1)<WS7&H&9HE#V43:A+MAQ&B)(\@CS!$B]G^T_\
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M!]TT5\Y_M5^"?C-XU_:.\ K\-]6DT/P_86PN]5O;C4#%80NFJ:>TJR6JPO\
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MLVU2S27%P >Y4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR#Q;^W9\-/ 7Q"\2
M>&=;U+Q%I.H>$-/.K:S<7?A35H=-TZS$<\BW,E\UL+40N+:X6-_-VR20O&A:
M0%*]?KP7X_?L67'QN\;>/M;A\31Z/<^*O#/A[2M,)T[[4NEZAHVJ7VIVUU*G
MF)]HA:>YA#P QEDA=?-4R!D .H\,?MG_  Z\5>!->\1)K&I:7IWA6\@L=:CU
MO0=0T>^TB2<Q>4UQ:7<$5Q%$PF1A*\8CV;GW;49@WXA_MJ_#CX9:[J&DWVL:
MEJ&N:7J)TFYTC0M!U#7=46Y%E;WSJMI9033NJ6UW:R.ZH4074 9E,B!N=T3]
MD6X^)4'Q9NOBO<:/J]U\8?#\'@_5-,T6.6"QM-%AAO(UMQ)(3)-,[ZC?2--B
M/"S11A/W/F2<+\.OV$/B!\'+SP3XTT_QUX;\6?%C1K7Q':>)=6UK19+2Q\3?
MVW=:?<RS"."4O!);'2M.AA!:13;6YA.TLDL0!WVI?\%(/@_I-Q<>;XBUAM/M
M_#+>,VUB'POJTVBMHJV7VXZ@NHI;&T>W\CD2+*5+XB&93LKU/X:?$G3_ (L>
M$X=:TNWU^ULYG>-8]9T*]T6[!1BIW6UY%%,HR."4 8<@D'-?,FN?\$NIM2_9
MTUSP#'XVC\S7/@QJ/PKGU)](^]=WJR&74_)$N%0R2NXMPV "%$F #7L_P!\*
M^.OAU>0^&]9AT6;PWI^FO<C4HK^]N[F[OI[R=S"&NYYI]D405F:1SEIT5-JQ
ME0 5/"O[>GPA\;?##X>>,]*\<:;>>&?BOK*^'_"=\D4P76;]C.H@12@96W6T
MX)<* 8R"02,RZE^W'\+K#PGXDUJ'Q-)JUGX1\4MX)U2/1]+O-5NH=:4QAK!+
M>VBDFEF'FQY6)&QDY^ZV/F[X)_\ !&NZ^"GAKP7:6_Q"34Y? NG>%8M*BN-)
M9;6TO--&CC5)HT6;A-0.@Z:X7EH9#>/ND-RX&IX9_P""0EYH>DV&F:E\6O$_
MB;3KC_A';C6VN;:/2[VZO=*NKFXDN[>YTPVLD4UT;R;S9G,MP6C@)F8(00#Z
M(\/_ +9?PQ\6:GX<L]+\7:?J5UXNBTZ?18[6*68ZG'?V]W<VKQ;4.Y7M["\E
M)Z)';2,^T#-9^M_MX?"GPUXP\9:%J/BB2PU#P#87FIZR;C2KV*VB@LXH)KMH
M;AH1#<M!'<V[2) \C1^<FX G%>2_ K_@FCK7P)^.G@'Q_8^.M+GUCP7X+TKX
M=7$:Z MO;ZOH=H+D2Q>5'*(K::1_[-G#PHJH]BZ!?*FVQX/Q7_X)2Z[\2/B+
M\9-:M_'FFZ7#\2]*\1Z?:#^S[RXDMQJ^EV-DT4R/>?9Q#'+807#&"&*:9H8
M941)%G /H;XH?ME?#KX-_$:#PKX@UR\M=7D2TDN#!H]]>6>DI=S-!:O?7<,+
MV]BDTJ.L;74D0<HV"=IQ#;_ML?#:YUG5;,:WJ$:Z/K4'AV:^ET+4(]-GU&;4
MXM*6UM[QH!;W,BZA-';2""1_)E)6385;'F/C?]BWXA_$&'XAZ7?>+/!MOH/Q
MN@M[?QLD.DW#7%FB0BRN/[/9IB/])TZ."%?-_P"/:=)+@>>'%NF;\1?^"<^O
M?&?]EC5?@3XK\1>&[SX7R:W87=NUO874&J7VG0>(;;5393R)<*(W%K"]F9XR
M6D>03XB*F%@#V;X8?ME?#OXT^+-/T?PGK&H^()=4L$U*WO;'0[^72S!(K/$S
MWP@^RQF6)1-$KRJTT,D4L8>.6-WP]3_X*)_"#1Y=>CN/$][')X>OI-,E3^P-
M29M1N8M4BTB:&P M\ZB\6I3P6D@L_.\N>>&-MK2(#R?@;]C;Q]IO[17@'QYK
MWC70+K5O"MD;#Q%K>D:9<:5?_$"U2TN[:"UU.VBG^QR".:XCO4F$>895EB@C
MBCFD+>0^*?\ @CGXBU[Q'XEOH?B+I]O'J'B"^UZSB^QZCF0W/C>P\5K'(1?
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MK:3X;\8>'6@74=-FT^^E>U,UO%<Q9:.%D.Z&:-_E8_>P<$$#Z>HH ^._#O\
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M*?QQ^)F@^#?"OQ@T?6/$WB:]CT[3+&/3;]'N[B0X2,,\ 4$GNQ ]Z[C]IO\
MX*>_ #]C+X@VWA3XI?%3PMX(\17EA'JD-AJ4SI+):O))&DHPI&TO#(O7JAJ]
MXC_X*(_!GP;X=TK5M9\<6>CZ?K2WLEK+?V=U;9BLFA6[G=7B#100FX@\R:0+
M&GFJ2P!KU_0=?L?%6A66J:7>VFI:;J4"75I=VLRS074+J&22-U)5D92"&!((
M((H ^3&_X+Z?L;JN?^&A?A[QSQ<R?_$5Z]^T?^W_ /!G]D/PKX;USXF?$3P[
MX-TGQ>&.C76H3,L>HA41R8\ Y 5T.?\ :'K7L%% 'R%_P_R_8W_Z.%^'O_@5
M)_\ $5ZOJ/\ P4*^#&F?LBM\>I/'VCR?"%65?^$FMTFN+1BU\+ 8$:,Y_P!*
M(BX7ALYP 37LU% 'Q?\ \1#7[&O_ $7+0_\ P5:E_P#(]>S_ +.7_!1#X,_M
M;_#+Q3XR^'7CJQ\3^&?!1==;OH;2YB2P*0^>VY9(U9L1_-\H/Y\5[310!\7I
M_P '#O[&<B*R_'+0RK#(/]E:ES_Y+UZ;^RE_P54_9_\ VX/B1>>$?A7\2--\
M8>(]/TV36+BRM[*[A:.TCEBA>7=-$BX$D\2X!S\XXP"1]!UXM\4/VWM#^$WQ
MUF\%:AX7\8W%KIMMHMSJ_B6UBLWTC1!J][<V-B)PURMV0UQ:LKO%;R1Q+(LD
MCI&LCQ@'YQ:1X+L_V6/AIX!^#.F:/^T1K>E? /7_ #],F'[/7B74M-N[U-+O
MM-U.6WN;*ZA::SO+RZEU&$B9Q&9I8U>2!H$M^\^%7]C_ !M\3ZW\/9/#7[1F
M@:=\2OB/;^,/[4NO@SXK\-O8%/$3:WY%QJ1NUBMUP6MUN8$MRN5D8,05/U8W
M_!3[3;KX:7'B[3?A/\3]8T6+Q1:>$HGL[SPXTMS=76I_V7 _EMJJO%&UVT28
MF$<BB96*!0Y3IM:_X*)_#_P?XN\::'XBCU[P]J7P^\'MXQUR*YM$N/LT4,,,
M][9(;:27SKRTBN].>:.+>N-4L_+>4R$* >-_MH?%/P1\'/!6@_!+2?AK\?$T
MOP=KOA;Q+;7WA#X6ZQXHTV1=+UJQUC[/]JA4B2:8V9CDE:1G5YVD?S&#*WRG
M\<[?P)\8/ ?B^PA\ ?M<Z5K?B^Z\;3W.I_\ "@O$UPJQ>(K#4K-8A;LZQ VW
MV^-BZ[3-]FQ^[\PLOZ#>*?\ @HAH?PL=(/B%X)\;?#?4)O#&O>+8;/7+C1Y)
M)[/1QIGVE5>UOYXC*[:I$D:>9\QMYRQ11&TG5?&/]L7PM\#]&^'=]K%KKDT/
MQ(UBPT>R6SMDFDT[[641+J[7>#':I++;Q22KN$;W,(/#;@ ?/7Q?^,?PN_X)
MA?M=7GQ$^+WQ4\*_#O3?BK:ZE%9:#I.B:E!;>)YX9[)O[2O8UEN(3?VT#0VQ
MGCCB>=)B9"RI!%;_ "E\'OVU?V,_V8/@W\&['X?_ +2WAF3QY\*8-/M[[7/$
M.B:]J4/BF&VT>?2VMV21GELK<">2>"&"0Q6SLX2,K-,'^_+S_@J#\.=/^(7B
MSPO-8^+(M9\'>(9] O87L(U$PCT;4=6%["3+B2T=-)U&W5^'^T6LB%%4>96U
MX _;W\/>+_A[XVUO5/"OC7P??> _#%OXSU'1-7ALY;Z72+B&ZEMKN%[2YGMG
M$IL;R-4\\2*]NV]$5HV< ^/=+^$7P4^!7PM\._M6:Y\=--;PQJ6I:-K=EXD;
MPU>+I5Q>R^)?$FJZB4L?-=_)N_\ A)+VVMDF$CV)@MY_-GD3)\\^+'[<O[&?
MQ;^%=]X3NOVJ-'LK74M<\::M/<6_A34#,L?B*TU2V\I \94-;C4MV]@RR&'!
M1 _R_:OA_P#X*L^%/%5CHZZ?X%\=7&M:OX@G\.?V3]MT%)+6>&QM;\N;EM2%
ME+&UO>6[#[/<2ON=D*!XY%3H/#W_  4,T[5/'?BC0]2^&_Q(\.KX3\8Z=X%O
M+^_.D26LFJ7Z:?-;I&+>_EE*&WU.UF+M&H"%E/[Q?+H ^;?!$GPR_P""AGPT
M\;?'GQ-\8O _CKP!X32'2?&1T3PG?V&CC2]*TG5I+ZW>.XF>Y+S0^()9G92Z
MQQ+%$BNXDFD\?\!?MV?L;Z#^S#X"^&^O?M:+XF?PCX\U+QQJ&O?V-J^EZEKK
MWFH:G?,C2V@C>";?J/S31, YB8^6JR;%^X?&/_!4;P/X-^)6A^&9?#OC2ZFU
MG7KKP^]W E@(;&:#6H-%\QXY+M9Y4>\N8@HMHII-A+,B=#O_  2_X*%^!?CY
M\06\+Z)9^)H=6A\2:_X7N([VQ6!;>ZT=T69R=YW0S))')#)'N#*V&\MU=% /
MF7]F[XG?"O\ X*#?&/QCX3^$OQT\,^+?!4GC30OBIJ^DQ>'+]=<L)=-N--FB
MMTO9W2)H9K[3+:5Y'BDD$;SP@?/'-!P?[$G[>7[''_!-;1]2^'\_[1>A:O\
MV;H>A^&=9M[GPYJ2S-J^D69TN\N/,99=L$T=O;!;128X'BG96?[0V/K[0_\
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MT6;<PR0V.GW+/Y3/S/'QYJO#]L?M+?M[Z%^RJ^AKXD\(^-KDZAX6U;QKJO\
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M\3$T<>$?&Q\+R>*3X+'C7RK'^P?[6!,1M_\ CZ^V8^UJ;/S!;>7]I&S?CYJ
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MNG>$[N*SU35=L>NS:5K/B.=[&[N(;..,RQZ?K%J4O$MD22^M%E\B%.!<UO\
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M^E^(G\)0"#P-KC-KVKI-=PR66F9M -2DCDL+L2&T,JQ"W=I&1!NK,D_X*[?
M.VN?#L-UXLUVRD\22I AN?!^M11Z3*VK-HWEZE(;39IK#4D:U87K0[9!@X!!
M(!]*T444 %%%% !1110 4444 %?+'[0O_!3&S_9V_;/NOAKK6E^&-/\ "N@^
M!H_'VO>(]2UJ_CO+:Q_XG+S_ &:RM]-N$G,$.C2R/YMS 6$JA [#!^IZ^>/V
MQ_'GP+_9WU==4^*MM#YGQ^_LWX3WWGQS75OJEH6U P07,63'#:HVHWHDN"JJ
M/M2B1\>6  9?@K_@JSX \;>/?#?@]/#/Q.T_QQXCUR303X:O?#4D>I:1)';V
M%V\]ZJLR6]N+34K6X,KO@*73_7*8J^E=0>XCL)VM8X9KI8V,,<LIBCD?'RAG
M"L54G )"L0.<'I7QE^R5:?LXZ;^V;=^"O!7AGQM_PLKP1<^([B36]>UK4=6D
MFE@AT"QOV>[N[R>:XS!/I,40FW!([9E3RPN&^TZ /SI\*?\ !P'9^/;OP]I^
MC_"RXN-7\3>$-!U*TAG\0BW@'B74-5TC3;GPZTIMLB2S.NZ;+)-LR4F)\E-N
M3T!_X+:_:=$UK[%\.=6U:ZT#_A&;B:]TA+N]TV]BU7QI-X9D@MR]O#.]R@MY
M98D,0\Z2.9%^6+?)[QX:_P""6_P#\(>+-.US3OAQI=OJVD^.;_XDV=Q]KNG-
MOK]]&L=U>*&E( =4CQ#CR4,412-3&A6;1/\ @F;\%?#>HV]QI_A.^M/LZ6*B
M"+Q'JBVLIL=>?Q#9O)!]I\J5X=4EFG1W5F432Q ^3(\; 'DO@O\ X+1>#_&'
M[1>C^&5\+^,+?PEKVD:.RZQ)H\XFT'6+[Q%JGAUM/U./&VVV:E81VH<,X>65
MB,PHTHCU;_@MM\/+Y_!E]H^GZ]8>'=<U6VN-1U+Q)ID^EHOABZT/7]6M?$%H
MI5FFMIET"Y"JP24*KEXT.P-YO9?M#?L8^'?V=9/C1X:\+>)->\.:MKEX+E["
M2]6\2[T%]9^(T4CPW-S'M1YXKJ^@Q\LPO[5&'V9@(_I7PA_P2S^ NA:-I\,'
M@>XO[&T,#V=MJ^OZGJD-I;Q6&H:?!91I<W$BQV,5IJVHQ1V2@6L8NY"L08@@
M L?L*?MQO^VQJGQ.DC\(ZYX0T[P3K>GZ;86^MV[6FJ7$-UHFG:F)+FW)/DMF
M^*A=QRBJ3@D@>@_M8?'+_AF']EKXE?$K^R_[<_X5YX5U3Q-_9OVG[+_:'V*T
MEN?(\W8_E[_*V[]C;=V=K8P:?[,O[('@']C_ $+6-/\  >FZM8PZ_=Q7NH2Z
MGX@U'6[J[EBMH;2(M/?3S2[4M[>")5#[52)%   JG^W)XN\#>$_V5/&$7Q*T
MG6-?\$>*((?".J:3I4$\][JRZO<1:4EI$L#++OFDO$B!C96&_(((R #Q'X;_
M /!8SPC>>'/#,OC#25MM0U^."_O)O"$E_KNC^&].N=0&FVEY?W=W8V$D*37@
MEB"BW8CR)7R8HWD7LM?_ ."F_A ?L0?$;XY:+HVOSZ#X)-Y9Z;#K5NVC#Q3?
MP[(88+:216(CFOI%LUG9-OFJY 9 &;%\9^ _V9?VD-8\,^,O'4=CX?\ $?A6
M"SLWTO7O$MQH%];)9B36K2SU>Q6ZC6Y6%+.:_C@ODE5(XIYE4*9&,VF7'[(/
MC3X)>$?A1:^-OA-K?@BZ9O&6A: /'$-W#K$5E?S7\EX%^TLUY:PW=M<22!S)
M &MI XQ&0H!YQIW_  63OO%5W\-ET_P+9V?_  F5GIR:M!<ZFTSZ+J;^.=+\
M):C9I(L:K.EO->73I. HE^SQG:JR<?=]?"NC^'OV!_!?Q+\(KH?B#X66^L?$
MOQD^F^'8-"\5R26-UKUG>Z9K#VD$=M.;:V=;W3]+E,($://)%&59[PQS_=5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2_ O\ Y+3\2/\
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MJ7Q6NO&VJ>)O$6M6NK17Z36$-K#//J/]BM/,%C^[A]&1@HX'VAQT5:^F***
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MZO\ 4K+3?$%Q<7\EKI<5A>6EO)=ZDD=H3''-]L'DB$R F'<[I&TDEO\ 6%%
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MXA_^0*/^(H']AG_HMTG_ (1/B'_Y K[ZHH ^!?\ B*!_89_Z+=)_X1/B'_Y
MH_XB@?V&?^BW2?\ A$^(?_D"OOJB@#X%_P"(H']AG_HMTG_A$^(?_D"C_B*!
M_89_Z+=)_P"$3XA_^0*^^J* /@7_ (B@?V&?^BW2?^$3XA_^0*/^(H']AG_H
MMTG_ (1/B'_Y K[ZHH ^!?\ B*!_89_Z+=)_X1/B'_Y H_XB@?V&?^BW2?\
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M+\"_^2T_$C_K[B_]#FKUJO)?@7_R6GXD?]?<7_H<U 'K5%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7DOP+_ .2T_$C_ *^XO_0YJ]:KR7X%_P#):?B1_P!?<7_H<U 'K5%%
M% !1110 4444 %>2_L@?\B;KO_88D_\ 145>M5Y+^R!_R)NN_P#88D_]%14
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M@#4[XV-K#%+XP>YUM8M+GN)$ >>.SNM/G>>*3?LM;9V*F.0J0#@OA=_P4_\
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M;S3=%\$^$='T[4FNGN[6QT>WMX;IKH*+DR(B!6,P1!(2#OV+NS@4 ==1110
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M#3??8.V6.36W-X T&XQYFBZ3)M\\#=9QG'GRK--V_P"6DJ)(_P#>=%8Y(!H
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MJ>5%Y?DP011_3%% %?2-+BT32;6RM]WD6<*01[CN;:H"C)[\"K%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M($8"X@2.X 4;), 'Z#45^8^C?M]_M9>%+/XO>,+KX7^./$_ASX>^(=)O-/\
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MX@T:&^,@6SUO3)=-OX=DC1GS()0'3)3<NX?,K*PX(H Z"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **_,ZY7]HCX,^*?CI\1X(?B)-8ZC\4#X9TZY\SQ)XDO\
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MHHH **** "BBB@ KR7]D#_D3=>_[#$G_ **BKUJO)?V0/^1-UW_L,2?^BHJ
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MCMU=Y&8DEB2>)O"VF>--$FTW6--L=6TVYV^=:7MNEQ!+M8,NY&!4X901D<$
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M]D'X<Z]\+_@S-8>)K6RL=9U+Q-XBU^6VM;K[5';)J.MWVH11^9M7<RQ72*Q
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MKK-CH/CK2+?6;"WU:T^RWD4,R!U$B99<X/WD9T889'=&5CWE>0_L;_L<Z/\
ML2?"K2?!/AGQ)XMU;POH6DP:786&L7%O-':LEQ=W$MPGEPQE7F:[VLBD0QQV
MUND,4*H0WKU 'A^E_MTZ/#\1?'>A^)O"/BSP-IOP]E@@U#Q!K=SI/]FW,US+
M''90VZV][-<R2W9E3R8S &9F6,A966-NQ\0?M4_#?PM\)M*\>7_C;P[;^"]<
MB6XL=;^V*UC<0F)IC,)1E?*2%))7D)"1QQN[E51F',?$W]BO1_B%KWB;6[?Q
M!X@T7Q!KVM:-XAM[V#[/(NEWFEA5@,<4D15XY%5DE23<2LC[&B?8Z<3\=?\
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M\&QV=QHK>(X;\ZK%]@FTY;;[6URMSN\ED%K_ *1D/GR/WO\ J_FJCX=_;O\
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M(64-EIL>EG3KM]+>;3K>T%MY=E;E])A?;;",![R^90C31F'F?!/_  1S\%^
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M*0PW+M .R\+_ +6OPS\<Z/XJO]#\<>&]:L_ ]JU[KDMA>I<KIT"^>#*^PGY
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MT7PS-&\=A,US;Z7J5Y?1EF>W.#.M_=V\VT F*4&,PRHLM>Z4 %%%% !1110
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M5U!/-EMWA+PR'R8Y' /NZBOBGPG^R#\>+#5-!33/&VI>&?"^LWFHW6JZ??\
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M[X3^-OA==<\&>)_#OB[16E> :AHNHPW]J9$QN3S(F9=RY&1G(S715^;OPO\
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M:W=WESID_P 1=&N--BB9I&:UA@\/MJ<$\D1C6.*60.7C4NEC5?V-?VEM5O\
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M,DB^7,B+,@+"0)*@D2.3=&NC110 4444 %%%% !1110 4444 %%%% !1110
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M@BB/VF&0Q 'NFL?MC?#O2;7X7W2^(K?4+'XQ:L-%\*WEBC7-OJ%P;2YNP"Z
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MY'\1O")\+ZUXDM/#LFFW&FP65@+;2EMK,W4R-,+BYO+N::20HVQ(1"JMO3[
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M[I^EZEK.K:[IFB6T6I7,EO:H;R\BMS([1H[?(LA8 #D@#(!R #GO^&%O!/\
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M2WM&$4L=P =E\7_A)^T[JO@;Q)<:'XB\:1^([S4/&5U9Q6>IZ3;PPI!%=?\
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MI.='GCN4U"60,FG>7'-&EE;[G+M(TDB+)+S/B_7OCS\!?"M]HDGB/Q=XNLO
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MPIE<C&XYM44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M//AO\4-#\%^(/&?AW1?%'B32[W6M,T^]O4@DO;.S"-<S(6(7;&L@<C.2B2L
M5BD*QZ=^U9\+M8U3[#9_$CP#=7W]E3:[]GA\06DDO]GPNT<UYM$F?L\<B.C2
MXV*R,"0010!WU%</HW[3GPU\1Q>&9-/^(7@>_3QI/<VOAYK?7;64:]-;%EN(
M[0JY\]XF5@ZQ[BA4AL8-4[7]K_X2WW@S2_$</Q0^'<WA[7-2_L;3=43Q)9M9
M:A??-_HD,PDV23_*W[M27^4\<&@#T2BO,O#W[:/PC\3_  "L?BI:_$OP.OPW
MU(*8/$MQK,%MII+-M"--(RJDF[*E&(8,"I ((K>F_:"\!6_CBZ\,2>-_"$?B
M6QMXKNYTEM8MQ?6\,LD4<<KP[]ZH\D\**Q #--& 264$ Z^BN7\=?&[P7\+_
M  /J'B?Q-XN\+^'?#>DS_9K[5M3U6"SL;.7S!%Y<DTC!$?S"$VL0=Q"]>*\V
M\<?\%(O@E\//&5QH6J?$3PQ;WFE^(U\+ZT\FH0Q6_AV\?2+K6(S>R2,JPPO:
MV<VV4DH9 8\[U<* >XT5RNI?'/P3HWBVZ\/WGC#PK:Z]8Z0?$%SILVK01W=O
MIH?RS?/$7WK;;_E\X@)NXSFN7\0?MI?#'POXZ\ :'>^,?#\/_"T-,N=5\,:D
M=1@&F:PD-QIUN(X+@OLEFFDU2U$*(6,H+[<[>0#U*BN2\4_'WP+X&\.WFL:W
MXT\):/I.GK<O=7M]J]O;V]LMO<"UN"\CN%417#+"Y)&R1@C88XK/?]J'X>V>
MI6=G?>,O#>DW6J:JNB:9%J.HPVC:Q=LD#I%:"1@;AG6Y@*B/<6\U<9R,@'>T
M5P6O?M5?"_PK;>)9M4^)'@+38?!=S#9^()+KQ!:0KH4\QQ#%=EI ('D/"K)M
M+'H#6K8_'#P7JC>*5M?&'A>X/@=F7Q((M5@?_A'RJ&1A>8;_ $<B,%SYFW"@
MGIS0!U%%<1X8_:9^&_C:Z\,P:+\0/!&KS^-H[F7P['9:[:W#:\EMN^T-:!')
MN!%M;>8]P3:=V,&HKO\ :G^&-AXLDT&?XC> X=<AU"VTF33I-?M%NTO+B62&
MWMC$9-XFEDAE1(R-SM$ZJ"5( !WE%<CX9^/W@3QKXCU31]&\:^$=6U?1+Y],
MU&QLM8M[BYL+M%=WMYHT<M'*JQ2,48!@(W)&%.)-:^.O@CPW>>'[?4?&7A6P
MN/%LD4.AQ7.K01/K3R@F);8,X,S. 2HCW%@#C.* .JHK@%_:N^%K7^FVH^)7
M@$W6LZH=#T^$>(;3S+[4 L3&SB7S,R7&V:$^4N7Q+&<89<R77[4GPRL=)\3:
MA-\1? D-CX+:%/$-R^OVBPZ"9L>4+MS)BW+Y&T2%=V1C- '=T5Y?\0?VSOAE
M\--4TNRU'QEX?>ZU2:)#';ZC!*UE#);M<"[N 'S%:^4H<S-\@#H<X8&NP\4?
M%?PMX'\.ZYK&M>)- T?2?"[!-9O;[4(K>WTEC''(!<2.P6$^7+$^'(^61#T8
M$@'045Q-C^TK\.=3UJ;3;;Q_X)N-1M]#7Q-+:Q:Y:O-'I+!2NH,@?<+4AT(G
M(\L[E^;D55\._M9?"OQ?I-_J&D_$SX?ZI8Z7I4FO7MS:>(K2>&STZ.26.2]D
M99"$MUDAF0RL0@:&0$Y5@ #T"BO+_BG^V5\-?@UX4\#>(M?\7:'9^$_B%?&R
MTGQ$;^ :.1_9EYJ:SR79<1+;M;6,Q67<59FC ^\#4GQP_;'^&/[.WAOQ1J'B
MSQMX=T^3P=X9F\8ZGIPOXI-2CTF(E3=K:AO->-I,1HRJ0\C*BDLP! /3**\S
M^'7[8'P[^(>DV;KXM\*Z7K$WAZW\4W>B7/B+3;C4-+TZ=(W2YF%M<31>3B6/
M]_'(\+;U*R,&4G?\'?'WP)\1/$EOHWA_QKX2US6+O2(?$$%CI^L6]U<S:;-M
M\F^6-'+-;2;UVS ;&W#!.10!UM%>'>!?^"DGP/\ B;XO\/Z1H'Q*\)ZI_P )
M5+>VFD7T.IP?8M2O+2[BM);*&4N!)<F65"D:9,B$.NY2K'TO0/C3X-\5W?B2
MWTOQ9X9U*X\'2M!K\=KJD$SZ'( 6*705B8& 5B1)M("D]C0!TU%<'X4_:F^&
M/CS4&M-#^(W@/6KJ.TNK]H;#7[2XD6VM91#=3%4D)\N&5ECD?[J.0K$$XIVE
M_M0?#/6[/PM<67Q$\"WEOXZ,Z^&Y8->M9$\0&#_7"S(DQ<>7@[_*W;<<XH [
MJBO(?!/[?7P9^(?@&3Q=I/Q*\'S>#8[&/4#XADU2&#2A&TEQ'@W$C*@=6MIM
MRD@J%R0 :[#_ (:!\!?\+ T7PG_PFWA'_A*O$ED-3TG1O[8M_P"T-4M"LCBX
M@@W^9+$5AF8.BE<1.<X4X .NHKB=2_:6^'.C:AXIM+SX@>";6Z\#"W/B2&;7
M+6.3P^+C_4&\4OFW\W^#S-N_MFK>J?'CP/H?B;0-%OO&7A2SUGQ7;O=Z)83Z
MO;QW6L0I&97DMHRX:9%C!<L@("@D\<T =717&^$?VBOA]\0-.N+S0?'7@W6[
M2T>ZCGGL-:MKF.%K4(;E69'(4PB6,R _<$B;L;AF[JWQG\'Z#X[T/PM?>+/#
M5GXF\31//H^D3ZG!'?ZM&BEW>W@9A),JJK,2@( 4D\ T =+17DOPR_;D^&'Q
MDU'5H_#'BO2]<T_1]5?1I=7LKJ*XTN2=--BU*39<QLT95+>4%FR,,CC^$UU?
MA7]H/P#XZ\*6&O:)XW\(:QH>J0RW-EJ-CK%O<6EY%%,MO+)'*CE'5)G6)F4D
M*[!3AB!0!U]%<'??M3?#'3-:CTVY^(W@.WU&;5_^$?2UEU^T29]2S$/L(0R;
MC<YG@'DXWYFCX^=<I_PU3\+_ /A+YO#_ /PLCP%_;UOJ<.BRZ;_PD%I]LCOY
MC*(;1HO,WB>0P3A8B-[&&3 .QL '>T5Y]K/[6GPK\.:%K>J:A\3/A]8:9X9U
M.31=8N[CQ%9Q0:5?QJSR6EP[2!8IU569HG(<!22, U27]M7X0CQ'XJTB;XE^
M";/4O ^L6GA_7(+S6(+5M.O[J))K:W?S&4%Y5?"!<[G21!EXY%4 ].HKG=;^
M+OA/PS\0=%\):EXG\.Z?XJ\2)-+I&C7.HPPZAJB0J7E:"!F$DH159F**0H!)
MP!61>_M/?#73?AJ_C2X^(?@:W\'QS2VSZ[)KUJNFK+%O\R,W!?RPR>7)N7=E
M=C9Q@T =S17)ZG\>O VB^-6\-7GC3PG:>(X](;Q VE3:O;QWJZ:I*M?&$OO^
MS @@RXV @\\5Q^A_M\?!'Q+XCU;2]/\ BQ\/;NZT+0;7Q1?/%KMNUO;Z7<RO
M%#=F??Y1B+I@L&.WS(2VT31%P#URBN/M/VA/ -_KOA72X/''@^;4O'5D=2\-
M6D>LV[3^(;41><9[- ^ZXB$7[S?$&79\V<<UFC]K?X4MX#O/%0^)WP]/AC3M
M1&CW>L?\)%9_8+6](0BUDG\SRUF(DC/EE@WSKQR* /0J*X/6/VIOACX=\6S>
M']0^(W@.QUZVN+:SFTVXU^TBNXI[F;R+>)HFD#AY9OW:*1EW^503Q3M8_:@^
M&GAW_A)O[0^(G@6Q_P"$*DCB\0_:->M8O[!>1&>-;O<X^SLR(S*)-I(4D9 -
M '=45Y/=_MW?!73M<\3:==?%CX>V=SX-T^PU;7#<Z];0Q:7:7VW['/+([A%2
M;?$4);D30G_EJFYOQP_;F^%G[/'BNZ\/>*/&&DV?B>STVWUJ711<)]O6PFNU
MLUN_+)'[E9F^9LX54=CPIH ]:HKC-)_:-^'NOR^$4L?'G@V]?X@)-+X76#6[
M:0^)$A4/,UEM<_:1&I#,8MP4')P*BT/]IWX:^)K_ ,/VNF_$+P/J%UXLGNK;
M0X;;7K6:369;4 W,=LJN3,T((,BQ[B@(W8H [BBO$_B-_P %"OA/X!OO"ME:
M^+M \4ZGXQ\:K\/]/L]$UJPFD76-AEFMY7DG2.)X8EWO&SB0EHHT22::&*3V
MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KR7X%_P#):?B1_P!?<7_H<U>M5Y+\"_\ DM/Q
M(_Z^XO\ T.:@#UJBBB@ HHHH **** "O)?V0/^1-UW_L,2?^BHJ]:KR7]D#_
M )$W7?\ L,2?^BHJ /6J\W_:N_9YC_:B^$">$Y=6DT18_$&@Z^+I+<7#!M+U
MBSU18]A(&)&LQ&3GY1(6P<8/I%% 'PC\(_\ @C#JG[+'BR3Q)\(_B_-X<\06
M7B77K[1H]=\-_P!N:5INAZI8:/9#1&@^U0S.EFFA:;]FF6XCV+;A'CE3(/30
M_P#!&_POH7PCL_!>B^+M:L-)L?@KK_P<66:W2XNI%U>2VEGU1WRH,PD@9_+"
MA"93C: !7V110!\Y_L<_L)77[*:^#81JGPY.G^#]'UG2([+PO\.;3PW%/]OG
MTJ99E99II(F4Z?*9EC<)=/<1O(NZVB-/\?\ [#6J:AXHF\3^%?&6G:/XJA^(
MDGQ"TZ76- ;5=.MY9?#S:#+;2V\=S;R2*;>2619$FB99&4'<F])/HFB@#Y:^
M(?\ P3'L=<^#'@?P%X<\87FC:#X-^$VM_!UGU#3UU"ZO-)U&PL+87 =9(52[
MBDTRSDWE'C=3.GEJ9$DBPOVN/^"4L_[6/BC76O/B5J6D>&-1T*_TC3M&BL[A
MX=%>[\-ZCH+M%"+M+(QK'J#S@FT^U;U:,W1@*0Q?85% 'S'XE_X)W75_\?4\
M<:+XZ;PW<S>(-4UJYN+/2G.J"&^LK"VEL(I3<?9&MW;3X)9$N[.Y#,J-&(98
MTF7E_P!F;_@E_P")OV:/B?IOCJU^*D7B#QA)>WO]NW6LZ/?ZC#J=A>V7ANTN
MHHC<ZG+=QW1'AFS>.XFNKA(S/.OD,OEK']B44 ?,^M_L%^)K_P#8[\%_">Q^
M*-WH_P#PA-W%%#JNGV5Y8OJFEQ13016ES]FOHKCS!#+&S2P7,*23P*6A,#R6
MC\B?^"26A:3\.]2TN;6K_7H;C2[JSDMH((].N+WS/"FE^'=J7 +>3)MTJ*=9
M<'8[J,8C4G[&HH ^9]!_8?\ %&F_LZ?!O3[;Q?H>F_%3X9ZU+XTO=;NM";4-
M)UGQ!?V6I0:Q<2V44]JWEW$NLZC.B131".1HN"BF)L7X#?\ !*ZQ_9]U7P-9
MZ7XSNK[PG\/=;TK7M+L;[3%>_EGL_!,O@]DGN5D6-XY+7[+< +;H4FBF&YTF
M18?K*B@#X1\._P#!$/3=!\':YX9F\=?VMH&N>#X/#Q74--O)9["]C\,6GAI[
MZWB%^+!5DL;1=R26<DV9YU^T^6R(GM7[;?["]Q^U_JUI-;^+8?#-O<^#?$/P
M_P!:C?23?27>CZY)IC7IMG$\7V>\5-,189G69$:4LT,FT+7T)10!\:^*O^"4
MFH:_)XFC3QYHLUA>7.O7?AZVOO#UX'T2;6/$UKXEGGDN+/4K6XDG@OK?-M+;
MR6K0A8&.]XF>78U__@EA:^*-:UC4M2\>:EJFIZU9WMM<WUWI-N;B:6Z'ADR7
M#^7L3>7\-1N0B(A:[;"J(U!^LJ* /B?4_P#@D5J$>C^/(]'^(EGINN>)-?GU
MG0/%$VF:M<Z]X0$]]J%\XMIO[86%9DFU"01O###$T9FCN8+M;B4'U+1/V*?$
M7A_P3\=='TWXCW'AZ/XM'4)=%70]/N+6W\&W-W]J:6_A26[E8WDLMR)IVMWM
M8))8?-2""::>67Z&HH ^4?V=/^";>L_L^_$[P5XBM_B0US_8-SK-WKWDV%^M
MYXK&H7-_="SN9Y]1G$EG;7%]YT*W"7%S')&Y6Y5;B=)'>*?^"6^F>)I=W_"6
M7%N67QD'*Z:A,A\1>)M-UYR?G&3;MIR0*>KK)N.TJ%/U910!\'?&3_@D5XD\
M9GXAZQ)\2-6\4>*/'VOZ-%:W]T]Q!<>&=$75-834E@DGN+A5G;0_$>KV<8MX
M[>%"(6CAA<EQZ?\ M*?L/:]\=OVH_"NLZ;J6@^'/!.CZ%8V&H!M*%U>7"VFN
M66II:VI$D?V3<;*(><!(%'W4#K'(GU%10!\C:E_P2P$?A#P;X?TGQK9V.CZ3
MX<3PIXA2?PZL\VK62ZA%?F2S=9T%A=/*C[YMLX8M&^P/$CCAO __  28\6ZW
M\/[V7Q!X[T_P[XGCOH+C0DT73;JUATN.#6]3U(K=S6=];W%XTO\ :4@W12VI
MB(!&YC*TOWE10!\N?#S_ ()>^&_!/A2UT>2\TF334U_1M8N-/M=%\NPDMM.\
M-VN@C35CFFFD^RM';M(%EEE91,R%I.7;.^#/_!/OQ'HG["/ASP3J_BOR?B9#
MKNE>,M0\0:I:KK7VG4K"\M9[.*^1'@%XL%M96=F75HF9;6.1&1U5A]:44 ?'
M7Q2_X)47WQL/C:T\2?$#3'T?QI'J.HR06'A;[/<VVM7_ (6'AFXG,S74@EL!
M9M*\=FZ%TD,(-R\<*1U+\9O^"2.F_%7Q5JVMVOC6^T+4KZ^U76+9[6R>'RKZ
M[UGPUJ\+R/!/#.R1S>&K>-_*EAEDBN) DT#JCC[ HH ^<;W]A34M+^$7PKTO
MPSXF\-Z#XK^%7BF^\8VNH3Z#>ZEI>I:C>V>KVUU)<6T^HF[D,C:Q<W#,U\TC
M3 ,7()%>.VW_  0TT/1? 'BKP;8>.;RX\*^(? Y\*6@U6UO+O4-$N_\ A$X/
M"HU& 1WT6G[C86Z%@UB9B\MP!<+&Z1Q_>%% 'R/\8O\ @EB/C5XG\<1ZKXTL
M_P#A$?%5UJNJVNG'PZLE_:7VI6$-A<_:+MIRMU:^3'($MS"A4M$&D=8(U';>
M /V$H_ O[;WB[XO/X@BU:U\3W#:E;Z9>Q7[W&C7KZ?8Z?*UO)]N^QB)X+&/(
M-CYV7(\_RU2-?H*B@#Y-3_@E[_:-Q<2:MXVBOFBU+5KG3GCT(1R6MO?>*K3Q
M((I&:=_,DCFMO*,B^6KJR-Y:M'\USX,?\$SX/A1X0^,6BS>*4U:/XG:;>Z+9
MZE);7\FIZ597$VH3"&9[B_G@F$4FH2,@MX+1<^8S*S2$K]344 ?(?Q'_ ."2
MFD_$+PAXQT<>,M0TN#Q=?W5ZSV=@L3V0F\%VWA41H5<?*L=N+GMDN8\;?F-/
MP[_P2?;2?'7@?Q%=>+-'OKO0[R&^\1636FO'3]?N+?6!JUM=I')K;R"[2?+&
M2^EOT+I"ZQ1^7M;[(HH ^4_AM_P3''@[Q3X2U/5/&BZRW@NXTX:?&NBB'S;7
M3[O5I[5)2TTFZ8+JFUY5"*6MPZQQ[MB\+^RA_P $_OB+^RI^TIX)M;6XTSQ!
M\/?!^E:5HRZA?7UQ'&;*Q\+PZ4+F"QCF6&+5WO;=09)()@+":9!=[C';Q?<U
M% 'R#?\ _!*G^W?'EKJ6H^/%DTOP[XINO$OANTMM#$-Q:"_\:Z7XPU&"\F,[
M+=;[S28(('CBMS##))Y@N9"''9?M6?L(ZI^T]\;/#WB1_B+JVB^'=%CL&D\/
M)%<M;RW-I>M=+.!'=10.9 PC<74%R4\F%H#;MYQF^C** /B7XC?\$C[6Y^%>
MD^%='U;[7#/KF@1:D[6\5G"-$MM"B\/ZM:/& WF+>Z2MQ"%7:8I;B&16!MT:
MO1OVNO\ @GU>?M;?&;1]<OOB-X@T;PG8V=M;W'AVT-RB230S7#FXC:.YC@\R
M1+@(6N+>X,9MX6A,)\WS?I2B@#X/\2?\$I/%'B+1H?"FJ>*M'U2U\4RZG>>(
MM?L-#BTFUTX'PC%X8M+>WTXRSF4O&L<SB20Q,(IT.U'BA'4^-/\ @EGK_C_7
MFUZ_^)FDV_B+Q'=ZC<>+Y;+PD8['4TNI=!8)8P/>.UB53P[9*S22W/F&>Z?"
MO(AC^QZ* /E7QI_P2YTOQAX;N--_X2N>UCN-"\>:*633(S@^*=>L]9EGQO W
M6\EF$'_/3S"Y*D8(/^"7&E#7],U+_A*96NM+\0:KKT;MI<;,3?>.K7Q@T.[?
MD*DMJEMD?>!\S 8!:^JJ* /CGX'?\$C[/X/>(_"=Y-XP_MC_ (0?5(9=,NI[
M6_GU&ZTRWT;7])M+"[ENM0N(B(DU^>8&UAM8?,$F(%$N(X- _P""46L>"/AY
M#X9T'XEV=A#::OX?U[3]8?P_<?VWH5_IOARV\/37-E<0W\42/-:6<)5)X9X!
MYUY%/%>07'DI]FT4 ?/OQD_8;G^+?[2:^,SXK@L?#VHMX9GUK2&TCSK^XG\/
M:G<ZIIIM;[SE^S1&YN,3Q/#,)(U=4,#2R2-S?C7]B7Q=X1^#'[+/@OX>ZWX?
M6Z^ FI6R-K.N:4UU;+;VWA/5]'CN&L8IX6D+37=O^Z2>/:'+!_DP?J:B@#XG
M\*?\$:].\!^%K'PC8>+M/U;P#I-K%<6VC^(O#G]H2W>IQ>"1X+5KR:.YA2;3
MWTQ0\EI'%%*\Y<BZ2-O*$?Q _P"":OQ(T_PZMUHOQ,L_%GB2ZB\!V%U-XCTJ
M>X*?\(]XT?78KE9I+UII88K6]NX/)GDENIA;VQ>],WFS2_;E% 'R+X0_X):3
M^&/$V@S2>/+6YTEGT/4?$]LOAWR;K4]2TC7+_7K:2PG%QBPM&U"_E#VK)<C[
M.HB22-GDF?F=?_X(Q6\GPG\)>'=(\?-:S^$;'0M/C:YTZ\CLM1ATW0+K0G6X
MBL+^SG99K>[=MJ7"!"H0^9&SHWW!10!\F^)_^"46@Z_I_BBW@\1?V>OB/P]X
MQ\/IY6DQM]A3Q"VE;I%)?+&W32HXU!/SK)@D;1F/X>_\$KK3P;\4=4\07GBJ
M'5H9/'+>,],\^RO9;VR635KS5I;%WGOI;;ROM-V2C6UK;,/*5G\Z0F2OK:B@
M#XOU/_@DYJVG_".V\(^&_B1I^DPV'@WPSX9T[4Y_#MRVIZ%>:(MW%#J=C/:Z
MA;&WD:*ZVB/#*-KJYEBE>$^I_M*?L0S?M#^.K?4G\6+8Z;<:'!HFJVEQI0NY
M+X6^IVNH0RQN)8TB):"1)%:*0.LJ[?+V'?[[10!\A:#_ ,$H+/PU\<[/Q?#X
MN_M.QFUZ?7-7T;4[:_\ LMTX\5:MXFL6ACM=0MX!-;76KS 27<-VI-M;.D<+
M*_F)X/\ ^"4%GX'U'X.^3XN_M73?AKX0\*>$M2T_4[:_%OK2^')GN-.O(H;7
M4+>"*X6XFDES=17B*R6YC6,QN9?KZB@#Y$_9]_X)7M\'/&OPO\0:IXZBUK4/
MA-%HVC:0++01IL%SHVD:)X@TJP@N(_/E!N\>(KN6:XC\N*3R(42VA 8GZG\$
MZ;JFC>#-(L]<U2'6]:M;*&'4-1BM!9QW]PJ*)9EA#,(@[AF"!FVAL9.,UJ44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>2_ O_ )+3\2/^ON+_ -#FKUJO)?@7_P EI^)'
M_7W%_P"AS4 >M4444 %%%% !1110 5Y+^R!_R)NN_P#88D_]%15ZU7DO[('_
M ")NN_\ 88D_]%14 >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>2_ O\ Y+3\2/\ K[B_]#FKUJO)
M?@7_ ,EI^)'_ %]Q?^AS4 >M4444 %%%% !7,_&O1/$_B;X->+M-\$ZU;>&O
M&>H:+>6V@:O<6RW,.E:@\#K;7+Q,"LBQRE'*$$,%((.<5TU<S\:_"_B#QO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR7X%_\ ):?B1_U]Q?\ H<U>
MM5Y+\"_^2T_$C_K[B_\ 0YJ /6J*** "BBB@ KG?B]KMAX6^$WBC4]4\3-X+
MTO3=)N[J\\0J]NAT&%(79[T&X22 >2H,F98WC^3YE9<@]%7%_M(_!>U_:1_9
MW\??#N^OKG2[+Q]X<U#PY<7ENJM-:1WEM);M*@;Y2RB0L >,@9H ^7?V$_C9
M9^)_'7@G2]3_ &KOB5\7_'%]IURVK>%I?"&DZ;:0/ LD4MU?VL&B6^H:/&TT
M;&%+VXCW2;8E>X(R_OG[('_(FZ[_ -AB3_T5%7)_LU?L:>./@)\8?$GBC4OC
M1K'BZS\::HVM:[I=QX8TNR34+L6%M812>;!&LBB.&SMP #SLYR#BNL_9 _Y$
MW7?^PQ)_Z*BH ]:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXU^!=/T/2+2'PCX[U+2H[62^A:/4H;2]\,:OK(+A9&C659=/A3 W*$>0<G#
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M'.IIJ%HVH^%M=L[6&^:]FUA4!NH$@L9);W1;B^\G]UYMQ"TQ5I+D--<^./\
MP2$\$_$SP#XHM]*U2^L_%GBV_:]U+6M6\R\CU%)KS0)[RWN(+>2V#+<6_AO3
MK5I(WCF"B27S&FDDD?N/V??^"??A_P"$F@>%Y->U";Q-XJ\+W=O=P:G LUA;
M(+2._M["".W,TI$-M9ZA);())99'2*-Y9)90TA //?B!XF_9/\/:_P",-!UB
MUD\-ZAX%LGDU#5+/3M9TF33O[*$MZT=CJ<"1M]KB37KAQ'9S&>2/4;A%#J95
M'+S_ !Q_9/UB'Q)XAO-=\6:AH=]/%XPUNQ_L[6CI]K<::1H1:]\J$";?)H\%
MO]DNGE2:2SBDCB;?YC^LW?\ P3-\&^-?&_Q*U;QIJ6M>)K7X@7FH3PZ8MW-9
MVNBI>V6GVDSPA)"PNMNGQ%+A"ABW.8UC>29Y>XTO]C[0=*TW5"FM>)9-<UG1
M8=!N];>6W-U+;Q7=U=I^Y\G[)Q+>3@IY'ELC!&1D&V@#Q#6OBU^S9\,?ARO@
MGQ3J7BY[/1=3U/QS=:A>Z'K-K<Z3JEU;7_B>]26ZMK>+[)?-8W%].]B#'-]E
MF,3P[)UCD\S\4_#3]D^W^%OQ7CN+KQMX9TOX@37'PZF\_P ,:M:Q_#Q[GPSH
MVB+!'9S6PBL7;34T^2.>YBWM%<O\Y@$BI[Y#_P $E?@W:^$1X;AL/$4'A3^Q
MDT@Z)%K=PEF[IH#>'%O3AO,-R-';[)NW["JQN4,L<<J['Q6_X)G?"GXR>/\
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M8:/%KV@W'A.VTRTT?4+743+=6$6GZ=-ID"@3B2.0&RN)HG\Q'W%UDXECCD0
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MM/$EC?6.LF.+18OM$K!)+/4IH;BUMUNY3'=3P&U<2R0Q1R)S_P +?VI?V6_
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MCI2R6GVWR70,C1_;;VUO[K!!'^MNK*UE;U:!>V0?1J* "BBB@ HHHH ****
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MA:5_:T-X=&MM&EN;6\^S>9;K):6J%H$_=^9)*>$=HS[W_P +^\!_]#MX1_\
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MX;TN:^U&\M;"RMQNEN+F58HHQG&69B .2!SZUS?_  O[P'_T.WA'_P '%O\
M_%T ==17(_\ "_O ?_0[>$?_  <6_P#\71_PO[P'_P!#MX1_\'%O_P#%T ==
M17(_\+^\!_\ 0[>$?_!Q;_\ Q='_  O[P'_T.WA'_P '%O\ _%T ==17(_\
M"_O ?_0[>$?_  <6_P#\71_PO[P'_P!#MX1_\'%O_P#%T ==17(_\+^\!_\
M0[>$?_!Q;_\ Q='_  O[P'_T.WA'_P '%O\ _%T ==17(_\ "_O ?_0[>$?_
M  <6_P#\71_PO[P'_P!#MX1_\'%O_P#%T ==17(_\+^\!_\ 0[>$?_!Q;_\
MQ='_  O[P'_T.WA'_P '%O\ _%T ==17(_\ "_O ?_0[>$?_  <6_P#\71_P
MO[P'_P!#MX1_\'%O_P#%T ==17(_\+^\!_\ 0[>$?_!Q;_\ Q='_  O[P'_T
M.WA'_P '%O\ _%T ==17(_\ "_O ?_0[>$?_  <6_P#\71_PO[P'_P!#MX1_
M\'%O_P#%T ==17(_\+^\!_\ 0[>$?_!Q;_\ Q='_  O[P'_T.WA'_P '%O\
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M*XOXH_\ (\?#?_L8IO\ TTZC7:4 %%%% !1110 4444 %%%% !1110 4444
M%%%% '%_'H;O ]CGG_BH]"_].]G79>6O]U?RKC?CS_R(]C_V,6A?^G:SKM*
M&^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J*
M&^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J*
M&^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J*
M&^6O]U?RH\M?[J_E3J* &^6O]U?RH\M?[J_E3J* &^6O]U?RKC-#C7_AH?Q1
M\J_\B[H_;_IYU6NUKB]#_P"3A_%'_8NZ/_Z4ZI0!V7EK_=7\J/+7^ZOY4ZB@
M!OEK_=7\J/+7^ZOY4ZB@!OEK_=7\JY'PXH7XX>*L ?\ ()TOM_TTO:["N0\.
M_P#);_%7_8*TS_T9>T =?1110 4444 %%%% !1110 4444 %%%% !1110 5Y
M+\"_^2T_$C_K[B_]#FKUJO)?@7_R6GXD?]?<7_H<U 'K5%%% !1110 4444
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M$_A0!]XT5\(?:?\ @IQ_SY_L(?\ @9XK_P#C5'VG_@IQ_P ^?["'_@9XK_\
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MJ /N^BOA#[3_ ,%./^?/]A#_ ,#/%?\ \:H^T_\ !3C_ )\_V$/_  -\5_\
MQJ@#[OHKX0^T_P#!3C_GS_80_P# SQ7_ /&J/M/_  4X_P"?/]A#_P #/%?_
M ,:H ^[Z*^#UN_\ @IPZ@BS_ &#R#R"+WQ7S_P"0J7[3_P %./\ GS_80_\
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M./\ GS_80_\  SQ7_P#&J /N^BOA#[3_ ,%./^?/]A#_ ,#/%?\ \:H^T_\
M!3C_ )\_V$/_  ,\5_\ QJ@#[OHKX0^T_P#!3C_GS_80_P# SQ7_ /&J/M/_
M  4X_P"?/]A#_P #/%?_ ,:H ^[Z*^$/M/\ P4X_Y\_V$/\ P,\5_P#QJC[3
M_P %./\ GS_80_\  SQ7_P#&J /N^N+T/_DX?Q1_V+NC_P#I3JE?(GVG_@IQ
M_P ^?["'_@9XK_\ C59EKX>_X*86?C*_UQ;7]A7[5J%E;6,BF^\5; D#W#H0
M/*ZDW#Y^@H _0*BOA#[3_P %./\ GS_80_\  WQ7_P#&J/M/_!3C_GS_ &$/
M_ WQ7_\ &J /N^BOA#[3_P %./\ GS_80_\  SQ7_P#&J/M/_!3C_GS_ &$/
M_ SQ7_\ &J /N^N0\._\EO\ %7_8*TS_ -&7M?'_ -I_X*<?\^?["'_@9XK_
M /C5>[_L1^'?C];1>*-7_:%C^#L7B?4)+:VTY?AU/J4EC]CA61@9A?(KB;S)
M9.4)4J%X!!+ 'O%%%% !1110 4444 %%%% !1110 4444 %%%% !7DOP+_Y+
M3\2/^ON+_P!#FKUJO)?@7_R6GXD?]?<7_H<U 'K5%%% !1110 4444 %>2_L
M@_+X1UY?XEUB3([C]W'_ (&O6J\EU?X(>*/"GBW4-2\$:Y9Z?!JTAEN+6[7Y
M$8DD[?D<8R3C@$ XR10!ZU17D?\ PBGQB_Z&7PW_ -\#_P"1Z/\ A%/C%_T,
MOAO_ +X'_P CT ?+NH_"WQA\&OV@O'6O>&?!=UJ'A^X\61^*M?\ $NO>%K/^
MW;98M3$LEJEX7D;5;$6<EU):,D:SZ?#'%;([M((;;RK]E7]HO]IK]J_X&WNO
M>$_B+XDUW4_#WAO7M0N[?3E\+ZC:OXCBLO#-QHVE-?6]N8+B&Z\W5KF1(#"\
M(O/L[N@A@D?[W_X13XQ?]#+X;_[X'_R/0/"?QB'_ #,GAO\ [X'_ ,CT ?+'
MQ&@_:7\<?$SQA+->?%GP[X+TGQOHEY80Z4FES70M;;Q/<0W*PNML)+FTFTAK
M*]>+RFVHL<!EGG2^67I](U3]J'XC:C/HMW<>,_"]K;ZMIFF7^K0:?HT;O$-?
MU7[=-:F2-]T;:2-+Q+LX61=F+A9PGT!_PBGQB_Z&7PW_ -\#_P"1Z/\ A%/C
M%_T,OAO_ +X'_P CT >8_LS?\+MO_$/QD;XG:UJ=S8L=1ATW1)?#T4%IIZB^
MO_L<EE?1M_I44NGFRW(59D*(7\J=IT;YQ_9)_8EU[XP>%/ /Q"\.S:#I/AW0
M_A/X7@\/SZ=IR-J&LNN@7UO-IUO?1W2I;V?GW,330/ ZR/&K!D90Z?;G_"*?
M&+_H9?#?_? _^1Z/^$4^,7_0R^&_^^!_\CT ?+O@?X?^*M1^-7P5\7>(_A-K
M6I6/@GX?6.D21:YX1M]7U&PUBU;?(UI,UZ@L9F_=XN0LJR[0,KL#5P\7[(WQ
MBM_@YXDT+XI>$Y+^37->TSXC+'IC?\+"T#4?$5S:WL.JZ?J&DW0LRVEF5+66
M*UC8I;SW,4Z7*BW,L7VU_P (I\8O^AE\-_\ ? _^1Z/^$4^,7_0R^&_^^!_\
MCT >,_L*?";Q5X:_:]^*GBSQQ\-])\+ZYXIBL;FWU%-#BN[BVA_L308I]/CU
MQ9RTUK'>07"+;FWCRUL9<XVY\'T#]D?XN:9\%;KP?\,_#FO>'_[-;7#HGBJ]
MMH?#'B/4+^[\*ZI:1W.L20RO]JOX;UK)&U=5!N9'$GEL(!/-]O?\(I\8O^AE
M\-_]\#_Y'H_X13XQ?]#+X;_[X'_R/0!\6>(/V2_B%\5_&?AO3?AM\.--^#7A
M?0_'5EXHTW5;+PT?#-U87\'AWQ.J)J\,5_(=5BMM0;0TFGCV17@NI8QYD:-(
M/1;GX4_'#_A@7P7XFT/PCJGA_P"-WAOQ?X@\16WA2?5[6Y>V_MBZUFU2WN+H
M2>3+;VD>K07C;6(?^SH]JE@J5]'?\(I\8O\ H9?#?_? _P#D>C_A%/C%_P!#
M+X;_ .^!_P#(] 'RO\(?V*?B-X=O=!T77='U6^\+^ _%.E^ ]+L[Z]M[R'4/
M!^G'6GM[^3YOG$]GJ=A:7$<BAY)=,+%"I4G0_9__ &(_&WP1U;P*W@/PSX5^
M'-Y!\0/B%?ZQ=R:#'=6C:5/J^I?V(LT%M=6S2*+&2U2W'F'R(@L>Q0-J_3'_
M  BGQB_Z&7PW_P!\#_Y'H_X13XQ?]#+X;_[X'_R/0!\-_ _]B+X\6WP5^$=G
M_9^L>'/&G@O5/#FN6MSJ.LG[+:WNG_#FWL3'>M#(SR6<NII+97*HK,\<\[)@
ME91TW[2/[*OQ(^*/_!.[]GOPO=>#M8;7=+N[J;Q!I\^FVOB*\T%YM UB&"4Q
M->V\4ES#=7-L(YA<;8IMDA(52R_7W_"*?&+_ *&7PW_WP/\ Y'H_X13XQ?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g352067g0002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g352067g0002.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***Q_!WQ"T'XBVU_-X?US1]=ATK4+C2;V33[R.Z6SO+>0QSVTA0
MD)-%("CQMAD8$$ C% &Q1110 45'=W<5A:R3SR1PPPH9)))&"K&H&223P !S
MDT6=Y#J-G%<6\L<]O.@DBEC8,DBD9# C@@CD$4 2445A^(?B;X;\)?#ZZ\6Z
MMX@T/3/"MC9G4+G6KN_BAT^WM@NXSO.S"-8PO.\MMQSF@#<HKF?#7QJ\&^,]
M7TC3]'\6^&=6O_$&C#Q'I=M9ZI!/-J6EDQJ+^!%8F2U+2Q 3("F94&[YAG>O
M]7M-*>W6ZNK>V:\F%O )9 AGD(+!%R?F8A6.!SA3Z4 6**YGX9_&GPC\9O\
MA(/^$3\2:-XC_P"$3UJY\.:S_9]TEQ_9>I6^WS[.;:3LFCWIN0X(W#(YKIJ
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M45E^-?&VB_#;PCJ7B#Q%J^EZ!H.CV[W=_J6I726MG8PH-SRRRR$)&B@$EF(
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MUG3K>\L[B&ZM+J-9H)X7$D<R, 596'#*0001P0:FH ***1W6)&9F"JHR23@
M4 +145C?0ZI90W5K-%<6]PBRQ2Q.'25&&596'!!!!!'!%<)X<_:P^%OC'XQ7
M_P .](^)7P_U3X@:5YGVWPQ9^(;2?6+/R\>9YEHLAF3;N&=RC&1GK0!Z!111
M0 454U[7K'PKH=YJFJ7EIINFZ; ]U=W=U,L,%K"BEGDD=B%5%4$EB0  2:XO
MQ[^U?\+?A5X0\.^(/%'Q*\ >&] \7&(:%J6J>(;2SL]:\U!)']EEDD5)]Z$,
MOEEMRD$9% '?T5G^)?%FE^"].CO-8U+3])LYKNVL(Y[RX2"-[BYGCM[>$,Q
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MP^T'P;J^M:AH^AZ/I-_XDNQ?ZO<V=G'!-JEP(TB$T[J 99!''&@=R6VQJN<
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M,L(2:X,OF*5_TE($242I!&J?%C^'?VK-1_9?\92> 8OVM+'QA#\'-/L_&/\
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M)/+:FV:_^S7,FVR;<)9BI>V(_4BB@#\M-5^!/QB\&VGQIUS6+/XP-^T!XO\
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MA2U58C/]DEN-\G[ZOTHHH _.'X=>$/VA=/\ B?\ !.+Q='\8KSPB^C>&-/\
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M;G1M0U/"X26XM+IWN(9BFW>L[&4L"7^<L*],HH **** "BBB@ HHHH ****
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M&,K2IB:E\0-6UGQIKEO>:;\0I_"OC;QYX:^(VNW<?P8\8Q:G:WVD1Z06L;6
MV3QO;SSZ+;,LTLX>&*:6/RI2J2#](J*Y*/'F$IM2CAI<RCRINI!NRFJB_P"7
M.ZJ+GONY-\SDM"GA9/[7X?+OVT/S3T&VT31? &@:)_9/Q>9M'^'_ (W\'O*O
MP6\5*DEQK]_874=P%^P_=C%I(),G<QD!&>:^^/V<Y(W^ 7@M8DU*..WT6T@
MU#3;C3;K]W"J9DMKA4FA8[<[)%##/(KM**\/B3BI9K1C34)1M*4O>E&6LY2E
M+:G"UY2;W:Z6-*-#D=_Z_-A1117QYT!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+?'#Q$WQ$YQ\11X<TD:A_P ?GG#_ $'[/]A_U&+;_4\K\_$GS5Z]10!\B_\
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M[Q%K_CJ]6<6GCJ?P[I,%[IQ<_NRMG% MH_E]M\1W9.<\8\A_X86_:2_Z/?\
MB+_X;KPE_P#(%?75% 'C_P"RO\"/B7\%IM=;XA?'+Q%\9$U);<6"ZKX;TC1_
M[(*>9YA0V%O#YGF;X\^9NV^4-N-S9\IO/V&_VCI[N9XOVVOB)#$[LR1CX=^$
MV\M2>%R;#)P.,GK7UM10!\Z? ?\ 91^-GPT^*VEZWXO_ &IO&GQ(\.V7G?:O
M#M]X+\.Z=;ZAOA=$W3VEG'.FQV60;'7)C .5+ I\=?V4/C=\2OBOJVM^$?VJ
M/&?PX\.WQA^Q^'+#P7X>U"WT[;#&C[9[NTDG??(KR'>YP9"HPH 'T910!\GZ
M+^Q%^T5I^LV=Q=?MJ?$+4+6"=))K5_A[X4C6Y0,"T99; ,H89&5((SD5Z7^U
M+\ ?B?\ &?5-'F^'_P >/$OP<M["*5+VWTOPSH^KKJ;L5*.S7]O*T90!AA"
M=W/05[+10!\B_P##"W[27_1[_P 1?_#=>$O_ ) KU[XD? WXD>+OV>=!\*Z'
M\;?$7A/QKIJVHU#QK:^'=)NKS6#'&5F+VD\#VL?G,0Y$<:[2H"X&0?7** /D
M7_AA;]I+_H]_XB_^&Z\)?_(%>N?"7X%_$KP-\!/$_AGQ'\</$7C;QAK'VO\
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MUDTLBQ(50/(S.P7+$DDU<^$W[('QW\#_ !)T;5O$?[6WCCQMH6GW(EO="N_
MWAJSAU2, YB::WLDFC!.#F-@W'6OIBB@#Y]_:'_9<^,WQ4^)EQK'@O\ :<\8
M?"_098(HX]!T_P 'Z!J<$+J,/()KRTDF)<\D%B >F!Q7#/\ L+?M)%3M_;@^
M(@;'!/PY\)''_DA7UW10!Y#^U3\"OB5\:FT'_A7OQP\1?!I=-^T?V@-*\.:3
MK']L>9Y7E;_M\$WE^5LDQY>W=YQW9VKCR/\ X86_:2_Z/?\ B+_X;KPE_P#(
M%?75% 'C_BCX#_$S6?V:-+\(:?\ '3Q)H_CRS:,W7CR+PWI$U]?[78N&LY+<
MV:!E(7Y(@1M!'.<^2_\ #"W[27_1[_Q%_P##=>$O_D"OKJB@#R'X1_ KXE>!
MO@-XH\,^)/CAXA\;^,-8^U?V3XQN_#FDV5WX?\VV2*'R[6W@2UF\F56F'FQM
MN+E7W( *\C_X86_:2_Z/?^(O_ANO"7_R!7UU10!XE^R_^SO\5?@WXIU*]\?_
M +07BGXP:?=V@@M=.U3POHNDQV,N\,9E>QMHG=MH*[68KAB<9P1Y]XC_ &)O
MVB-6\1:A=6/[:'Q TJQNKF2:WLH_A]X5E2SB9R4B#O8EV"*0NYB2<9)S7U=1
M0!\Y? K]D_XW?#7XK:3K?B[]JCQG\1O#MB9?MGAV_P#!7AW3[?40T,B)NGM+
M2.=-DC)(-CC)C"G*DBE^._[*'QM^)?Q6U76_"/[4_C3X;^';WR?LGAVP\%^'
M=1M].V0HC[9[NTDG?>ZO(=[G!D(&%"@?1E% 'R7I_P"P[^T9:ZA;R3?ML?$2
MZACD5I(3\//":B9002N189&1D9'(S7IW[4G[/_Q0^,VKZ//\/_CUXF^#MK8P
MR1WMMI?AG1]774G9E*2,U_;RLA4!AA" =W/(KV:B@#Y%_P"&%OVDO^CW_B+_
M .&Z\)?_ "!7K7Q4^!'Q+\:_ 'PSX8\/_'+Q'X-\9:/]E.J>,K3PYI%W=Z]Y
M<#QS>9:W%N]K$)I&64^3&NTH%7"E@?8** /D7_AA;]I+_H]_XB_^&Z\)?_(%
M>M?#SX#_ !,\*?L[^(/"NM?'3Q)XH\;:H9SI_C:Y\-Z1;7FC;T58PEI#;I:2
M"-E9QYL;%BY#9  'L%% 'R+_ ,,+?M)?]'O_ !%_\-UX2_\ D"O6/V6/@+\3
M/@O>:Y)\0OCIXD^,D6HI MC'JGAK2-'_ +)*&3S&0V%O"9/,W("),[?+&,9-
M>Q44 %%%% !1110 4444 %%%?D)X]_X+$?M=?M]?M:?$SP%^Q+\,_ %]X!^$
MVI?V)J_C3Q;,"+^]1I%9H/W\<8B=HI%1$29RBI*S1>:L:@'Z]T5^2/\ ;W_!
M8G_H"_LW_P#?:_\ QVC^WO\ @L3_ - 7]F__ +[7_P".T ?K=17Y(_V]_P %
MB?\ H"_LW_\ ?:__ !VC^WO^"Q/_ $!?V;_^^U_^.T ?K=17Y(_V]_P6)_Z
MO[-__?:__':/[>_X+$_] 7]F_P#[[7_X[0!^MU%?DC_;W_!8G_H"_LW_ /?:
M_P#QVC^WO^"Q/_0%_9O_ .^U_P#CM 'ZW45^2/\ ;W_!8G_H"_LW_P#?:_\
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M"_LW_P#?:_\ QVC^WO\ @L3_ - 7]F__ +[7_P".T ?K=17Y(_V]_P %B?\
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MO^"Q/_0%_9O_ .^U_P#CM 'ZW45^2/\ ;W_!8G_H"_LW_P#?:_\ QVC^WO\
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MDC_;W_!8G_H"_LW_ /?:_P#QVC^WO^"Q/_0%_9O_ .^U_P#CM 'ZW45^2/\
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MM]?DC_P9X?\ )C7QH_[+!JG_ *;].H _6ZBBB@ HHHH **** "BBB@ HHHH
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MI]I#?W3VVH13+;6TT9EAF<JQ"QR1@NKG"LH)!(YK#A_:@^&EQ\,+GQO'\1/
MLG@NSF-O<:^NO6ITN"0,%*/<^9Y2MN91@MG) [U^*/[?'PGF\-_M*_MQZ)X=
M\*WL?PA\,^(_@H_COP_X9L3"3X+M=/NA>06T%N PAC5(25A "11.3M1&(]4_
M;H\9?L3?$[X&^$?%/P0^(GP7^%,7@?QE'K-I-/\ #2>Z^'GB?5+;2YC'I^I1
MQ6J6K3BVN"$D4M<P_,(E,BJ$ /V,TK5;77=+MKZQN;>\LKR)9[>X@D$D4\;
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MA_R8U\:/^RP:I_Z;].H _6ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+)(;3RKBXED"R)/,DGEG8%4Q+Y) /UXHK\+?V@O^"I'QO^%?P[T;P3=?%WQ
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MLM$>77H'TJ:0W0D^PM!=S6%RDT45RJ&WG-Q,7CFV1>3]+_\ !Q99^ ?#M_\
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M(8;UF0FXC12559=P4<  5VUO!':0)%%&L<<:A$1!M5 .  .P%?D/_P %=O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCKX>_M?Z7X?M_'>CWUY<>$M3&LZ'J.F:Q>Z-J>C7@1H_.M[RREAN(CM<@A9
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M  4B_P"QTL?_ $LU:@#];J*** "BBB@ HHHH *_)'_@SP_Y,:^-'_98-4_\
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M:ZT6'P9H6GZ]K?\ :?A[5-,WVMZ9([6XL4N;='U"&XGAEAMWM!,)Y J1EV=
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MDU"-8PLS6C7%T]OMVB-[F1ADD$>BZ5^W[\*_$7AOPOJFDZ]J6K0^-M+UG6-
MALO#^I7-UJUOI)47WE01V[3&1&956+9YDI8"))#Q7#?"C_@K'\-/B#^S/\.?
MB+J5CX]T6;XBZ /$%OH$'@G7-3U."".WMIKN=8(+)I9;* W4"?;DC^S2&6+R
MY&,J!@#F])_X(]^&? >@>!U\(^+M4TK7?!OAR7PC)JFIZ+INM?VKIKW<EY&)
M(+B Q)<032S-#+&%4">02),"H3M&_P"":OA9_C&GC5O$7B1M27Q_IGQ#,6VU
M2%[RP\-_\(_'"52%0L+V_P"]8(%(D^Z53Y*]\\'^,-)^(7A+2]?T'4K'6=#U
MRSBU#3M0LIUGMKZVE021312*2KQNC*RLI((((X->37?_  4(^%^D^*/$VCZI
M?^*]#O/">A:IXFNSJ_@S6M.@NM-TQXTOKJSEGM$CODB,L)/V5I2RS1,H99$8
M@'GUK_P2*^'LOP9^'?@+4]:\4ZKX=^'O@?Q#X!6.2:&*35M/UJWAM[IIGCC4
MK(L<0"-%L +$D'C'/^+_ /@CS!\6=)\6-X^^,WQ&\<:YXH\+:?X1^W:G8Z1Y
M%K9Z?J2:C:AK5+,0W'F3)BZ6X$B7*RRH52,K&GI'A_\ X*G_  +\0^$?&6O+
MXSNM/TGP)HEKXEU&XU3P_J>FBZTNZ>6.UOK%;BW1M1M[B2&2.&2S$RS/L6,L
M9(PT?[&O[="?M>_'/XR:%I^EWVG:#\.;G2+6R_M70]0T/5V>[L?M,JW=G?1Q
M31,K%2F8E#1NCC<K*Q .J_9 _9$L?V1]*\;QVNN7FO7OQ \2GQ5J<TMA:6$,
M%RVGV-B8K>"UBCCC@"6,952&?YCODD;+GP_2O^"0D]A^SOX+^&=Y\:O&GB+P
MS\,;O1KSP?9:SH&B7%IIITQ'B@CN88[2,7T31. 1.2RR1131M'-&L@U/V"O^
M"M_@7]J;X9>&/^$JU.#PGXWU;0=2U^ZBN-(U#3M"E@T^<17S6>I742VEU]E\
MR+SUAGD:$LX<+L<+UUG_ ,%8_@/-X!USQ->>+-8T+2/#MKI&H7C:YX2UC2)S
M9ZK>"RT^\B@NK6.6>UFN"(Q/$CQ*<[F4 D '-^&/^"5T/PML_!ESX$^+'CKP
M?XH\)GQ-;3:_;Z7HMQ<:O8Z]JYU>\@E@DLC:QM'="-X'AA18BA!C>-WC-]?^
M"4'P^?XC>-/$T^HZ_=7GQ'OM6'BJ-Y(TC\0Z1J6GPV=QH]QL16:V5H$N(G#"
M:&9I=DBI/-')TWB7_@IC\'_!>JZ=8ZQK'BC2;F\L[#4+Q;SP9K4"^'+>^N'M
M[275F:T"Z2LLL<@!OC!Q&[G"(S#@_P!G?_@K#X/\>_$CQ)X+\92W6B>)K'XC
M^(/ FDFR\.:K-I5W)82W+6]L^H"![1=1FM;=IA:^<)7!39'^\C# $D__  3K
M_P"%??LC_%/P/-J%U\4M/\0>!;SPMI^AMI>D:#=ZG%]EECCCFOH((RUW+N1#
M<,4B4A7$2,&8]S\"OV);'PY_P3PM?@=XZNI_$?\ PD7A>\TKQO?QW,BRZ[?:
MHDSZQ=B7.]6N+JZNY=V<@R^U=I\,_P!K/X>_&*X\"0^&O$4>J2_$OPH_C?PX
MB6EQ&U_HZ&S#73!T'DC.H6H"3;)"9& 4F.395A_;#\#O\<[/X=S2^*+'Q'J5
MY/IVGR7WA/5;/2M4NH+>2YEM[;49;9;.>58(II-L4S$B";&3%($ /&?$7_!)
M^S^*ND^(3\1OBMX_^(&OZII%AX;T[6KZ#3[6XT72[74H-1,2)!;I%)/<SVUN
M;B>129/(BV+"%(/LW[8O[+.D_ME? 34/ >M7UQI]K<W^G:M#/'!#=1BYL+Z"
M^MQ-;S*T5Q;F:VC$L,BE9(RZY4D.O(_%+_@I+\,_A_\  2'QYI]]JGB:WUCX
M<WGQ2T"QT[1[Z2YUS1;=+-C.JB M%DZA9 K*JN@G+LH2.4IY1JW_  67\)^$
MOB9X0N/$&C^*]&^'?BCX9W/CN2<^"->NM<TU[>^CMYC/916K3PV4<9D=KF2!
M8B/*82%)8RX!W'P*_P""77A?X&>/_"_B:#Q5XFU75/#?BS7?&0$]O8VT%U>:
MO8K9W$9BMX(T2%%7=&J ,"1N:3DG@?B)_P $J;-9_P!FOPEH?]K:IX7^&?C3
M4O$7B'6+R_BAGGTZ2[?6DTV2)%43QRZW!H\I4)M$>F_,<XW>Q_%/_@IE\$_@
MWXFATS6_&4C+]@T_5KS4M-T74-4T?1;&_=TLKO4-0M8)+2PMYC&Y26ZEB0HK
M/G8"PQOCC_P4H\$>!K;QYIOAS4X[OQ)\-]0T^QU^35M"UR'0M,DN+^QMVMY-
M0M[&:(W9BOHWC@0L[;T=@D.^9 #L?VJ/V3?^&BM8\#^(M'\8:Y\/_'7PWU*?
M4=!UW3;>WN@JW%M):W-K<6]PCQS6\L4@)7Y75XH75U*<X?P>_P"">WA?X,_$
M#X?^)K/7/$>I:QX$MO%*R75\;;S-?N_$6H6NHZE>W0BAC02M<VVY5A6.-!*R
MJ@545;6L_P#!1SX1^%?'WC#PUKVM^(?"^I>!=$U'Q)J\GB#PAK.CV(TVPGC@
MNKNWN[JUCM[N)))H@&MI)1()%9-ZG-<?\2?^"E&@:]X8T>P^&LEU)X\USQYH
M?@E='\5^&-3T>\TXWK"ZGN9["\2UNO+72H;^XB? 21[9DW920( =)\>?V"[7
MXW?';5_&T?C3Q%X=3Q9X"NOAYXDTJTMK2:WU>P<7C6\@>6)I()8);ZXD!C8"
M0[ X*K@\Y\2?^"4'@#XMZ-;Z?KFL>)YK6U^'NG?#Z#RI+=7MX]/OH;^TU!=T
M+*;J*YMX9 '5H28P&B925/0_$[]M:'Q-\*?BY_PJ&WU#Q#XX^'.E:O-:'5/"
MFK1>'M1U'3FDBFL4U!HX;:=Q<Q/;N+>X=HW63*L8G42?'C_@H7X1^"O[*/@7
MXP0:7XF\3>&/B%J7ANTTI-'T:]U&X:#6;JVBBN&CM(9W4)%<;PI7][(([>,F
M:>)& *W@S]@>+3;[P/J&O^+IM6U+P)XQ_P"$QLO[.\/Z=HMHTHTB^TL0-%;P
M@LACOYI69W9S(!M*1XC$&K_L'V_@RS\+:]X5U"\U/Q3\,_$_C+QWX=L=1NTM
M+'5-4U]M6E>UNY4@D>.V2759%5XT9U5$)$A!5N3\#?\ !67P>/VF_B5X$\8_
MVGH-GX=\1^'M&T&[7PKK!5(]8TO3+BU.K2_9S%ILDM[?M;1K=FW+,FS&]'QZ
MQIG[>/POUGXUGP#:ZYJ4VN'5+G0HKE= U#^QKO4[:WDN+G3X=3\C[#+=Q113
M%[=)VE5K>="N^&54 ,GXM?L97G[1O[&'AOX9?$+QI>:]XDTB/0[[4/$B:; D
M.MZMID]M="XN+!@T$EO-=6X:2U8%2C%596"R+Y7XT_X(WZ!XS_9=\1?"&;XA
M>(I/!WCC6=7UCQ/!=Z!HET=0EU*2.626W#602SN+>1&:UEA4"$RLS)*ZQ/'T
M"_\ !:G]G23P1)XCC\6>*IM'71D\21S1> /$+M=Z0T;2/J<$8L=\UE"J$3W,
M:M%;LR),T;R(K=Y^V+^W5X:_8[^%?A'QA?:7XA\6:3XP\2:/X?M&\-Z5=ZP=
MNH7,<*W(%I#,655DWHH&Z=ML<6^21$8 YG]N;]F'QQ\=?B3^S[=>!?$&H>$_
M^%?>+;[5M0U^W%I>76EP-X=U6RB;RKQ9%N%DGN889%P9#'-(RO&P$J;W[/W[
M!6@_L_\ BKP9KMOX@U_7-:\*Z;XIM;N]OUMEDUZ[\1:M8ZMJ5]<+#%&BR-=6
M0*)$J1HDK*%PJ8T-8_;]^%^@?%FU\%WFK:_#J]Q?V6D2W)\+:K_9.G:A>) ]
MI87>H?9OL=I>3+<VVRVGFCE)N8!LW31AMOXU_M=^ _V??B)X.\(^)M0U9?%'
MC\73Z!I>F:#?ZM=:BEJ]LERZI:0RE5B^UP,Y?:%C+N?DCD90#Q[X<_\ !+2W
M^%L6AZ?I/Q6\?1^'?AO;:DGPRTJ2&PDB\ W%Y:7%FMRC&WW7K6EO=3PVR71D
M2.*5ED6=MLBS>!_^"3O@GX97/A^U\/\ B3Q=8>&_#7BG1O&MIHSS03PG5["R
MGLY[MY7B,K/?))%+<DO^\N(6G&V2>=I.F/\ P5"^"*:CX@AD\6:A#;^&['6M
M1FU&;PWJD>F:A%H^[^U!87C6PM]0DMMDF^*SDFD_=2X5O+DVTK?_ (*S_ )O
M"?BK7KKQM=:3HO@[3M/UK4+W5?#FJ:=#-IM_<FUM-2M6GMD^V6,DP*B[MO-@
M PQ<(58@&=\#_P#@FK#^S9;7^E^!/B!JGAGP];VE];>'(+;PWHTM_P"'_M+F
M15^VS6LDEQ';EBL*2\[,+*TY :F_LX?L-^+/V5_B1X>M?"OC:WM_A_=:KKOB
MSQK8Q:79V2:WJEY#:V]I:6EG#;B*RL8@D]PYBD65YU1I#.T\[UUGB;_@H]\*
M?!>G6-UK%]XRTF&YTX:S>?;? VNVTGAW3VGFMUO=622S#Z5;-);W&V:^$",E
MO/("8X9'3;MOVWOAO<ZIXUB.K:O;Z;\/+74+O7]?N?#VHV_AVR6P<)?*-5>
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MZ=9:K;VNHVNVX">5(^KRM)#("RK;H%<F0E/9_B!_P5&_9]^'OP9C^(4GQ?\
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M 6>L0Z#<ZU-82I?2VYN$A^S7UO='*!E)W"$J/F&"P/.,5X5^TY_P2EN/C_\
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MX^\*>#?$EOKVN?##44TGQ-!!;S+'IMVV_P#<^:R".5E,<B-Y3.$>-T;:ZE0
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M[>[CTX%IA<27!M+N"<M' T"I(%:59/W= 'RO^UK^P5\2OBCXN_:,\,:'X?\
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M/$#:[XBMFT'7+;PU=Z%=>$-9M?$W]IW,*3V]I'HTEJNHRR2P.)D$=NP:)9)
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M4-1BNM0U&_BLELQ KI>'[>+&61Y#%]CC<J[LX@3Q^T_X)A_'3X<_LJZU\/\
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M/Q1_98\;:5_P1FT#X8^%U\;>)M3TF'0DO-,UF&V&LZKH<.KVL]]I4L/VI89
MVF)/:FVDN=LT?[B23]XS5]NUP'Q>_:D^'_P$NKZ'QAXFL=#FTSPW?^+[I)U=
MC#I-B\"7=V=JGY(FN8 0/FS(, \X /@OX9?\$^(_&NK_  ETNX\"ZEJWPHE^
M*^IZ[KOAO5?!-MX7T#3K#_A#KBT00Z,)&,=E-J*P.\4J*);IYY#%LD\R2M\!
M?V%;CX5_&S]EWQ!XR^",GB.S\"7OC_PG;73Z/::M=>$()/%45UX4F9YG,L-G
M:6$$Y@E0M]E60*NPRX;]/** /S!_8G_8:U;X0?&;]D_Q-XZ^#?VS6M"^%>M^
M%+O5&T:TO;SPOK/]I65S9R7%QDM JVHU!8YE8[3-+&"#-M?S.3]@3XFZUX ^
M%_AWQ]X3\41VUE\"?!'AKPIJ.D^#;7Q!J_@7Q!9VMQ'J,=G<M=1-HNH),]G.
M+[*12&WA#3?Z*J5^N?@SQ]HGQ%TVZO-!U;3]8M;&_N]*N);2=95@N[6=[>Y@
M8J>)(IHY(V4\JR$'I57XC_%?P[\(M/TR[\2:M;:1;ZSJUGH5E)/G%Q?7DZP6
MT"X!^:25U09XRPR10!^:7C+]C+Q)J?[65MJ-]\#=?U_XH6_[0MKXWN_BBJ6O
MV<>$!=H+. 7CSK.\-O:"WMVT]$98Y+1K@Q#]W,WT[^U/^SQHVM?\%,/@3\3-
M0^$=KXT6Q\-:]X:/B.+P_::C/X:U*2^T:ZTJZG>0B6**%(-7*3)GRFN)%!5K
MC#_2OPY^)OAWXP>$H=>\*ZYI?B+0[B:>WBO].N4N;>22"9X)D5T)4F.:*2-@
M#PR,#R#6Y0!^;/\ P3<_97\3?#SXV?!.\M_A!XB^&?BSP3X0U.R^-WB[58K6
M-OB/K5Q':#>UU'-++J\DU\D]^EW(6\E-R%HI)WAKT37?V1?'5S_P44N/#EOH
MLR_ ;7/%EA\;=1U,R(MJ=;M+)K$Z*(E;S-QU"WTG60Y4(9(KD$[CS]Q44 ?E
M/^S=^P%KGB6#P'H,GP/O/!_C#1_ 6OZ+\;_$GB.VM)+7XIZM>V<<8$UQYDK:
MP;C40=06XF#"WC1HV,4DQ@/*I^PYKFK?L[_LY:/K'P:NM+^&?AWX8W7AO7_#
M,WPTM=>DTKQ<38K<:B^EK-&?.NO)NA'J2!V0B5B\277F2?K!-\5_#MO\5[;P
M,^K6R^++S29==ATPY\Z2QBFC@DG'&-JRS1*><Y<<5T5 'Q_^UY\+/$^G_L%_
M"GP;-X,;XP+8W&B:7XLN?&7AV'Q=J%G:Q6;I+JT^F+<!-0O!<+#N6.241O.]
MP%G$&Q_G']F[]AG5_AY\1/V2_$_Q!^!<VN-X)U/QYX>F>7PYIEW>>#_M/B=;
MSPU.\:33+:VEI:Q3-"]M++'9B14C;$@+?J=5:?6;.UU2WL9+JVCO;Q'D@MVE
M"RSJFW>RKG+!=Z9(Z;ESU% 'RY^TU^SWH>K?\%._@+\3-3^$=OXVCT_PUK_A
MQ_$4.@VE_<>'=1>^T:ZTNXFEDQ+#'%'!K!CF7/E-<2J-K7&'^3O@G_P37^(W
MP,_95^%=C\,/ \WP]^*&M?LT>+/#'BO6+*Y6QU ^*I;31!I O+U7\TS0S)>B
MWD+D6RJZQF.,!:_5VJUGK-GJ-[=VUO=6T]QI[K'=11RJSVSL@=5< Y4E&5@#
MC(8'H10!\;?\$HOV<K;X,>+/'&J:/X7\0?#W1-4TC2+!_#+^ +/P=I,-W!)?
M,\JP0W$QN;Y4FCAGNU)BFCCM0LL_E9C\U^&7[*WQYT[XG^#_ -HC4-/T&+Q#
MK7Q2NO$6L>$6TRXC\0V'A[6!;Z&UI/>)>O;2?9-+M-%O984ME)ETC =F!,OZ
M.44 ?EG\&/\ @G7XN^%NB?!WQ-IOPUN-'^(%]#\1-)\?:I T2ZAJ&G7<5^VE
MVM[+YF;B RQ:=Y$;%UAV1A1& 17-Z]_P2Z\>:)^S#>>'O ?PW;0/$'Q!_95N
M-"\8I#<16O\ PD/C*,Z>]M'?2&3$U_\ O-21;B4G D<-*$QC]<** /S0^*WA
MKXC?&#7_ (^^-F_9_P!2O?!_Q,N_ 5K#I?CKPY;ZW(--LY+H7^H'0X[G=<RV
MK,CI:R,LF1'*(Y=JQ/I_\$^/V2OB3\*?C-\"KK7/!-YX=\/^#6^+$+0"VM;.
MWT.SU37].NM)@2VMY9([>.2WBD,<,3.D2Q[,@*,_H;XJ\4Z;X&\,:EK6LW]I
MI>CZ/:RWU]>W4HB@LX(D+R2R.V J*JEBQ.  33/#OC/2/%W@ZQ\0Z7J=AJ&@
MZI9QZC::C;SK):W-M(@D29) =K1LA#!@<$$'I0!^?/[5/[._QD\"_M??%GX^
M?#'X>S>+O&O@W5/#EWX0TN6\BLX?&=E/I4^F:M8><TBB..,S6UV=^ TNF08!
MX->=^.?^":_Q2^%W@KXE>%]!TR]\2^'1??#Z[U^XDLH;UOB+;6C7=QXAE-F\
MR"Z>:]N'O)[61U%R&FB E\SRG_5;3]0M]6L(;JUFANK6ZC66&:)P\<J,,JRL
M."""""."#4U 'Y->(?V!M:TSP3\.5/A?Q#XE^"UIK_B?5+KPIJ_PNM[[3/#]
MY>)IBV$UMX4-SF.R5H-8V?(TL$VJR.($BD,L<'CW_@G/JG@FX\0+!\)O$WCS
MQ+XN_9=F\&>&O&&J:%ILNN:?X@@L-8A>&_NDE9[6[ELKNQLED$CB8)Y9E81D
MU^I?PY^*_AWXN6.J77AO5K;5[?1=6O-"OGASBVOK29H;F!L@?-'(K*<<9'!-
M'@/XK^'?B??>(K;0-6MM4G\):L^A:PD.<V%\D44S0/D#YA'/"W&1AQS0!^:_
MQZ_X)V>+/B%IWQN\4-\-;C4OB!I>E> +CX:ZHS1F_P!*U&PBMC>RZ=*9 ;69
M'@C65T*&58D1C(BJHY[X&^%/#NK?\%$_#GCSQ]X"M%MV^._C'2_#/C__ (13
M3;[4O$&KQOK-C;:5<ZE_:+:B;6UAMYS&ITN*.%K&T19A%:BYO/UJKB-(_9G^
M&_A_XQ7WQ$L/A_X(L?B!JD9AO/$]OH5K'K%W&552DEVJ"9UVJHPS$84#L* /
MA/\ X*-_LI>)OBQ\;?C4+[X1ZY\1_$WC?PGIMC\$?&&GQV[K\-]6@BN0TGVJ
M26.72)(;YX;Y[F+!N(PD:F:2!8*^A/V*_P!D;3?@I^U_^TYXV;P!X=T"^\<>
M,K.ZTS7K72+:WNM7LWT#1S=D2H/,\M]3CO9'5CAIS+(068L???#/Q7\.^,?'
M7B;PSI>K6UYKW@Y[:/6K),^9I[7$(FA#Y&/GC(88)XKHJ /S!\8?LL^-OBKI
MGQD^'/PO^&GQ+\+_  K\<^"?%[>(/ OQ(33Y- T_Q3=%)-+DT%S-/Y;2WAN;
MAT@F;3X@P=1!-M5LO5_V3M%\2^&O UQXD_93\3>*OAA-\)#X6\*^!(- L;*3
MP7XI>^NWU&X>R\U(M/GO]UH\>IHP\K[/(S2PF;,GZ3>"OCIX1^(WPJ;QQH>N
M6>I>$T2ZD;4XMWDA;:22*<\@'Y'BD4\=4-:W@'QUI'Q1\"Z+XF\/WT.J:#XB
ML(-3TV]ASY=W;3QK+%*N0#M9&5AD X- 'Y_?LZ?LM>*OAG^T[H-W\?OA;KOQ
MN^(#:'X)M/#'Q!M$M]2@\+2Z?I\$6JM]JN98GL6&HB\OI70![V*Z2,+.Z>0O
MS[\&_P#@G/\ %SPY^P)>?#WQM\,=>\2>-O$'A'P%!I'B&*\BAN-!TFQU72?[
M2\+;8YE-D]J\,]Z)X"INUFWLQGM,G]F:* /S.^)_[">I?#?QO\1-%T?X,OJ'
M[.=O\6_#WBB_^'WAVUMK?3?$.C1^%_(NC;Z:C)#/'%K"V-U-:;5\\V4A"2NV
MV3G-*_8;^,]K:Z=-\-_"^J?#72[NZ^)E]\/=-FN(K<_#6WU70[>#2HWC1V6S
M634DN;M+>+(MEN5C*QF,QI^JE5M5UFST*U6>^NK:S@:6*!9)Y5C4R22+'&F6
M(&YY'5%'5F8 9) H _(K2OV#O&6I:-X]7X"_ 'Q+\!_[0^! \'-]L>STF;7]
M<BU"UDN[<-'=;FNY;998/[1F:/[0Y5_M#)&LJ]1X5_X)R_\ "7Q^%;?2/ OB
M#_A7>L_%CP_JOB+PA+X'M_!7AVRM+;2=5@O9TTI9R72?S[.WN\H(;E8HTVS(
M92?T]\/?$30?%OB3Q!H^EZQINH:MX5N8K/6;.WN%DGTN:6".XCCF0',;/#-%
M( V,JZD<&MF@#X;^ G[.LGP2_P""I6MZEX-^$D%OX7UZTGAUO7]8\)V=C=^%
M(K:RLK:QM](U>&4FYTRX2VC5=-\LFV:)W9X L=NWG/[<W[(7B;XK_'WXS>5\
M)==\2?%7QIJ>@3?!SXG1F&2U^'MI:6MAOQ=M()=,%KJ,6HWLL4:@WJ78C47#
M,T2_I510!\N_\$__ -DBQ^ OQN_:>\0R?#_0?"]Q\0/B8]_I]_;:9;6\NL:6
M=&TH;B\8W-$;[^T7VOUEDG?&Z1F;YI^ W_!.#0W\,?#OX=ZE\!+'1=#\,_M"
M>*];\7HF@6UCI.NZ/-9>+VTF4F':+NR6"_TJV\MU,8206[)L62-?TXHH _*[
MXB_L4>+]*\,_"_0=>^'TVL_!_P ):S\2M/3PW<>"8/&EAHHN/%1E\.SC27G0
M^2-(2:WMYHD<VD5QY>(HYF9?H?X]?L^^.M#_ &*OV<9M%TGQC\3->^!>N>&O
M$6KZ'JMU9IXB\3V]I926=R)&>?[+)J$(N?M85K@K)/9A1*697/HFD?\ !6K]
MF/4=!TR_N_CU\)_#W]KV-MJEM9^(?$]GHNH&UN84GMIGM+N2.>-9H)(IHRZ+
MOCE1QE6!/H&O?MA?"3PM\6=-\ ZI\4OAUIOCK6A"=/\ #EUXDLX=6OO._P!3
MY5JT@ED\S^':IW=LT ?+_P"UUK>K?M9)\*_$VM_ ?XB>)O@QX6\47G_"7^#-
M?T&SFN]=BDTN:.SU'^R))GDNK:UO) I@F191(4N(X76!):\R^'7_  37OOB?
MI?PYT/XE?"N;4/ NC^"?B>NE>&->:"\A\+Q:CXCTNX\.:5,J32PF:WTU72)5
M=TMVM@(W!AC>ON'P[^W-\$_%]]XIM=)^,/PMU2Y\#6EQ?^)(K3Q783R>'[:!
MML\UXJRDV\<; AWEVJAX)%8_A?\ X*2?LZ^-[76)]%^/GP5UB#P]8-JNJR67
MC?3+A=,LUDCB:YG*3$10B26)#(^%#2H,Y8 @'YE_'']DCQK^S9^Q5XD\2WGA
M#6-"U3Q5^S[X03Q_?Q:@+>\\0>-8=9ADN)+RY$H>34LW%QF[=MP\P?O<*NWT
M[5?V9=1TRV\?W7@C]F2U\*_!'QEXD\,6MSX,\0>";36(]&N+6TU1-4\10^&X
M;E(9W>1]'LPR,Y9K9[SRIXX4,OWOXM_:5^!?C_\ 9NN/&^N^/OA1K7PANI%A
MN->O];L+GPY,ZSB-4>X=S;LPG"J 6R) !]X8JSX\_;?^"_PL\+>%]<\3_%[X
M7^'-$\;0&Z\.ZAJGBJQL[77X0(V,EI+)*%N$"RQ'=&6&)$/\0R ?!O[*?_!-
M76/B+HOP=\,_&[X5G6/"GA3P7\2]-GT;7[>VDL]-FN?%EC)HEN;>&>:!-NFI
M(;=(I)(X%B7RG!CC88_A[]G3XAZ7XI_9O^$_B#2[ZY7]I'X>^$[SXNB^NWFO
M=,O/!T%G-J4UWF0F8ZDL^GZ5._(VQ(&)+@G]'/%O[5GPO\ ?%W2OA_KWQ(\
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MFPSQP%)/,5(P,#]E7]DGQ9X?_;Y_X23Q=HOB;3?&VG_$+Q1K-YXFM/!=J/\
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M31=0-]=W!8'RK9K_ $R[N(@WRF1].B7DX!\A\9_M#?%WXT?L]^&?BYJ2>./
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M^&K^:S<_Z.HU+1+"=F"CRE\0WKG&]\^I?L$_%WQMX-O_ !;K7Q<U?XC-X?\
M@C8:=\&XY;RTU&\D\5ZS#J]S;RZZUK&DLETU[:R:!(MT X0SWF651(P^]**
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M37KI<).[+>1I>W+>7?77FSQ^3!$LX2,1U^F-% 'Y!_!7QQ^TE+X(\:>(M/\
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MP-H_PYT+^R]!TRRTG3_M-Q>&"UB$://<3R7%Q,P'WI)9Y997<Y9WD=F)9B2
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M]"L=,\2V+:EI^FZOI^NP0?:985%Y8W45Y:2-Y;+O$=Q!%($?*%HUW*0,5TE
M'Y/?"SXG^)I/ OPMTWXT>,OCIX9^%D7BCXB6Z:AH>I>(QJ%]>0ZI /#5G<:B
MB#5KF![";4FMEG8&[D@M%<3/Y<;\)\)O&WQA^&'[*?PS\(^&[SXH>';J#X"V
MESJ^D:=:RKK6EP-XNL+?5;Z"RV$C4X-*EO6C*Q&574!%)VJ?V<KB?#O[._A#
MPM\=/$?Q*M=,GD\;>*K&VTN]U.[U"YNVBL[?)CMK:.61H[2$L3(\=LL:RR'S
M) [_ #4 ?G?=_%KQ'\/K[7O%7PZ\:?%G6?V:O#GQ&\#Z@FOZOJ^JZNT-NS7,
M7B%([R\>2^N])C']F/(7>6&.62\ 95BD6+0^&^L_$#]J;XF^ =)U?7?CAI?@
M/QC\9/'OVSR=0UKPU>2Z%#:2W.E1M-&T-W:6IDC@:(*T1*GRQ\KNC?IM10!^
M;_PQC^)>B_%SP;XXG\1?%Z_U35OVEO%7@Z\L+_5]1ET:V\)AM?-O#_9^1:BW
M62*UDBNY(VE4F*-)Q (H5X[]E+X-_$/XJZ3^SC:>+OB#^T=$OQ3^&_BC4_'\
MW_"9:O8SO?V-QI"Z4@977^S7B6><@V@MY;KRO])>Z#3B7]4:* /Q^\3_ !H^
M.WQ5\/?#O_A+O'.L_#OQ)JGP4\%ZYX.U^[UG7=%BO/$]S;W#ZI(=.TZ!K76+
MU;H67FZ9>1NHA\L1P*L\S-Z[+;_$ZR^-<_C^/Q1\8FU33?VEX_"%KICZM?MH
M1\*W")%-$VG9^RRVX-S+(MR\;21/''LF1(P@_22B@#X__P""0W@K0/A?\*_B
MEX9T:[\82^)]#^)/BZ+5K'Q)KVL:E]C5_$>JS:>RF_EE"^?926]PTL/S7'G"
M>4R22;V^.-!^+_Q*N_V:KC4/ OB[X\:]\6I/@?XQU/XT0:Q<ZWM\->*!I:26
ML=I;3A(-,O4U0SI:V^G1Q+);!W59(XX9!^P]% 'R5^T)H>K?LW?\$:/C%JFD
M^+/'T_B^S^%6N^(6\0:OK]W=:Q'JG]C2RM<QRN_^BL)E\Q8;98886XBCB4!1
M\S>-OC-XDL;+XO#X4^+OCUX@^$-G#X%@\8^(-3@\0W/B#2+JXU^XC\4'3Q<1
M"YM;B/1S$]S;V,48T\[6BBMY0P7]+OBQ\+=!^./PL\3>"?%-C_:GAGQAI5UH
MFKV?G20?:[.YA>&>+S(V61-T;LNY&5AG((.#704 ?E'\0?B=J0^#7CN^\._$
M+XB2?!GPQ\1HKSP.?$'BSQ9I=Q\1+-/#JF^TF#Q'!YFJ>3_:,SRVDI:87%Q;
M26R++$$$>+\>?%5W\(=5_;.^).E2?%?X<_$K7?@5HGB_PU:ZMKNJBYLPMA<B
MY9X3.]F;BTN!!$V 3#([A-HG?S/UVKF?C1\'/#?[0OPF\1>!O&.FKK/A7Q98
M2Z9JMB9Y(!=V\JE7CWQLKKD$C*L".Q% 'YN^(?BWK>F:?\4&^&'BSX]>(_@7
M:ZGX$A\6:WJ<NOSZ[H33:C?KXH%E+=(M_;F.R72?M4=IM%@);HQ);S1RB/?^
M&EKXG^+NN^$_"WA[QU\:KCX'ZW\=[S3O#^MMK^LPZOJOAD>!+Z\N8CJ<Y%]-
MIYUM)XX;IY6<A4\B<!+>0?I310!^3WQ$\>?$[1_#OPS\)>,O%GC#3OAI8W7Q
M&T;_ (2?6O&VO^&+B:]TSQ6]AHB7VLZ8GVF2<Z1'*8%N6$=XWF2.)Y8X\/\
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M>"M1C:YU'6+33=8UN*+5CK$+V<;K8;H(Y[>5K:2()#+<^;'&DLSN_P"E%%%
M!1110 4444 %%%% !1110 5^2/\ P0;_ .4SO_!2+_L=+'_TLU:OUNK\D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7Y(_P#!!O\ Y3._\%(O^QTL?_2S5J_6ZOR1_P""#?\ RF=_X*1?]CI8_P#I
M9JU 'ZW4444 %%%% !1110 5^2/_  9X?\F-?&C_ ++!JG_IOTZOUNK\D?\
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M'&I=B!EY'5%&<EF &20*EU+6K/1OL_VRZMK7[5,MO!YTJQ^=*V=J+D_,QP<
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M@9.,5F^+O@7X)^(%E);Z]X.\*ZW;S:@NK/%?Z3!<H]XJ*BW)#H09@BJHD^\
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M#+/9LEP&O(6C,R21NN!^WEIX4TO3_$%YJUOINGPZKJ")%=7L=NBW%RB<(KR
M;F"Y. 2<9XK.\'_"3PI\/1JO_"/^&/#VA_V[.USJ7]GZ=#:_VA*V09)MBCS&
M.3EFR3DT ?C9\5?^"GGQE^&'A'X2^!? GQTTGQ%;S?!-O&5AX[FU/PAIEKXF
MUW^T;BW^Q7UUJ96T>TL$MA!/%8[+TEVDDDW(V[!_X*,?MU^.OC_<_$+PKXW^
M-WP_\%?\(SXK^&FFVGP=M;"QNY_$QN'T75;O4;:^+FYD5;B=BDD): 6]F59"
M\RRC]F]0_9F^&^K>#](\.W7P^\$77A_P_*9M+TR70K5[/39"2Q>"(ILC8L2<
MH <DFM?6/A1X6\1>)?[:U#PUX?OM8^R)8?;KC3X9;G[,DRW"0^8REO+69%E"
M9VAU# ;@#0!\0_\ !53XQZE\*/\ @HG^RQ_9=KX=^V/X6^)NI6]_?:/;7=[I
M\]IH-O+&UM/*AD@R21((RHD4;7W*,5S?_!+/]JCX\^,_VB_@]I?Q2^*EC\1M
M%^-7P @^)_V%/"MGH_\ PCNH+<:;'LAD@^>59(KX^;YN098R\8AC80I^B>J>
M%M+UR_MKJ]TVPO+JS26.WFGMTDD@650LBHQ!*AU # ?> P<U%I?@G1=#GL9;
M+2-+LY=+LO[-LW@M4C:TM?D/V>,@#9%^[C^1<+\B\<# !^(?[?OB'Q%9:E_P
M51\,>(_CA=^)$T_1=+OM,\"WRV$;QVUQ::1/'>01JHG6*S6:.RW)A)#*DDQ>
M=@]>I?M/?\%$_P!I']AK5_C=X%U[XD6WQ&E\.^*/AW9KXSC\.:3X>D\&V'B'
M[>M_(!,6L(XHWL8TMY;]G2)KQ?/EF"Y/ZN:W\(?"?B77[S5M2\+^'=0U34M/
M_LF[O+G389;BZL]^_P"S2.REFAW_ #>625SSC-7-5\ :#KRZLM]HFDWBZ];+
M9ZF)[..3^T8%#A8IMP/F(!(X"MD#>W')H ^$?V</VTOB[J__  26_:1^(7B;
MQ3X:UCQ=\,XO%DGA/7K#5-"UJZ-I::8+VQ;4CI3R:=]NA>0QR1QI$K+#&QA
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M_P F-?&C_LL&J?\ IOTZ@#];J*** "BBB@ KXW_X*'_MH_&/X-?M)>"OA?\
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MCOQ-XBT'X1^$+'4/%]A>Z5JL7V9I;&XM+W'VR!;1V-O''.% D6.-1(.&R.*
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M +/FH_"F/P7H?_"N=62]CN_#[P>993K>3RW-SE6)^_--))P>&;(Q@8\ZMO\
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M7QU#K]I8W8N[)1(L.FCR[^$)%-'<%V63D<)7JNB?\%5O'TO_  4P\/?#-9/
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MOOACX3NOB9=V,FG7.N2VFZ:ZADMVM7\U,^7([6[O 9'4N8F,>[9\M<S\/O\
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M_#99K'PGXBSX<U6+39[F(76M2;--NKA);=A/8VX$L:M@2$H[+]'?$7_@DO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[CPQI=DFH78L+:PBD\V"-9%$<-G;@ 'G9SD'%?"__!GA_P F-?&C_LL&J?\
MIOTZ@#];J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K\D?^"#?_ "F=_P""D7_8Z6/_ *6:M7ZW5^2/_!!O
M_E,[_P %(O\ L=+'_P!+-6H _6ZBBB@ HHHH ***Y7XZ1>+[CX)>,8_A]+I,
M'CZ30[U?#4FJ FQCU,P/]D:?:"?)$WEE\ G;G@T =57Y(_\ !GA_R8U\:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQH_[+!JG_IOTZ@#];J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\D?^"#?_*9W_@I%_P!CI8_^EFK5^MU?
MDC_P0;_Y3._\%(O^QTL?_2S5J /UNHHHH **** "O.?VP+&RU3]DKXI6NI>#
MM0^(FG7'A'5HKKPI8/)'=^)HFLY0^GQ-'\ZR7"DQ*4^8&08YQ7HU<+^U!//;
M?LT_$22U\:6OPWN8_#.I-%XMN422'PLXM92NHNKE49;<XF(8A2(SD@<T ?#O
M["&H^'+/X_\ PM\-:-=>$_B%I]C>>(/$20>&?&>O:])\/-3OX))KJ]U,ZB9&
MEDE>6ZMEEN7M[A9=1GV6S">Y:#RW_@SP_P"3&OC1_P!E@U3_ --^G5ZQ^PMX
M\UKQ#^UIX-M+FW\8?"VUCM+XFR\0>+/B-K:^.@+9@+-$\4Z386J3QD+>&6&2
M:\V6;J (7N'KR?\ X,\/^3&OC1_V6#5/_3?IU 'ZW4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y(_\$&_
M^4SO_!2+_L=+'_TLU:OUNK\D?^"#?_*9W_@I%_V.EC_Z6:M0!^MU%%% !111
M0 5PO[444EQ^S-\1(X?!</Q)ED\,:DJ>$9G6./Q2QM9<:<S.K*%N/]22RD 2
M<@CBNZHH _.G]A?PWJ5E^UCX+N+C4/$7Q6CCM;Y9+C5O#_Q#TH_#XFU;_2V;
MQ-JE];27$A_T+8D=O>[;N1AF$7*#R?\ X,\/^3&OC1_V6#5/_3?IU?K=7Y(_
M\&>'_)C7QH_[+!JG_IOTZ@#];J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\D?^"#?_*9W_@I%_P!CI8_^
MEFK5^MU?DC_P0;_Y3._\%(O^QTL?_2S5J /UNHHHH **** "BBB@ K\D?^#/
M#_DQKXT?]E@U3_TWZ=7ZW5^2/_!GA_R8U\:/^RP:I_Z;].H _6ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HK\R_P#@K=/\/_&__!5#]G;P/^T?K&GZ7^SGJ'AG6]5L
M[36]4.G^'=<\40/"(X]08NL+>5;-NA$Q ,DI1<F0HWD/[2'[?_\ PSE:^/\
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MDBN(W 971ER&5E(((.""#7YX_LU_M4>+_P!J/_@EM^UVOC#Q=I?Q)M?AW?\
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M<:5\8/AK>S1QZ?X;U[P7:66I^([N&*ZT*]L5:3RY[1(PJ:A_ID2KO61A*Y0
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M8?\ Y04 ?KM17Y$_\,B?\%CO^CI?V=__  4P_P#R@H_X9$_X+'?]'2_L[_\
M@IA_^4% 'Z[45^1/_#(G_!8[_HZ7]G?_ ,%,/_R@H_X9$_X+'?\ 1TO[._\
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M7 USJ MG5[<32%=TGE.JLFXG85!7! K\K_\ AD3_ (+'?]'2_L[_ /@IA_\
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M^SO_ ."F'_Y04?\ #(G_  6._P"CI?V=_P#P4P__ "@H _7:BOR)_P"&1/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
